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ABSTRACT 
 
Mature skeletal muscle has a uniquely robust capacity for regeneration. This 
ability is due in large part to the resident population of muscle stem cells in the tissue, 
known as satellite cells. These adult stem cells reside in a quiescent state near the basal 
lamina of skeletal myofibers, but are rapidly activated by myofiber injury from trauma, 
strenuous exercise, or disease. Upon activation, satellite cells proliferate to produce 
many daughter myoblasts at the injury site. These daughter myoblasts subsequently 
undergo an ordered series of steps to remake functional syncytial myofibers, including 
migration, cell cycle withdrawal, expression of pro-differentiation genetic programs, and 
cell-cell fusion. However, the molecular cues that regulate these steps are still 
incompletely understood. 
Over the past decade, there have been various reports demonstrating that 
skeletal muscle cells are prolific secretors of cytokines and other soluble factors. In fact, 
myoblasts express and secrete different cytokines at distinct points during proliferation 
and the stages of differentiation. These observations gave rise to the idea that perhaps 
muscle cells could influence their own differentiation in an autocrine or paracrine manner 
by regulating cytokine production. This was intriguing, as it was long assumed that the 
immune cells that infiltrate the muscle tissue in high numbers after injury—largely 
neutrophils and macrophages—were the source of any secreted factors observed during 
skeletal muscle regeneration. Still, the functions and underlying molecular mechanisms 
of these cytokines are mostly unexplored.  
 We performed a functional RNAi screen in order to better understand the roles of 
these muscle-derived cytokines in myogenesis, which is described in chapter II of this 
thesis. After screening 134 cytokine genes, we were able to categorize the resulting 29 
positive hits into four functional groups (Table II.3). Class I and II cytokines represent 
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potential positive regulators of myogenesis, while Class III and IV cytokines are potential 
myogenic inhibitors. Curious about the functions of these cytokines, we set about 
characterizing in detail the molecular mechanisms they use to affect myoblast 
differentiation and fusion.  
Tumor necrosis factor superfamily member 14 (Tnfsf14) emerged from our 
screen as a potential positive regulator of myogenesis, though no function for Tnfsf14 in 
muscle tissue had been reported. Through the studies described in chapter III of this 
thesis, we found that Tnfsf14 promotes myogenesis through cell survival, by maintaining 
a sufficient number of myoblasts available to fuse into myotubes. This action is 
dependent upon the Akt signaling pathway, and can be modulated in vivo to enhance 
muscle regeneration after injury. 
In chapter IV, we describe chemokine (C-X-C motif) ligand 14 (Cxcl14) as a 
negative regulator of myogenesis. We found that Cxcl14 expression in myoblasts 
prevents cell cycle withdrawal, thereby preventing subsequent differentiation. 
Interestingly, Cxcl14 inhibition during skeletal muscle injury sped up the regenerative 
process in vivo. We observed this rapid regeneration even in aging animals, which 
generally have decreased regenerative ability. 
Lastly, chemokine (C-C motif) ligand 8 (Ccl8) is described as a positive regulator 
of myogenesis in chapter V of this thesis. Ccl8 may be multifunctional: it appears to 
promote sufficient myoblast number by enhancing proliferation and survival in 
proliferating cells, and possibly functions in differentiating cells through a distinct pro-
myogenic mechanism. We also observed that Ccl8 expression can be blunted by 
inhibition of the protein kinase mTOR. Further work will be necessary to fully 
characterize the function of Ccl8 in myogenesis, and to better understand how Ccl8 is 
regulated by the cell. 
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There are still many cytokines from our RNAi screen that remain to be 
investigated. More complete characterization of these secreted factors and the signaling 
pathways they fit into can help us to better understand how skeletal muscle is 
developed, maintained, and regenerated. Indeed, these cytokines may represent novel 
therapeutic targets for managing muscular diseases or age-related muscle wasting. 
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CHAPTER I: INTRODUCTION 
 
I.1. Skeletal Myogenesis 
I.1.1. Overview of skeletal myogenesis 
Embryonic development—The skeletal musculature of the limbs and trunk 
takes its origin from the dermomyotome, a mesodermal tissue that constitutes the dorsal 
region of the somite [1, 2]. As illustrated in Fig. I.1, the somite is organized into epaxial 
and hypaxial domains, which are dorsal and ventral to the notochord, respectively. 
Cellular commitment to the skeletal muscle lineage begins in the epaxial dermomyotome 
with activation of Myf5, which encodes a basic helix-loop-helix (bHLH) transcription 
factor in the MyoD family [1]. The other members of the MyoD family—Mrf4, MyoD, and 
myogenin—are also required for successful muscle formation, and are collectively 
referred to as the myogenic regulator factors (MRFs). The pattern of sequential 
activation of the MRFs is illustrated in Fig. I.2. Embryonic triple-knockout of Myf5, Mrf4, 
and MyoD results in a complete loss of skeletal muscle tissue due to lack of myogenic 
specification [1, 3]. In contrast, myogenin is required later for differentiation of committed 
myoblasts; thus embryonic loss of myogenin prevents the formation of mature skeletal 
myofibers, but does not affect the number of undifferentiated myoblasts [3].  Mrf4 also 
has a role in differentiation, in addition to its function in myogenic commitment [1, 3].  
Besides the MRFs, there are other transcription factors families that are 
necessary for robust myogenesis. Pax3, a member of the paired box (PAX) family, is 
required for Myf5 and MyoD expression; as such, Pax3 knockout mice do not develop 
limb muscles [4]. Another important family of myogenic transcription factors is the 
myocyte enhancer family-2 (MEF2) proteins. During differentiation, the MEF2 
transcription factors coordinate the expression of muscle-specific genes, including Mrf4 
and myogenin [3].  
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Adult regeneration: myogenic progenitor cells—Mature skeletal muscle 
tissue contains a resident population of stem cells that imparts a great capacity for 
regeneration. These myogenic progenitor cells, called satellite cells, exist in a quiescent 
state under the basal lamina of myofibers until stimulated to divide by muscular injury [5]. 
Quiescent satellite cells express the transcription factor Pax7—which is essential for 
their survival and maintenance of the stem cell pool [6]—but Pax7 must be 
downregulated as the myogenic progenitors re-enter the cell cycle [4]. After reactivation, 
a subset of the activated satellite cells downregulate MyoD and begin to express Pax7 
again, allowing for self-renewal of the muscle stem cell pool [4]. The remaining activated 
cells proliferate to increase myoblast numbers at the site of injury, thereby allowing for 
myofiber regeneration. 
Satellite cells comprise less than 10% of the total nuclei in a given myofiber [7], 
but they represent a crucial component of the myogenic niche. Satellite cell numbers 
dwindle during normal aging and drastically so in some muscle pathologies (e.g. 
Duchenne muscular dystrophy), resulting in a functional loss of regenerative potential 
[6]. Though satellite cells are viewed as professional muscle stems cells and are largely 
responsible for skeletal muscle regeneration, other cells have been identified to have 
some level of myogenic potential under experimental conditions. Myo-endothelial cells, 
pericytes, and mesangioblasts—cells all associated with blood vessels—are capable of 
enhancing myogenesis when injected into injured muscle [8]. However, the role of these 
cell types in muscle regeneration under normal physiological or pathophysiological 
conditions is still unknown [7, 8]. 
Adult regeneration: remaking the mature myofiber—Effective myogenesis 
depends on the new myoblasts successfully completing a number of different processes, 
including transcription and translation of many of the same pro-differentiation genes 
seen in embryonic development, such as the MEF2 and MyoD families of transcription 
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factors [1, 3]. As illustrated in Fig. I.3, the differentiating myoblasts must also undergo 
massive cytoskeletal rearrangement, migration, cell-cell adhesion and alignment, and 
finally membrane fusion in order to recapitulate a mature multinucleated myofiber [9]. 
Membrane fusion occurs in two distinct stages. The first stage represents fusion 
between differentiated myoblasts, leading to small, nascent myotubes containing only a 
few nuclei. The second stage of fusion occurs between myoblasts and these nascent 
myotubes, allowing for the formation of mature myotubes with many nuclei. Interestingly, 
there are a handful of known myogenic regulators that influence only the second stage 
of fusion, perhaps representing a control mechanism over the ultimate size or shape of 
the resulting myofiber [10].  
I.1.2. In vitro models of myogenesis 
The development of in vitro myogenic systems has greatly enhanced our ability 
to study skeletal myogenesis. One of the most commonly used cell lines is the C2C12 
murine myoblast cell line, which is a well-established in vitro model of myoblast 
differentiation. When maintained subconfluently in serum-rich media, C2C12 cells grow 
and divide as myoblasts. Upon growth factor deprivation, these cells rapidly withdraw 
from the cell cycle, initiate the differentiation genetic program, and fuse with each other 
to form multinucleated myotubes. Primary myoblasts isolated from the muscles of 
neonatal mice are also commonly used, and robustly differentiate under similar 
conditions to C2C12 cells. First isolated in pure culture by Rando and Blau in 1994, 
primary myoblasts offer the advantage of transplantation back into an animal to study 
the effects of a particular gene therapy [11]. Other less-commonly used cell culture 
models include the L6 rat myoblast cell line and human primary myoblasts. Human 
primary myoblasts can be difficult to obtain and culture in vitro, but are particularly 
interesting as they can be isolated from muscle biopsies of patients with specific 
muscular diseases. 
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I.1.3. In vivo models of myogenesis 
The molecular steps involved in skeletal myogenesis are highly regulated, and 
the fundamental principles underlying each step are well-conserved across species [10]. 
As such, a wide variety of animal models have been employed to study both the 
embryonic development and adult regeneration of skeletal muscle, including the fruit fly, 
zebrafish, and rodents, to name a few [10]. The mouse is a commonly used model of 
myogenesis, and regeneration studies are typically performed by injuring a particular 
muscle mechanically (e.g. crush injury) or by injection of a myotoxin. All in vivo 
experiments described in this thesis were performed using localized injection of 1.2% 
barium chloride (BaCl2) into the easily-accessible tibialis anterior (TA) muscle as a 
method of injury.  
As shown in Fig. I.4, the muscle tissue becomes largely necrotic one day after 
injury (AI) with BaCl2.  By day 3 AI, the damaged area is filled with small mononucleated 
cells, but distinction between cell types (e.g. infiltrating macrophages, activated satellite 
cells) is only possible with cell-specific immunolabeling. Regenerating myofibers can be 
clearly seen by day 5 AI and are identified by the presence of centrally positioned nuclei, 
allowing new fibers to be distinguished from existing uninjured myofibers with 
peripherally located nuclei. This distinct pattern of nucleus localization is useful for 
accurate quantification of regenerating myofiber number and cross-sectional area. The 
regeneration process is typically complete by day 21 AI [12].  In our lab, saline (0.9% 
NaCl) injection is performed on the TA muscle of the opposite limb of each mouse as 
non-injury control. 
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I.2. Cytokines in Skeletal Muscle 
I.2.1. A brief history of cytokines 
The exact definition of what constitutes a cytokine has been evolving since their 
discovery in purulent exudates in the 1940s [13]. Many of the secreted factors we now 
know as cytokines were originally categorized as either “monokines” or “lymphokines,” 
based on their primary source from either monocytes or lymphocytes, respectively [13]. 
Other forms of nomenclature centered on function, such as the “chemokines,” so named 
for their chemoattractant properties. Today, it is well established that nearly every cell 
type can produce these secreted factors to some degree, and that individual cytokines 
often have pleiotropic functions. Thus many of the older terminologies have been 
discarded in favor of the umbrella-term “cytokine,” which includes interleukins, 
chemokines, adipokines, interferons, the tumor necrosis factor (TNF) family, and 
mesenchymal growth factors [13]. Cytokines are generally considered to be small (<30 
kDa), secreted proteins, although exceptions to this already broad interpretation certainly 
exist: some members of the TNF family include biologically active membrane-bound 
forms (e.g. Tnfsf14), and several cytokines are larger than the 30 kDa molecular weight 
cutoff (e.g. IL-12, VEGF).  
I.2.2. Secreted factors in myogenesis 
For years, it had been accepted that the secreted factors influencing muscle 
regeneration in vivo are largely of immune cell origin. Indeed, immune cells have been 
reported to reach concentrations over 100,000 cells/mm3 in regenerating muscle tissue 
[14].  Recently, however, various analyses have shown muscle cells to be prolific 
secretors of a wide variety of cytokines [15-18], including several that in fact attract 
immune cells to muscle tissue [19]. Secretome studies show that myoblasts secrete 
different factors during proliferation than during differentiation, and even at different time 
points throughout differentiation [16, 20, 21]. Another study identified numerous 
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chemokine mRNAs expressed by differentiating myoblasts, which may be involved in 
regulating cell migration during myogenesis [17]. Our lab also noted that conditioned 
medium from fully differentiated myotubes can rescue cells pharmacologically halted at 
an immature myotube stage [22], implying an important myogenic function for myocyte-
secreted factors. Taken together, these studies suggest the intriguing possibility that 
muscle cell-secreted proteins have a previously under-appreciated role in modulating 
muscle development and regeneration.  
Functions of the newly identified muscle-secreted cytokines are mostly 
unexplored. Using RNAi, we conducted the first functional screen of cytokines for their 
impact on myogenic differentiation in C2C12 myoblasts, which allowed us to identify 
potential regulators of myogenesis in distinct functional groups [23]; this study is detailed 
in Chapter II. Several of the chapters in this thesis detail the characterization of 
individual cytokines discovered from this screen.  Further characterization of the new 
candidates will likely add interest and complexity to our understanding of cytokines in 
myogenesis. As many cytokines are notoriously lowly expressed in non-myeloid cell 
types, it is possible that individual cytokines are primarily responsible for fine-tuning 
mechanisms during differentiation and regeneration. Our RNAi screen also hints at 
possible functional redundancy within the groups of secreted factors; it is not unlikely 
that a network of cytokines governs the various processes necessary for myogenesis, 
such as cell proliferation, survival, or differentiation. Table I.1 lists the myocyte-produced 
cytokines with reported myogenic function thus far. 
I.2.3. Cytokines in muscle disease 
Though they play a necessary role in a variety of physiological processes, 
dysregulation of cytokines has long been associated with human diseases, especially 
those that involve acute or chronic inflammation. Renowned immunologist and physician 
Charles Dinarello describes the paradoxical role of cytokines particularly well: 
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“Here lies the conundrum in cytokine biology, particularly for the 
immunologist. The innate response is required for host survival but is also 
causative in disease. For example, interferon (IFN)-γ, essential for 
defense against several intracellular microorganisms such as 
Mycobacterium tuberculosis, is also a major cytokine in the pathogenesis 
of several autoimmune diseases. The issue of the “good cytokine versus 
the bad cytokine” has its greatest impact in therapeutic arena. IL-2 is 
needed for the generation of cytotoxic T cells (CTL) and forms the basis 
for several vaccines but the same cytokine drives graft-versus-host 
disease and limits the success of bone marrow transplantation” [13]. 
 
Compared to immune-mediated pathologies like graft-versus-host disease, 
cytokines play a less obvious—though equally important—role in the pathogenesis of 
skeletal muscle diseases. Below, we briefly review reports of cytokine involvement in 
three muscle disorders: muscular dystrophy, cachexia, and sarcopenia. 
Muscular dystrophy—Muscular dystrophy is a broad term for the suite of 
diseases that are characterized by progressive loss of skeletal muscle function and 
strength. The variants of muscular dystrophy include limb-girdle, Becker, Walker-
Warburg, and Emery-Dreifuss, to name a few. Each of these dystrophies are caused by 
different genetic mutations, and they feature distinct patterns of muscular weakness [24]. 
The most common and perhaps most studied variant, Duchenne muscular dystrophy 
(DMD), is caused by mutations in the dystrophin gene [25] leading to complete loss of 
expression of the dystrophin protein. Dystrophin is found in the membranous 
sarcolemma of muscle fibers and is an essential component of the dystrophin-
associated protein complex, which provides structural integrity to contracting myofibers 
[26]. As such, patients with DMD generally present in late childhood with increasing 
weakness in the limbs and shoulders, which progressively worsens with age [24]. 
 While not directly responsible for the development of DMD, cytokines may indeed 
be involved in the pathogenesis of dystrophic muscle symptoms. One study 
demonstrated that the muscles of patients with Duchenne or Becker muscular dystrophy 
contain higher levels of the cytokine transforming growth factor (TGF)-β [27], which 
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promotes both the fibrosis and impaired regeneration phenotypes seen in muscular 
dystrophies [27, 28]. Similarly, heightened levels of NF-κB activation in the myofibers 
and immune cells of the DMD mdx mouse model has been linked to fibrosis and poor 
regeneration [29], and activation of NF-κB is often downstream of the TNF family of 
cytokines [30]. Indeed, a common therapy for DMD is low-dose treatment with the 
corticosteroid prednisolone, which slows progressive loss of muscle strength and 
function [31, 32], likely through mild immunosuppression. 
Cachexia—Cachexia is characterized by extreme wasting of lean body mass 
and occurs with an underlying chronic illness, such as cancer, congestive cardiac failure, 
or AIDS [33]. The development of cachexia in a chronically ill patient brings bad tidings, 
as it is associated with a poorer overall prognosis and survival rate. Indeed, cachexia is 
the cause of 20% of all cancer-related deaths [34]. Muscle atrophy during cachexic 
states ultimately stems from ubiquitin-mediated breakdown of myofibrils [35].  
Significantly, a well-documented association exists between cachexia and the 
dysregulation of cytokines, most notably the pro-inflammatory cytokines tumor necrosis 
factor alpha (TNFα), interleukin-1 (IL-1), and interleukin-6 (IL-6) [35, 36]. However, 
clinical trials aimed at pharmacologically inhibiting each of these cytokines individually 
have had limited success in reversing the symptoms of cachexia [35]. It is possible that 
TNFα, IL-1, and IL-6 play an important, interconnected role in muscle wasting, but other 
factors—perhaps other cytokines—are also at work. This hypothesis is bolstered by a 
recent study demonstrating that inhibition of Fn14, the receptor for TNF family member 
Tnfsf12 (TWEAK), can ameliorate cachexia and prolong survival in tumor-bearing mice 
[37]. Interestingly, this effect was only achieved by inhibiting tumoral Fn14, not the 
endogenous TWEAK-Fn14 axis [37], indicating that Fn14+ tumors may be secreting 
another unknown factor that signals muscle atrophy. The exact mechanism and 
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physiological source of pro-inflammatory cytokines in cachexic skeletal muscle atrophy 
is still unclear. 
Sarcopenia—The progressive loss of muscle mass that comes with advancing 
age is termed sarcopenia. This form of muscular atrophy is quite common, affecting 
approximately 50% of people over the age of 80 [35]. Sarcopenia occurs in the absence 
of any underlying illness, and is correlated with physical frailty [35, 38, 39]. Frailty 
detracts from safety and quality of life in the aging population, due to its close 
association with increased incidence of falls and fractures, hospitalization, and mortality 
[35, 38, 39]. The clinical definition of frailty requires meeting at least three of the 
following criteria: unintentional weight loss, exhaustion, weakness as measured by grip 
strength, slow pace of walking, and low physical activity [39].  
Similar to cachexia, the pro-inflammatory cytokines TNFα and IL-6 are highly 
correlated with loss of muscle mass, osteoporosis, and overall increased markers of 
frailty in the aging population [35, 38]. Indeed, TNFα alone is capable of inducing muscle 
breakdown, possibly via both NF-κB activation and upregulation of ubiquitin ligases [40, 
41]. However, it is likely that other cytokines also play a role in pathological muscle 
breakdown. The TNF family member TWEAK, for example, can induce muscle wasting 
in mice, also through NF-κB [42, 43]. Additionally, sarcopenic muscle demonstrates 
increased levels of cell death [35], a process commonly directed by a variety of 
cytokines. A better understanding of the network of cytokines involved in the 
maintenance of muscle mass—as well as how those cytokines are regulated—could 
shine some light on how muscle catabolism increases with age and how to prevent it. 
I.2.4. A note about “myokines” 
While technically defined as any cytokine secreted from skeletal muscle cells, the 
term “myokine” has come to represent in the literature primarily those cytokines that are 
released from muscle cells but exert beneficial effects on other cell types in a paracrine 
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or endocrine manner (reviewed in [44, 45]).  Often the focus of myokine studies is on 
proteins released during muscle contraction, in an effort to identify novel anti-
inflammatory factors that may mediate the health benefits of exercise, as well as factors 
that may exert metabolic regulation. Some well-known examples of myokines include IL-
6 and irisin. IL-6 is secreted by exercising muscles and has been touted as the first 
myokine [46]. At normal physiological levels, IL-6 may be beneficial primarily through 
suppression of the pro-inflammatory TNFα expression [47], as well as by enhancing 
glucose and lipid metabolism [48].  
Irisin secretion is also induced by exercise, and leads to “browning” of white 
adipose tissue through upregulation of the uncoupling protein UCP1, thereby decreasing 
obesity and insulin resistance in mice fed a high-fat diet [49]. Though the role of 
myokines in overall metabolic function remains an active area of research, our interest 
lies more specifically in those cytokines made by muscle cells to influence skeletal 
myogenesis. Thus, this thesis will focus instead on cytokines with demonstrated cell-
autonomous functions in skeletal muscle growth, differentiation, and repair. 
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I.3. Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. I.1. Schematic diagram of a developing embryo in cross-section  
Skeletal muscles arise from the dermomyotome, a region found in paired mesodermal 
tissue blocks called somites. The somites flank the neural tube and notochord, and 
mature in an anterior to posterior direction in the developing embryo. 
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Fig. I.2. Sequential expression of the MyoD family in the embryo  
The members of the MyoD family of transcription factors are activated sequentially 
during the early stages of embryonic myogenesis. Myf5 expression is the earliest, 
beginning in the epaxial dermomyotome. Myf5, Mrf4, and MyoD are necessary for 
specification of committed myoblasts, while Mrf4 and myogenin are involved in the later 
steps of myogenic differentiation.  
Myf5 Mrf4 MyoD myogenin 
Myogenic specification Myogenic differentiation 
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Fig. I.3. Skeletal muscle regeneration 
In mature muscle, myogenesis occurs in response to injury via activation of quiescent 
satellite cells. These cells divide to make numerous daughter myoblasts, which 
subsequently proceed through the myogenic differentiation program to reform the 
mature, functional myofibers. 
  
satellite 
cell 
Withdrawal from cell 
cycle, elongation and 
migration 
Myoblast-
myoblast 
fusion 
Myoblast-
myotube 
fusion 
myoblasts differentiating myoblasts nascent 
myofiber 
mature myofiber 
Activation, 
proliferation 
Pax7 + 
MyoD + 
Self renewal 
myogenin + 
MHC+ 
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Fig. I.4. Skeletal muscle regeneration after BaCl2-induced injury  
The tibialis anterior (TA) muscle of a male 8-10 week old FVB mouse was injured via 
injection of 1.2% barium chloride (BaCl2). An equal volume of saline (0.9% NaCl) was 
injected in the opposite hindlimb as a non-injury control. Whole muscles were isolated 
from mice on days 1, 3, 5, 7, and 14 after injury. Each muscle was frozen in 2-
methylbutane, cryosectioned, and stained with hematoxylin and eosin (H&E). 
Regenerating myofibers containing centrally-located nuclei can be seen from day 5 after 
injury (D5AI). Scale bar indicates 50 microns.	
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Table I.1. Summary of muscle-derived cytokines with reported positive or negative 
regulatory function in myogenesis 
The results of a literature search for cytokines reported to be both expressed in muscle 
cells and with a myogenic function. “+” indicates a positive regulator of myogenesis while 
“-“ indicates a negative regulator. 
 
 
Family Cytokine Other names Myogenic Function References 
Chemokines 
Cxcl12 SDF1 + [17, 50-55] 
Cxcl14 BRAK - Chapter IV 
Cxcl16  + [56] 
Ccl2 MCP1 + [57-60] 
Ccl8 MCP2 + Chapter V 
Cx3cl1 Fractalkine - [61, 62] 
Growth Factors 
IGF1  + [63-66] 
IGF2  + [12, 67, 68] 
HGF Scatter factor + in MPC activation, - in diffrentiation [69-74] 
PDGF  - [75-78] 
NGF  + [79, 80] 
VEGF  + [81-83] 
TGFβ  - [84-87] 
Myostatin GDF8 - [88-94] 
GDF11  - [95-97] 
FGF1 Acidic FGF - [98] 
FGF2 Basic FGF - [98-100] 
FGF6  + [101-103] 
FGF8  + [104, 105] 
FGF13  - [106] 
CCN2 CTGF - [107-110] 
CCN3 NOV - [111, 112] 
Progranulin  + [113, 114] 
Follistatin  + [115-122] 
Activin A  - [116, 123-126] 
BMP2  - [123, 127] 
BMP4  - [128-130] 
BMP7  + [123, 131] 
BDNF  + [132, 133] 
Hedgehogs SHH  + [134-137] 
Interferons IFNγ  + at low levels,  - at high levels [138-140] 						
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Table I.1. (continued)		
Interleukins 
IL-1  - [141-147] 
IL-4  + [148] 
IL-6  + at low levels, - at high levels [47, 149, 150] 
IL-7  - [151] 
IL-8  + [152] 
IL-10  + [153-158] 
IL-12  + [159, 160] 
IL-13  + [148, 161] 
IL-15  + [162-170] 
IL-17  - [171, 172] 
LIF  + in early diff,  - in later diff [173-177] 
CT-1  - [178, 179] 
OSM  - [180] 
CNTF  + [181, 182] 
G-CSF  + [183-185] 
Tumor 
Necrosis 
Factors 
TNFα Cachectin - [141, 186-191] 
Tnfsf12 TWEAK - [42, 43, 192] 
Tnfsf14 LIGHT + [193] 
Tyrosine 
Kinases Flt3L  + [194] 
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CHAPTER II: RNAI SCREEN REVEALS POTENTIALLY NOVEL ROLES OF 
CYTOKINES IN MYOBLAST DIFFERENTIATION1  
 
II.1. Introduction 
During embryonic skeletal myogenesis, cells in somites are guided by various 
environmental cues to undergo myogenic commitment, and pass along the myogenic 
pathway by terminal differentiation and fusion to form multinucleated myofibers [1, 2]. In 
adult skeletal muscles, injury or other remodeling cues induce satellite cell activation and 
proliferation, followed by differentiation to form new myofibers or repair existing ones [3]. 
Skeletal myogenesis in vivo can be largely recapitulated by differentiation of cultured 
myoblasts, which follows a series of ordered steps including cell cycle withdrawal, 
myogenic protein expression, cell elongation, migration, and fusion to form myotubes [4].  
Cytokines are broadly defined as cell-secreted signaling proteins that modulate 
cellular functions. The earliest defined cytokines were those secreted by immune cells to 
modulate immune responses, such as interleukins [5, 6]. Other major families of 
cytokines include the TNFα family [7] and the TGFβ family [8]. Chemokines are a family 
of structurally related cytokines that regulate chemotaxis by signaling through the G 
protein coupled receptor family of chemokine receptors [9], and are best known for their 
functions in immune cells. The expression and function of various cytokines in skeletal 
muscle have also been reported. For instance, myostatin, a TGFβ family member, is 
expressed almost exclusively in skeletal muscle and negatively regulates muscle mass 
[10]. On the other hand, the expression of follistatin, which antagonizes myostatin and 
promotes myocyte fusion [11, 12], is not restricted to muscle. The prototypic 
                                                
1 This work was performed in collaboration with Dr. Yejing Ge and published as:  
Ge, Yejing, Rachel J. Waldemer, Ramakrishna Nalluri, Paul D. Nuzzi, and Jie Chen. 
RNAi screen reveals potentially novel roles of cytokines in myoblast differentiation. PLoS 
One, 2013: e68068. 
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immunoregulatory cytokine interleukin-4 (IL-4) has been found to be expressed in 
skeletal myocytes and play a key role in myoblast recruitment and late-stage fusion to 
allow growth of myotubes/myofibers [13]. Interleukin-6 (IL-6) is also expressed in muscle 
[14, 15], and it promotes myogenic differentiation [14, 16] as well as satellite cell 
proliferation during muscle growth [15]. Some cytokines that reportedly modulate 
myogenic differentiation have not been shown to be expressed in muscle cells and may 
act through endocrine or paracrine mechanisms, the bone morphogenic proteins (BMPs) 
being an example [17, 18]. 
Injury-induced muscle regeneration is accompanied by immune cell infiltration 
and inflammatory responses. Many cytokines have been found to be expressed in 
regenerating muscles (e.g., [19]), but the source of these cytokines can be infiltrating 
immune cells or muscle cells, or both. Recent proteomic analyses of the secretome of 
the myogenic C2C12 cells have revealed tens of cytokines and growth factors that are 
expressed during differentiation in a regulated manner [20, 21]. Another study has 
identified numerous chemokine mRNAs expressed by differentiating mouse primary 
myocytes in culture [22], which may be involved in regulating cell migration during 
myogenesis. It is possible that other processes of myogenic differentiation may also be 
regulated by various families of cytokines. To systematically examine the potential roles 
of cytokines in skeletal myogenesis, we took an RNAi approach to screen a large portion 
of cytokine genes in the mouse genome for their involvement in the differentiation of 
C2C12 myoblasts. A wide range of cytokines has been identified from this screen as 
candidates for positive and negative regulators of myogenic differentiation. Based on the 
knockdown phenotypes, these candidates are divided into four groups. Selected 
cytokines representing each group have been further confirmed for their roles in 
myogenic differentiation. 
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II.2. Materials and Methods 
II.2.1. Reagents  
Anti-MHC (MF20) was obtained from the Developmental Studies Hybridoma 
Bank developed under the auspices of the NICHD, National Institutes of Health and 
maintained by The University of Iowa, Department of Biological Sciences. Anti-mouse 
IgG-FITC was from Jackson ImmunoResearch Laboratories, Inc. All shRNA constructs 
(in the pLKO lentiviral vector) in the form of bacterial glycerol stocks were purchased 
from Sigma-Aldrich (MISSION® TRC). All other reagents were also from Sigma-Aldrich.  
II.2.2. Cell culture  
C2C12 myoblasts were maintained in DME containing 1 g/L glucose with 10% 
fetal bovine serum at 37 °C with 7.5% CO2. To induce differentiation, cells were plated 
on tissue culture plates coated with 0.2% gelatin and grown to 75-100% confluence 
before switching to differentiation medium (DME containing 2% horse serum). The cells 
were replenished with fresh differentiation medium daily for 3 days.  
II.2.3. Lentivirus-mediated RNAi screen and other shRNA constructs 
Lentivirus packaging was performed as previously described [23], scaled down for the 
96-well format. A panel of 134 cytokine genes was selected and for each gene, 2-5 
shRNA constructs were used (Table 1). A non-targeting shRNA (Addgene plasmid 1864; 
[24]) was included as a negative control. For the primary screen, C2C12 myoblasts 
seeded in 96-well plates were transduced with individual lentiviruses and selected in 3 
µg/mL puromycin for 2 days, followed by 3-day differentiation. Each experiment included 
the control shRNA virus at several titers of viral transduction, resulting in several 
different cell densities at the time of differentiation. Comparisons were made to the 
control of similar cell density (nuclei number). Each knockdown was repeated as least 3 
times. The secondary screen was performed with C2C12 cells seeded in 12-well plates, 
and the shRNAs of primary hits were examined in several groups. The control shRNA 
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was included in each group from viral packaging, infection to differentiation for side-by-
side comparison. Myocytes at the end of differentiation were fixed and immuno-stained 
for MHC and DAPI. Myotube formation was quantified by differentiation index, fusion 
index, and myonuclei number per myotube (see below for detailed description). 
II.2.4. Immunofluorescence microscopy and quantitative analysis of 
myocytes  
Differentiated C2C12 cells were fixed and stained for MHC and DAPI as 
previously described [25]. The stained cells were examined with a Leica DMI 4000B 
fluorescence microscope, and the fluorescent images were captured using a RETIGA 
EXi camera, and analyzed with Q-capture Pro51 software (Q-ImagingTM). The 
differentiation index (% of nuclei in MHC-positive myocytes), fusion index (% of nuclei in 
MHC-positive myotubes with at least 2 nuclei), and myonuclei number per myotube were 
calculated. Each data point was generated from quantifying all cells in 5 randomly 
chosen microscopic fields, totaling 1000-2500 nuclei. 
II.2.5. RT-PCR  
C2C12 cells were lysed in Trizol (Invitrogen), and total RNA was isolated 
following the manufacturer’s protocol. cDNA was synthesized from 1 µg RNA using 
qScript cDNA synthesis kit (Quanta Biosciences) according to the manufacturer’s 
protocol, followed by PCR using gene-specific primers for limited cycles (15-25). β-actin 
was used as a loading control. The sequences of primers used in this study are shown in 
Table 2. The PCR bands were quantified by densitometry, and normalized to β-actin 
control. 
II.2.6. Statistical analysis  
All data are presented as mean ± SD (n≥3). Whenever necessary, statistical 
significance of the data comparison was analyzed by performing one-sample or paired t 
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test. The specific types of tests and the p-values, when applicable, are indicated in the 
figure legends. 
 
II.3. Results 
II.3.1. An RNAi screen of cytokines for novel regulators of myoblast differentiation 
To search for cytokines potentially involved in myoblast differentiation in a cell-
autonomous manner, we carried out an RNAi-based functional screen in mouse C2C12 
myoblasts. In determining the coverage of this screen, we did not limit the gene set to 
those reported to express in skeletal myocytes or muscles. We reasoned that such 
expression profiling was incomplete at the time of our screen and, in addition, some 
bona fide myogenic cytokines might be expressed at ultra-low levels in C2C12 cells but 
nevertheless functional in those cells, IL-4 being an example (our unpublished 
observations). Instead, the screen was performed with the TRC collection of lentivirus-
delivered shRNAs targeting mouse cytokine genes that were not yet reported to have a 
clear cell-autonomous myogenic function at the time that we initiated the screen. The 
pLKO vector-based TRC lentivirus system had been used extensively in our previous 
studies with C2C12 cells, and no toxicity had been found with infection by the control 
virus expressing a non-targeting hairpin sequence (e.g., [26]). 
A total of 134 genes were included in the primary screen, each targeted by 2 to 5 
distinct shRNA constructs (Table 1), some of which were commercially validated for 
efficient knockdown. C2C12 myoblasts were infected with lentiviruses expressing 
shRNAs in a 96-well format, selected with puromycin (for the lentiviral vector), and 
subsequently induced by serum withdrawal to undergo myogenic differentiation (Fig. 
1A). At the end of 3-day differentiation, cells were immuno-stained with the MF-20 
antibody, which recognizes all isoforms of sarcomeric myosin heavy chain (MHC) 
expressed in differentiating myocytes [27], and visually inspected under the microscope 
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for changes in myotube size and number. The primary screen was repeated 3 times, and 
genes with at least 2 shRNAs consistently eliciting a visible change in myotubes were 
considered primary hits. The primary hits were then subjected to secondary screen (Fig. 
1A). C2C12 cells were seeded in 12-well plates and infected by the shRNA-expressing 
lentiviruses, followed by puromycin selection and then differentiation for 3 days. Upon 
MHC and DAPI staining, the myocytes were quantified for three parameters: 
differentiation index defined as percentage of nuclei in MHC-positive cells, fusion index 
defined as percentage of nuclei in cells containing 2 or more nuclei (myotubes), and 
average myonuclei number per myotube as a measurement of myotube size.  
The chemokine Cxcl12 (also named SDF-1) was included in the screen as a 
positive control, since it is expressed by myoblasts and muscle tissues, and regulates 
myoblast migration and myocyte fusion through its receptor CXCR4 [22, 28-30]. Cxcl12 
was indeed recovered as a positive hit. Cxcl12 knockdown by two independent shRNAs 
resulted in smaller myotubes as indicated by decreased fusion index and average 
myonuclei number, without affecting the differentiation index (Fig. 1B&C). This result 
recapitulates the observation by Griffin et al. in mouse primary myoblasts [22], in full 
agreement with the reported role of Cxcl12-CXCR4 in regulating myocyte migration and 
fusion in both primary myoblast [22] and C2C12 cultures [28]. Of note, Odemis et al. [31] 
reported that recombinant SDF-1 inhibits C2C12 differentiation, which is at odds with our 
and others’ observations. Although clonal variation of C2C12 could be one explanation 
for this discrepancy, it should also be pointed out that the results of Odemis et al. came 
from adding recombinant SDF-1 to the cultures [31] whereas knockdown of SDF-1 was 
performed by Griffin et al. [22] and in our study. It is possible that SDF-1/Cxcl12 has 
multiple functions in regulating distinct steps of myogenic differentiation, and different 
experimental approaches may reveal different functions. Taken together, our 
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observation with Cxcl12 knockdown suggested that the experimental system was 
sufficiently robust for the screen. 
II.3.2. A variety of cytokines are candidate regulators of myoblast differentiation 
With 2 independent shRNAs for the same gene eliciting consistent phenotype as 
the criterion, our secondary screen led to the identification of 29 genes (22% of genes 
screened) as potential regulators of myoblast differentiation (Table 3). The results of 
myotube quantification for the knockdown of these genes are shown in Table 4, with 
additional data shown in Figs. 2-6. These genes represent a diverse collection of 
cytokines, including interleukins, TNF-related factors, chemokines, and other families. 
Interestingly, this candidate list consists of a higher number of potentially negative 
regulators (23) than positive ones (6) (Table 3). Although this may reflect the secretion of 
a large number of differentiation suppressors by myoblasts to maintain undifferentiated 
state and homeostasis, it is equally possible that our assay was biased toward revealing 
an enhanced differentiation phenotype due to sub-optimal differentiation conditions 
associated with the 96-well format screen.  
Despite the much smaller size of the positive regulator list, different classes of 
cytokines are found in each of the two lists, including TNF superfamily members, two 
major subclasses of chemokines (Ccl and Cxcl families), and others. However, the six 
interleukins identified are all potential negative regulators, in contrast to the reported 
positive functions of IL-4 [13] and IL-6 [14, 16] in myogenesis. This may not be surprising 
given the diverse functions of interleukins in other cellular contexts. 
Pavlath and colleagues recently reported the mRNA expression of numerous 
cytokines/ chemokines, their receptors, and related signaling molecules in myoblasts 
and/or differentiating myocytes [22]. Of the 51 cytokines/chemokines reported to be 
expressed, 45 are among the 134 genes covered by our RNAi screen, and 12 of them 
are in our positive hit list (Table 3) in addition to Cxcl12. Henningsen et al. identified 59 
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cytokines and growth factors secreted by differentiating C2C12 cells in a regulated 
manner [20], of which 14 were included in our screen and 2 emerged as positive hits 
(Ccl8 and Gdf15) other than Cxcl12. Because we had limited numbers of shRNAs per 
gene and adhered to the two-shRNA-per-gene criterion for scoring phenotypic changes, 
it is possible that we had missed some potential regulators among those shown to be 
expressed in myocytes. 
Based on the phenotypes defined by the 3 parameters – differentiation index, 
fusion index, and average myonuclei number per myotube, we have further divided the 
29 genes into 4 categories – class I-IV (Table 3). The different groups of cytokines likely 
impinge on various processes of differentiation via distinct mechanisms. Below we 
describe validation of representative cytokines from each group. 
II.3.3. Class I: cytokines required for initiation of differentiation 
Of the candidates for positive regulators, 4 cytokines (Ccl8, Cxcl9, Flt3L, and 
Tnfsf14) appeared to regulate an early stage of differentiation because their knockdown 
led to a decrease in differentiation index, as well as fusion index and myotube size 
(Tables 3 and 4). As a representative of this group, the results of Cxcl9 knockdown are 
shown in Fig. 2A&B. Furthermore, Cxcl9 expression in C2C12 cells, and its knockdown 
by two independent shRNAs, were confirmed at the mRNA level by RT-PCR (Fig. 2C). 
Cxcl9 is one of three interferon-induced ligands for the inflammatory chemokine receptor 
CXCR3, a key regulator of inflammation and a major player in autoimmune diseases [32, 
33]. But a function of Cxcl9 in muscle cells has yet to be reported. The other cytokines in 
this group, Ccl8, Flt3L and Tnfsf14, are also known as regulators of immune responses, 
and none has been reported to have a function in myogenesis. Although these 4 
cytokines elicit a similar phenotype when knocked down, they signal through distinct 
families of receptors – the Ccl8 and Cxcl9 receptors are GPCRs, the Flt3L receptor is a 
receptor tyrosine kinase, and the Tnfsf14 receptor belongs to the TNFR superfamily of 
 43 
trimeric receptors. Future characterization of the myogenic signaling pathways activated 
by these cytokines will likely be informative.  
II.3.4. Class II: cytokines regulating myocyte fusion 
The knockdown of Gdf15 and Scgb3a1 resulted in a distinct phenotype – 
reduced fusion index and myotube size with unchanged differentiation index, suggesting 
that, like Cxcl12, these two cytokines may regulate myocyte fusion. Myotube morphology 
and quantification of the indexes for Gdf15 knockdown by two independent shRNAs are 
shown in Fig. 3A&B. The expression and RNAi depletion of Gdf15 were confirmed by 
RT-PCR (Fig. 3C). shRNAs of Scgb3a1 yielded very similar results (Fig. 3D&E). 
However, Scgb3a1 mRNA was not detected by RT-PCR in C2C12 cells at any stage of 
differentiation, thus, the knockdown efficiency was not yet confirmed. Nevertheless, the 
consistent phenotype resulted from two independent shRNAs is likely an on-target 
effect. It is not impossible that a gene expressed at a level below detection has a key 
function. IL-4 is such an example. We confirmed the reported function of IL-4 as a fusion 
factor [13] in C2C12 cells by RNAi, but did not detect IL-4 mRNA in these cells even with 
commercially validated PCR primers (data not shown).  
Gdf15 belongs to the TGFβ superfamily, and has been associated with a range 
of biological processes, most notably erythropoiesis [34]. Scgb3a1, also known as HIN-1 
(high in normal-1), is found to be down-regulated at its gene expression level by 
hypermethylation in many human cancers [35, 36]. The biochemical mechanism of 
Scgb3a1 signaling remains elusive.  
It is noteworthy that both Gdf15 and Scgb3a1 knockdown resulted in stubby, ball-
like myotubes, a morphology resembling that of Brag2-knockdown myotubes reported by 
Pajcini et al., termed “bragball” [37]. Brag2 is a guanine nucleotide exchange factor, and 
it controls ARF6 activation and paxillin localization necessary for myoblast elongation 
and proper fusion [37]. It will be interesting for future studies to examine possible 
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connections between Gdf15 and Scgb3a1 signaling and the Brag2-ARF6-paxillin 
pathway. 
II.3.5. Class III & IV: cytokines inhibiting differentiation 
The majority of candidates identified fell into the group of potential negative 
regulators. As a representative of class III candidates (Table 3), Cxcl10 knockdown by 
two independent shRNAs was confirmed (Fig. 4A), and the enhanced myotube formation 
was evident from myotube morphology (Fig. 4B) and from an increase in all 3 
parameters – differentiation index, fusion index, and average size of myotubes (Fig. 4C). 
Interestingly, Cxcl10 shares the same receptor with Cxcl9 – CXCR3 [32, 33]. Our 
observations suggest that the two ligands may have opposite roles in myogenic 
differentiation (neither reported before). This may not be too surprising considering that 
the inter-relationship among the three CXCR3 ligands – Cxcl9, Cxcl10, and Cxcl11 – is 
complex in immune responses, and that redundancy, synergism, and antagonism are all 
possible [32]. Further investigation of these ligands and their receptor in myogenesis 
should prove interesting. 
The knockdown of another cytokine in class III, TNFα, had very similar effects on 
myotube formation (Fig. 5). TNFα, as a major proinflammatory cytokine, is secreted by 
immune cells at sites of muscle injury and found to suppress myoblast differentiation [38, 
39]. However, it has also been reported that mechanical stimulation leads to release of 
TNFα by myoblasts, which is necessary for myogenic differentiation [40]. It was not clear 
whether the two reported opposing functions of TNFα in myogenic differentiation could 
be attributed to the different sources of TNFα – in one case from the infiltrating immune 
cells and the other from muscle cells. Our results for the first time provide evidence that 
muscle cell-produced TNFα also inhibits differentiation. Apparently, the distinct biological 
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contexts – serum withdrawal versus mechanical stimulation – determine the specific cell-
autonomous function of TNFα.  
 The cytokines in class IV (Table 3) are also candidates of negative regulators. 
However, they are distinct from those in class III in that their knockdown led to increased 
differentiation and fusion indexes without a change in average myonuclei number in 
myotubes. Thus, the higher fusion index was manifested in increased myotube number 
rather than size. The data for IL1f9 knockdown are shown as an example (Fig. 6).  
Six additional cytokines were confirmed for their RNAi knockdown efficiencies. 
They are Cmtm5, Cxcl14, and Gdf3 in class III, and Ccl9, Ccl17, and IL-18 in class IV 
(Fig. 7). Together, these cytokines represent a group of novel inhibitors of myoblast 
differentiation that may control the homeostasis of muscle formation. 
 
II.4. Discussion 
Our RNAi screen has revealed a diverse group of cytokines as potential 
regulators of myogenic differentiation. It is important to point out that this functional 
screen specifically uncovers myoblast/muscle-secreted cytokines that regulate 
myogenesis in a cell-autonomous fashion. While our study was in progress, several 
other cytokines were reported to modulate myogenic differentiation. Cardiotrophin-1 (CT-
1) and Oncostatin M (OSM), both IL-6 family members, have been shown to suppress 
differentiation and muscle regeneration [41, 42]. On the other hand, granulocyte colony 
stimulating factor (G-CSF) stimulates myoblast proliferation and supports muscle 
regeneration [43]. It is not clear from the reports, however, whether any of those 
cytokines function cell-autonomously in skeletal muscle. All three genes were included in 
our RNAi screen; they did not make it to the positive hit list, but each had one shRNA 
eliciting a phenotype consistent with its reported myogenic function (data not shown). 
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Deeper interrogation of the genes in the initial list (Table 1) with better shRNA coverage 
may reveal additional candidates for myogenic factors.  
Together with the recent realization that numerous cytokines and chemokines 
are expressed in muscle cells [20-22], our findings suggest widespread involvement of 
these immunoregulatory molecules in myogenesis that is independent of their 
immunological functions. Further investigations will be necessary to uncover the cellular 
and molecular pathways by which these cytokines function in myogenesis, and may 
reveal novel therapeutic targets for improving muscle regeneration. 
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II.5. Figures and Tables 
 
Fig. II.1. RNAi screen procedure and control 
(A) A flow chart of the screening process. For the primary screen, lentiviruses 
expressing shRNAs against 134 genes, packaged in 96-well plates, were used to 
transduce C2C12 myoblasts seeded in 96-well plates. After 2 days of puromycin 
selection, the cells were induced to differentiate for 3 days, at the end of which they were 
fixed and stained for MHC and DAPI. shRNAs that induced morphological changes 
detectable by visual inspection were subjected to secondary screen with C2C12 cells 
seeded in 12-well plates, following the procedure described above. Quantification of 
myotube formation was then performed.  
(B) As a positive control, Cxcl12 was included in the screen and recovered as a positive 
hit. Shown are results of the secondary screen with two independent shRNAs. Cells 
were stained for MHC and DAPI, pseudo-colored green and red, respectively. A non-
targeting shRNA served as a negative control.  
(C) Myotube formation in B was quantified for differentiation index, fusion index and 
average nuclei number per myotube (see Material and Methods for definition). Data 
shown are mean ± SD (n = 3). Paired t test was performed to compare data to control. 
*P <0.05. Scale bar: 100 µm. 
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Fig. II.2. Knockdown of Cxcl9 impairs overall myoblast differentiation  
C2C12 myoblasts were transduced overnight with lentiviruses expressing shRNAs for 
Cxcl9, selected by puromycin for 2 days, and differentiated for 3 days.  
(A) At the end of differentiation, the cells were fixed and immuno-stained for MHC 
(green), and DAPI stain (red) identified nuclei. Scale bar: 100 µm.  
(B) Myotube formation in A was quantified for differentiation index, fusion index and 
average nuclei number per myotube.  
(C) Before differentiation, total RNA was isolated from transduced and selected cells, 
and subjected to RT-PCR. Data shown are mean ± SD (n = 3). Paired (for B) or one-
sample (for C) t tests were performed to compare data to control. *P <0.05. **P<0.01. 
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Fig. II.3. Knockdown of Gdf15 or Scgb3a1 impairs myoblast fusion 
C2C12 myoblasts were transduced overnight with lentiviruses expressing shRNAs for 
Gdf15 (A-C) or Scgb3a1 (D-E) as described in Fig. II.2 legend.  
(A) MHC (green) and DAPI (red) staining of Gdf15 knockdown cells at the end of 3-day 
differentiation.  
(B) Quantification of myotube formation shown in A.  
(C) RT-PCR results for Gdf15 mRNA.  
(D) MHC (green) and DAPI (red) staining of Scgb3a1 knockdown cells at the end of 3-
day differentiation.  
(E) Quantification of myotube formation shown in D. Data shown are mean ± SD (n = 3). 
One sample (C) or paired (B & E) t tests were performed to compare data to control. *P 
<0.05. **P<0.01. Scale bars: 100 µm. 
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Fig. II.4. Knockdown of Cxcl10 enhances myoblast differentiation  
C2C12 myoblasts were transduced overnight with lentiviruses expressing shRNAs for 
Cxcl10 as described in Fig. II.2 legend.  
(A) RT-PCR results for Cxcl12 mRNA.  
(B) MHC (green) and DAPI (red) staining of Cxcl10 knockdown cells at the end of 3-day 
differentiation. Scale bar: 100 µm.  
(C) Quantification of myotube formation shown in B. Data shown are mean ± SD (n = 3). 
One sample (A) or paired (C) t tests were performed to compare data to control. *P 
<0.05.  
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Fig. II.5. Knockdown of TNFα  enhances myoblast differentiation  
C2C12 myoblasts were transduced overnight with lentiviruses expressing shRNAs for 
TNFα as described in Fig. II.2 legend.  
(A) RT-PCR results for TNFα mRNA.  
(B) MHC (green) and DAPI (red) staining of TNFα knockdown cells at the end of 3-day 
differentiation. Scale bar: 100 µm.  
(C) Quantification of myotube formation shown in B. Data shown are mean ± SD (n = 3). 
One sample (A) or paired (C) t tests were performed to compare data to control. *P 
<0.05.  
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Fig. II.6. Knockdown of IL1f9 enhances myoblast differentiation without increasing 
myotube size  
C2C12 myoblasts were transduced overnight with lentiviruses expressing shRNAs for 
IL1f9 as described in Fig. II.2 legends.  
(A) RT-PCR results for IL1f9 mRNA.  
(B) MHC (green) and DAPI (red) staining of IL1f9 knockdown cells at the end of 3-day 
differentiation. Scale bar: 100 µm.  
(C) Quantification of myotube formation shown in B. Data shown are mean ± SD (n = 3). 
One sample (A) or paired (C) t tests were performed to compare data to control. *P 
<0.05.  
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Fig. II.7. Validation of expression and knockdown of 6 additional candidate genes 
C2C12 myoblasts were transduced overnight with lentiviruses expressing shRNAs as 
indicated. After 2-day puromycin selection, total RNA was extracted and subjected to 
RT-PCR. The results were quantified by densitometry and normalized to β-actin control. 
One sample t test was performed to compare each data point to control. Data shown are 
mean ± SD (n = 3).  *P <0.05. 
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Table II.1. List of cytokine genes and their shRNAs covered in RNAi screen 
Symbol Gene Description Clone ID Clone Name Hairpin Sequence 
A2m alpha-2-macroglobulin 
TRCN0000
080503 
NM_175628.2-
1511s1c1 
CCGGCCAGGCTCATTATATTCTAAACTCGAGTT
TAGAATATAATGAGCCTGGTTTTTG 
A2m alpha-2-macroglobulin 
TRCN0000
080504 
NM_175628.2-
3091s1c1 
CCGGCGGGTTACCAAAGACAATTAACTCGAGTT
AATTGTCTTTGGTAACCCGTTTTTG 
A2m alpha-2-macroglobulin 
TRCN0000
080505 
NM_175628.2-
230s1c1 
CCGGCCTCCTGTTCAACCACCTAAACTCGAGTT
TAGGTGGTTGAACAGGAGGTTTTTG 
A2m alpha-2-macroglobulin 
TRCN0000
080506 
NM_175628.2-
4031s1c1 
CCGGCCTCCAGACATCCTTGAAATACTCGAGTA
TTTCAAGGATGTCTGGAGGTTTTTG 
A2m alpha-2-macroglobulin 
TRCN0000
080507 
NM_175628.2-
2093s1c1 
CCGGCCTAAAGGATATGGGCTTAAACTCGAGTT
TAAGCCCATATCCTTTAGGTTTTTG 
Areg amphiregulin TRCN0000089050 
NM_009704.2-
649s1c1 
CCGGCGAATGCAGATACATCGAGAACTCGAGT
TCTCGATGTATCTGCATTCGTTTTTG 
Areg amphiregulin TRCN0000089051 
NM_009704.2-
449s1c1 
CCGGCCACAAATATCCGGCTATATTCTCGAGAA
TATAGCCGGATATTTGTGGTTTTTG 
Ccl1 
chemokine (C-
C motif) ligand 
1 
TRCN0000
077013 
NM_011329.1-
206s1c1 
CCGGGTTTATCCAGTGTTACAGAAACTCGAGTT
TCTGTAACACTGGATAAACTTTTTG 
Ccl1 
chemokine (C-
C motif) ligand 
1 
TRCN0000
077016 
NM_011329.1-
114s1c1 
CCGGGCCGTGTGGATACAGGATGTTCTCGAGA
ACATCCTGTATCCACACGGCTTTTTG 
Ccl1 
chemokine (C-
C motif) ligand 
1 
TRCN0000
077017 
NM_011329.1-
167s1c1 
CCGGCTGCTGCTTGAACACCTTGAACTCGAGTT
CAAGGTGTTCAAGCAGCAGTTTTTG 
Ccl11 
chemokine (C-
C motif) ligand 
11, Eotaxin 
TRCN0000
067458 
NM_011330.1-
206s1c1 
CCGGCAACAACAGATGCACCCTGAACTCGAGT
TCAGGGTGCATCTGTTGTTGTTTTTG 
Ccl11 
chemokine (C-
C motif) ligand 
11, Eotaxin 
TRCN0000
067460 
NM_011330.1-
176s1c1 
CCGGCACACTACTGAAGAGCTACAACTCGAGT
TGTAGCTCTTCAGTAGTGTGTTTTTG 
Ccl11 
chemokine (C-
C motif) ligand 
11, Eotaxin 
TRCN0000
067461 
NM_011330.1-
297s1c1 
CCGGGCCACAAAGCACCTGGACCAACTCGAGT
TGGTCCAGGTGCTTTGTGGCTTTTTG 
Ccl11 
chemokine (C-
C motif) ligand 
11, Eotaxin 
TRCN0000
067459 
NM_011330.1-
142s1c1 
CCGGGCTGCTTTATCATGACCAGTACTCGAGTA
CTGGTCATGATAAAGCAGCTTTTTG 
Ccl11 
chemokine (C-
C motif) ligand 
11, Eotaxin 
TRCN0000
067462 
NM_011330.1-
218s1c1 
CCGGCACCCTGAAAGCCATAGTCTTCTCGAGA
AGACTATGGCTTTCAGGGTGTTTTTG 
Ccl12 
chemokine (C-
C motif) ligand 
12 
TRCN0000
067653 
NM_011331.1-
206s1c1 
CCGGGCTGTGATCTTCAGGACCATACTCGAGT
ATGGTCCTGAAGATCACAGCTTTTTG 
Ccl12 
chemokine (C-
C motif) ligand 
12 
TRCN0000
067654 
NM_011331.1-
117s1c1 
CCGGCGTGCTGTTATAATGTTGTTACTCGAGTA
ACAACATTATAACAGCACGTTTTTG 
Ccl12 
chemokine (C-
C motif) ligand 
12 
TRCN0000
067655 
NM_011331.1-
63s1c1 
CCGGCCACCATCAGTCCTCAGGTATCTCGAGA
TACCTGAGGACTGATGGTGGTTTTTG 
Ccl17 
chemokine (C-
C motif) ligand 
17 
TRCN0000
067558 
NM_011332.2-
166s1c1 
CCGGAGGAAGTTGGTGAGCTGGTATCTCGAGA
TACCAGCTCACCAACTTCCTTTTTTG 
Ccl17 
chemokine (C-
C motif) ligand 
17 
TRCN0000
067559 
NM_011332.2-
279s1c1 
CCGGGAAGGCCATCAGATTGGTGAACTCGAGT
TCACCAATCTGATGGCCTTCTTTTTG 
Ccl17 
chemokine (C-
C motif) ligand 
17 
TRCN0000
067560 
NM_011332.2-
123s1c1 
CCGGCCGAGAGTGCTGCCTGGATTACTCGAGT
AATCCAGGCAGCACTCTCGGTTTTTG 
Ccl19 
chemokine (C-
C motif) ligand 
19 
TRCN0000
067608 
NM_011888.2-
376s1c1 
CCGGCTGTTGTGTTCACCACACTAACTCGAGTT
AGTGTGGTGAACACAACAGTTTTTG 
Ccl19 
chemokine (C-
C motif) ligand 
19 
TRCN0000
067609 
NM_011888.2-
461s1c1 
CCGGGAAGTCTTCTGCCAAGAACAACTCGAGT
TGTTCTTGGCAGAAGACTTCTTTTTG 
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Ccl19 
chemokine (C-
C motif) ligand 
19 
TRCN0000
067610 
NM_011888.2-
339s1c1 
CCGGCGCTACCTTCTTAATGAAGATCTCGAGAT
CTTCATTAAGAAGGTAGCGTTTTTG 
Ccl2 
chemokine (C-
C motif) ligand 
2, MCP1 
TRCN0000
034471 
NM_011333.1-
433s1c1 
CCGGGAATGTGAAGTTGACCCGTAACTCGAGT
TACGGGTCAACTTCACATTCTTTTTG 
Ccl2 
chemokine (C-
C motif) ligand 
2, MCP1 
TRCN0000
034472 
NM_011333.1-
190s1c1 
CCGGCTGCTACTCATTCACCAGCAACTCGAGTT
GCTGGTGAATGAGTAGCAGTTTTTG 
Ccl2 
chemokine (C-
C motif) ligand 
2, MCP1 
TRCN0000
034473 
NM_011333.1-
329s1c1 
CCGGGAATGGGTCCAGACATACATTCTCGAGA
ATGTATGTCTGGACCCATTCTTTTTG 
Ccl2 
chemokine (C-
C motif) ligand 
2, MCP1 
TRCN0000
034470 
NM_011333.1-
207s1c1 
CCGGGCAAGATGATCCCAATGAGTACTCGAGT
ACTCATTGGGATCATCTTGCTTTTTG 
Ccl2 
chemokine (C-
C motif) ligand 
2, MCP1 
TRCN0000
034469 
NM_011333.1-
362s1c1 
CCGGCGGAACCAAATGAGATCAGAACTCGAGT
TCTGATCTCATTTGGTTCCGTTTTTG 
Ccl20 
chemokine (C-
C motif) ligand 
20 
TRCN0000
067704 
NM_016960.1-
315s1c1 
CCGGCCTAAGAGTCAAGAAGATGTACTCGAGT
ACATCTTCTTGACTCTTAGGTTTTTG 
Ccl20 
chemokine (C-
C motif) ligand 
20 
TRCN0000
067706 
NM_016960.1-
274s1c1 
CCGGCCAAAGCAGAACTGGGTGAAACTCGAGT
TTCACCCAGTTCTGCTTTGGTTTTTG 
Ccl21a 
chemokine (C-
C motif) ligand 
21a 
TRCN0000
067788 
NM_011124.3-
401s1c1 
CCGGCTAAGTCTGGAAAGAAAGGAACTCGAGT
TCCTTTCTTTCCAGACTTAGTTTTTG 
Ccl21a 
chemokine (C-
C motif) ligand 
21a 
TRCN0000
067789 
NM_011124.3-
217s1c1 
CCGGAGGAAGCAAGAACCAAGTTTACTCGAGT
AAACTTGGTTCTTGCTTCCTTTTTTG 
Ccl21a 
chemokine (C-
C motif) ligand 
21a 
TRCN0000
067790 
NM_011124.3-
195s1c1 
CCGGCTACAGTATTGTCCGAGGCTACTCGAGT
AGCCTCGGACAATACTGTAGTTTTTG 
Ccl21b 
chemokine (C-
C motif) ligand 
21b 
TRCN0000
089509 
NM_011335.1-
419s1c1 
CCGGCTGAACAGACACAGCCCTCAACTCGAGT
TGAGGGCTGTGTCTGTTCAGTTTTTG 
Ccl21b 
chemokine (C-
C motif) ligand 
21b 
TRCN0000
089511 
NM_011335.1-
380s1c1 
CCGGCTGGAAAGAAAGGAAAGGGCTCTCGAGA
GCCCTTTCCTTTCTTTCCAGTTTTTG 
Ccl21b 
chemokine (C-
C motif) ligand 
21b 
TRCN0000
089512 
NM_011335.1-
129s1c1 
CCGGACAGGACTGCTGCCTTAAGTACTCGAGT
ACTTAAGGCAGCAGTCCTGTTTTTTG 
Ccl21b 
chemokine (C-
C motif) ligand 
21b 
TRCN0000
089508 
NM_011335.1-
594s1c1 
CCGGGCCCTGCTTCAACCATTACATCTCGAGAT
GTAATGGTTGAAGCAGGGCTTTTTG 
Ccl21b 
chemokine (C-
C motif) ligand 
21b 
TRCN0000
089510 
NM_011335.1-
254s1c1 
CCGGCTAAGCCTGAGCTATGTGCAACTCGAGT
TGCACATAGCTCAGGCTTAGTTTTTG 
Ccl21c 
chemokine (C-
C motif) ligand 
21c (leucine) 
TRCN0000
067748 
NM_023052.1-
172s1c1 
CCGGCGAGGCTATAGGAAGCAAGAACTCGAGT
TCTTGCTTCCTATAGCCTCGTTTTTG 
Ccl21c 
chemokine (C-
C motif) ligand 
21c (leucine) 
TRCN0000
067749 
NM_023052.1-
132s1c1 
CCGGCCTTAAGTACAGCCAGAAGAACTCGAGT
TCTTCTGGCTGTACTTAAGGTTTTTG 
Ccl21c 
chemokine (C-
C motif) ligand 
21c (leucine) 
TRCN0000
067750 
NM_023052.1-
256s1c1 
CCGGCTATGTGCAAACCCTGAGGAACTCGAGT
TCCTCAGGGTTTGCACATAGTTTTTG 
Ccl22 
chemokine (C-
C motif) ligand 
22 
TRCN0000
067833 
NM_009137.1-
1041s1c1 
CCGGGCTCAGAATCAGATTTCTTAACTCGAGTT
AAGAAATCTGATTCTGAGCTTTTTG 
Ccl22 
chemokine (C-
C motif) ligand 
22 
TRCN0000
067834 
NM_009137.1-
380s1c1 
CCGGGCTACTCCATAAACTGTCCTACTCGAGTA
GGACAGTTTATGGAGTAGCTTTTTG 
Ccl22 
chemokine (C-
C motif) ligand 
22 
TRCN0000
067835 
NM_009137.1-
257s1c1 
CCGGGCCATCACGTTTAGTGAAGGACTCGAGT
CCTTCACTAAACGTGATGGCTTTTTG 
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Ccl24 
chemokine (C-
C motif) ligand 
24 
TRCN0000
067878 
NM_019577.2-
248s1c1 
CCGGCATCACCAAGAAGGGCCATAACTCGAGT
TATGGCCCTTCTTGGTGATGTTTTTG 
Ccl24 
chemokine (C-
C motif) ligand 
24 
TRCN0000
067879 
NM_019577.2-
156s1c1 
CCGGACGTCCTTTATTTCCAAGAAACTCGAGTT
TCTTGGAAATAAAGGACGTTTTTTG 
Ccl24 
chemokine (C-
C motif) ligand 
24 
TRCN0000
067880 
NM_019577.2-
390s1c1 
CCGGCGTGGCAATAGCACCGAGGTTCTCGAGA
ACCTCGGTGCTATTGCCACGTTTTTG 
Ccl25 
chemokine (C-
C motif) ligand 
25 
TRCN0000
067915 
NM_009138.1-
295s1c1 
CCGGCCAGAAAGTAGTGTGTGGGAACTCGAGT
TCCCACACACTACTTTCTGGTTTTTG 
Ccl25 
chemokine (C-
C motif) ligand 
25 
TRCN0000
067917 
NM_009138.1-
281s1c1 
CCGGAGATTCTACTTCCGCCAGAAACTCGAGTT
TCTGGCGGAAGTAGAATCTTTTTTG 
Ccl28 
chemokine (C-
C motif) ligand 
28 
TRCN0000
065743 
NM_020279.2-
241s1c1 
CCGGGCTGTCATCCTTCATGTTAAACTCGAGTT
TAACATGAAGGATGACAGCTTTTTG 
Ccl28 
chemokine (C-
C motif) ligand 
28 
TRCN0000
065744 
NM_020279.2-
282s1c1 
CCGGCCCGCACAATCGTACTTTGAACTCGAGTT
CAAAGTACGATTGTGCGGGTTTTTG 
Ccl28 
chemokine (C-
C motif) ligand 
28 
TRCN0000
065745 
NM_020279.2-
152s1c1 
CCGGCTGAGGTGTCTCATCATGTTTCTCGAGAA
ACATGATGAGACACCTCAGTTTTTG 
Ccl3 
chemokine (C-
C motif) ligand 
3 
TRCN0000
068003 
NM_011337.1-
210s1c1 
CCGGCGCCAATTCATCGTTGACTATCTCGAGAT
AGTCAACGATGAATTGGCGTTTTTG 
Ccl3 
chemokine (C-
C motif) ligand 
3 
TRCN0000
068004 
NM_011337.1-
196s1c1 
CCGGGCCGGAAGATTCCACGCCAATCTCGAGA
TTGGCGTGGAATCTTCCGGCTTTTTG 
Ccl3 
chemokine (C-
C motif) ligand 
3 
TRCN0000
068005 
NM_011337.1-
275s1c1 
CCGGGACTAAGAGAAACCGGCAGATCTCGAGA
TCTGCCGGTTTCTCTTAGTCTTTTTG 
Ccl4 
chemokine (C-
C motif) ligand 
4 
TRCN0000
068048 
NM_013652.1-
408s1c1 
CCGGCCTGATGCTTCTCACTGAGAACTCGAGTT
CTCAGTGAGAAGCATCAGGTTTTTG 
Ccl4 
chemokine (C-
C motif) ligand 
4 
TRCN0000
068049 
NM_013652.1-
261s1c1 
CCGGGCTGTGGTATTCCTGACCAAACTCGAGT
TTGGTCAGGAATACCACAGCTTTTTG 
Ccl4 
chemokine (C-
C motif) ligand 
4 
TRCN0000
068050 
NM_013652.1-
203s1c1 
CCGGGCTTCACAGAAGCTTTGTGATCTCGAGAT
CACAAAGCTTCTGTGAAGCTTTTTG 
Ccl5 
chemokine (C-
C motif) ligand 
5 
TRCN0000
068098 
NM_013653.1-
327s1c1 
CCGGTCTTGATTCTGACCCTGTATACTCGAGTA
TACAGGGTCAGAATCAAGATTTTTG 
Ccl5 
chemokine (C-
C motif) ligand 
5 
TRCN0000
068099 
NM_013653.1-
265s1c1 
CCGGCCAGAGAAGAAGTGGGTTCAACTCGAGT
TGAACCCACTTCTTCTCTGGTTTTTG 
Ccl5 
chemokine (C-
C motif) ligand 
5 
TRCN0000
068100 
NM_013653.1-
225s1c1 
CCGGCGTGTTTGTCACTCGAAGGAACTCGAGT
TCCTTCGAGTGACAAACACGTTTTTG 
Ccl6 
chemokine (C-
C motif) ligand 
6 
TRCN0000
089328 
NM_009139.1-
701s1c1 
CCGGCGGGTAATATCTAGCTGAGATCTCGAGA
TCTCAGCTAGATATTACCCGTTTTTG 
Ccl6 
chemokine (C-
C motif) ligand 
6 
TRCN0000
089329 
NM_009139.1-
143s1c1 
CCGGCGTCGCTATAACCCTCCAATACTCGAGTA
TTGGAGGGTTATAGCGACGTTTTTG 
Ccl6 
chemokine (C-
C motif) ligand 
6 
TRCN0000
089330 
NM_009139.1-
114s1c1 
CCGGGCCTCATACAAGAAATGGAAACTCGAGT
TTCCATTTCTTGTATGAGGCTTTTTG 
Ccl7 
chemokine (C-
C motif) ligand 
7 
TRCN0000
068135 
NM_013654.2-
313s1c1 
CCGGCGAGGAGGCTATAGCATACTTCTCGAGA
AGTATGCTATAGCCTCCTCGTTTTTG 
Ccl7 
chemokine (C-
C motif) ligand 
7 
TRCN0000
068136 
NM_013654.2-
110s1c1 
CCGGGCCGCTGCTTTCAGCATCCAACTCGAGT
TGGATGCTGAAAGCAGCGGCTTTTTG 
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Ccl8 
chemokine (C-
C motif) ligand 
8 
TRCN0000
068173 
NM_021443.1-
322s1c1 
CCGGCTTGACCAGAAGTCTCAAATTCTCGAGAA
TTTGAGACTTCTGGTCAAGTTTTTG 
Ccl8 
chemokine (C-
C motif) ligand 
8 
TRCN0000
068176 
NM_021443.1-
207s1c1 
CCGGCGAGAGAATCAACAATATCCACTCGAGT
GGATATTGTTGATTCTCTCGTTTTTG 
Ccl8 
chemokine (C-
C motif) ligand 
8 
TRCN0000
068174 
NM_021443.1-
162s1c1 
CCGGTCATGTACTAAAGCTGAAGATCTCGAGAT
CTTCAGCTTTAGTACATGATTTTTG 
Ccl8 
chemokine (C-
C motif) ligand 
8 
TRCN0000
068177 
NM_021443.1-
312s1c1 
CCGGCATGGAGATCCTTGACCAGAACTCGAGT
TCTGGTCAAGGATCTCCATGTTTTTG 
Ccl9 
chemokine (C-
C motif) ligand 
9 
TRCN0000
077008 
NM_011338.1-
915s1c1 
CCGGGCCCTTTAGTTAGTAGTATTTCTCGAGAA
ATACTACTAACTAAAGGGCTTTTTG 
Ccl9 
chemokine (C-
C motif) ligand 
9 
TRCN0000
077009 
NM_011338.1-
327s1c1 
CCGGCCTGTCCTATAACTCACGGATCTCGAGAT
CCGTGAGTTATAGGACAGGTTTTTG 
Ccl9 
chemokine (C-
C motif) ligand 
9 
TRCN0000
077010 
NM_011338.1-
457s1c1 
CCGGCGGAGAGTTCAGAGATGCATTCTCGAGA
ATGCATCTCTGAACTCTCCGTTTTTG 
Cd40lg CD40 ligand TRCN0000066583 
NM_011616.2-
871s1c1 
CCGGCCTGTGTTGAACTGCCTATTTCTCGAGAA
ATAGGCAGTTCAACACAGGTTTTTG 
Cd40lg CD40 ligand TRCN0000066584 
NM_011616.2-
286s1c1 
CCGGGAAGACCTTGTCAAGGATATACTCGAGT
ATATCCTTGACAAGGTCTTCTTTTTG 
Cd40lg CD40 ligand TRCN0000066585 
NM_011616.2-
426s1c1 
CCGGGTGGGCCAAGAAAGGATATTACTCGAGT
AATATCCTTTCTTGGCCCACTTTTTG 
Cer1 
57erberus 1 
homolog 
(Xenopus 
laevis) 
TRCN0000
098175 
NM_009887.1-
1017s1c1 
CCGGCCCTCTCTCTTCTCTCTATTTCTCGAGAA
ATAGAGAGAAGAGAGAGGGTTTTTG 
Cer1 
57erberus 1 
homolog 
(Xenopus 
laevis) 
TRCN0000
098176 
NM_009887.1-
484s1c1 
CCGGGCATCGGTTCATGTTCAGAAACTCGAGTT
TCTGAACATGAACCGATGCTTTTTG 
Cer1 
57erberus 1 
homolog 
(Xenopus 
laevis) 
TRCN0000
098177 
NM_009887.1-
640s1c1 
CCGGCTTTGGCAAATGCAGTTCCATCTCGAGAT
GGAACTGCATTTGCCAAAGTTTTTG 
Cklf chemokine-like factor, CKLF 
TRCN0000
089298 
NM_029295.1-
308s1c1 
CCGGCGTGTGGACTTGACAAGATAACTCGAGT
TATCTTGTCAAGTCCACACGTTTTTG 
Cklf chemokine-like factor, CKLF 
TRCN0000
089299 
NM_029295.1-
462s1c1 
CCGGCCTGACAGTAACATGTACTATCTCGAGAT
AGTACATGTTACTGTCAGGTTTTTG 
Cklf chemokine-like factor, CKLF 
TRCN0000
089300 
NM_029295.1-
152s1c1 
CCGGCCTTCTGCTGTACTCTGAAATCTCGAGAT
TTCAGAGTACAGCAGAAGGTTTTTG 
Cklf chemokine-like factor, CKLF 
TRCN0000
089301 
NM_029295.1-
307s1c1 
CCGGACGTGTGGACTTGACAAGATACTCGAGT
ATCTTGTCAAGTCCACACGTTTTTTG 
Cklf chemokine-like factor, CKLF 
TRCN0000
089302 
NM_029295.1-
397s1c1 
CCGGGTGTCTGTGTTGGCTCTAATACTCGAGTA
TTAGAGCCAACACAGACACTTTTTG 
Clcf1 
cardiotrophin-
like cytokine 
factor 1, CLCF1 
TRCN0000
088928 
NM_019952.1-
173s1c1 
CCGGGCTCTTAATCGCACAGGAGATCTCGAGA
TCTCCTGTGCGATTAAGAGCTTTTTG 
Clcf1 
cardiotrophin-
like cytokine 
factor 1, CLCF1 
TRCN0000
088930 
NM_019952.1-
628s1c1 
CCGGCCTCCAGAAGATGGATGACTTCTCGAGA
AGTCATCCATCTTCTGGAGGTTTTTG 
Clcf1 
cardiotrophin-
like cytokine 
factor 1, CLCF1 
TRCN0000
088931 
NM_019952.1-
468s1c1 
CCGGCCACAGCTGAACTCCGACGTACTCGAGT
ACGTCGGAGTTCAGCTGTGGTTTTTG 
Clcf1 
cardiotrophin-
like cytokine 
factor 1, CLCF1 
TRCN0000
088929 
NM_019952.1-
360s1c1 
CCGGTCAACTTGGAAGTGTGGCGAACTCGAGT
TCGCCACACTTCCAAGTTGATTTTTG 
Clcf1 
cardiotrophin-
like cytokine 
factor 1, CLCF1 
TRCN0000
088932 
NM_019952.1-
295s1c1 
CCGGCCCTTTCAACGAGCCTGACTTCTCGAGA
AGTCAGGCTCGTTGAAAGGGTTTTTG 
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Cmtm2a 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 2A 
TRCN0000
241352 
NM_027022.4-
474s21c1 
CCGGTTCCTTGGAGGTGGCATATACCTCGAGG
TATATGCCACCTCCAAGGAATTTTTG 
Cmtm2a 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 2A 
TRCN0000
241353 
NM_027022.4-
803s21c1 
CCGGCAACCTTAAACCTTAACTAACCTCGAGGT
TAGTTAAGGTTTAAGGTTGTTTTTG 
Cmtm2a 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 2A 
TRCN0000
241354 
NM_027022.4-
578s21c1 
CCGGCATCGACATGTTACTTCAATTCTCGAGAA
TTGAAGTAACATGTCGATGTTTTTG 
Cmtm2b 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 2B 
TRCN0000
246548 
NM_028524.2-
317s21c1 
CCGGGTAATCCTGCTGCTTACTATGCTCGAGCA
TAGTAAGCAGCAGGATTACTTTTTG 
Cmtm2b 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 2B 
TRCN0000
246549 
NM_028524.2-
601s21c1 
CCGGTCGAAAGTTTATTCTACTTACCTCGAGGT
AAGTAGAATAAACTTTCGATTTTTG 
Cmtm2b 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 2B 
TRCN0000
246550 
NM_028524.2-
452s21c1 
CCGGTTCCTCATAGGTGGTATATTCCTCGAGGA
ATATACCACCTATGAGGAATTTTTG 
Cmtm3 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 3 
TRCN0000
090318 
NM_024217.2-
1402s1c1 
CCGGGCGGTTACTGTGTGTGTCTTTCTCGAGA
AAGACACACACAGTAACCGCTTTTTG 
Cmtm3 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 3 
TRCN0000
090319 
NM_024217.2-
564s1c1 
CCGGGCCACAATTGTGTTCGCAATTCTCGAGAA
TTGCGAACACAATTGTGGCTTTTTG 
Cmtm3 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 3 
TRCN0000
090320 
NM_024217.2-
381s1c1 
CCGGGCCGTTTACTTCCTCTTTGCTCTCGAGAG
CAAAGAGGAAGTAAACGGCTTTTTG 
Cmtm3 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 3 
TRCN0000
090322 
NM_024217.2-
612s1c1 
CCGGGCCAAATTCCTCAAGCAAGGACTCGAGT
CCTTGCTTGAGGAATTTGGCTTTTTG 
Cmtm3 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 3 
TRCN0000
090321 
NM_024217.2-
295s1c1 
CCGGCGGGTCTTTCATTCATCACCTCTCGAGA
GGTGATGAATGAAAGACCCGTTTTTG 
Cmtm4 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 4 
TRCN0000
126359 
NM_153582.3-
908s1c1 
CCGGCCGACTTTAATGACTGCTCTACTCGAGTA
GAGCAGTCATTAAAGTCGGTTTTTG 
Cmtm4 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 4 
TRCN0000
126360 
NM_153582.3-
506s1c1 
CCGGCGGAAATTGCTGCCGTGATATCTCGAGA
TATCACGGCAGCAATTTCCGTTTTTG 
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Cmtm4 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 4 
TRCN0000
126361 
NM_153582.3-
401s1c1 
CCGGCCCAGATCAACTGGAATCTAACTCGAGTT
AGATTCCAGTTGATCTGGGTTTTTG 
Cmtm5 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 5 
TRCN0000
090798 
NM_026066.1-
707s1c1 
CCGGCCCATCTTTGTCATCTTTGAACTCGAGTT
CAAAGATGACAAAGATGGGTTTTTG 
Cmtm5 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 5 
TRCN0000
090799 
NM_026066.1-
579s1c1 
CCGGGTCTCCGTCTTTGCCTATGATCTCGAGAT
CATAGGCAAAGACGGAGACTTTTTG 
Cmtm5 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 5 
TRCN0000
090800 
NM_026066.1-
608s1c1 
CCGGGATCTACCGAACTGAGCTGATCTCGAGA
TCAGCTCAGTTCGGTAGATCTTTTTG 
Cmtm6 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 6 
TRCN0000
121352 
NM_026036.1-
963s1c1 
CCGGCCGGAGATTTAATGAGTGTTTCTCGAGAA
ACACTCATTAAATCTCCGGTTTTTG 
Cmtm6 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 6 
TRCN0000
121354 
NM_026036.1-
426s1c1 
CCGGCCTCAGCTGAAATTGCTGCAACTCGAGT
TGCAGCAATTTCAGCTGAGGTTTTTG 
Cmtm6 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 6 
TRCN0000
121355 
NM_026036.1-
526s1c1 
CCGGGCTGAGAAAGCCCGAGAACAACTCGAGT
TGTTCTCGGGCTTTCTCAGCTTTTTG 
Cmtm7 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 7 
TRCN0000
127226 
NM_133978.1-
345s1c1 
CCGGGCACTATTTAATCGGCACGCTCTCGAGA
GCGTGCCGATTAAATAGTGCTTTTTG 
Cmtm7 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 7 
TRCN0000
127227 
NM_133978.1-
383s1c1 
CCGGCCATAGTGATAGCCTCCAAGACTCGAGT
CTTGGAGGCTATCACTATGGTTTTTG 
Cmtm7 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 7 
TRCN0000
127228 
NM_133978.1-
494s1c1 
CCGGTCACCTGTATAACCCAGTCTTCTCGAGAA
GACTGGGTTATACAGGTGATTTTTG 
Cmtm8 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 8 
TRCN0000
104920 
NM_027294.1-
783s1c1 
CCGGCCAGAACGAATCCCACTGTTACTCGAGT
AACAGTGGGATTCGTTCTGGTTTTTG 
Cmtm8 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 8 
TRCN0000
104921 
NM_027294.1-
503s1c1 
CCGGACCCTGACTTACACCAGGATTCTCGAGA
ATCCTGGTGTAAGTCAGGGTTTTTTG 
Cmtm8 
CKLF-like 
MARVEL 
transmembrane 
domain 
containing 8 
TRCN0000
104922 
NM_027294.1-
691s1c1 
CCGGCTATGCTGGAAACACGTACTTCTCGAGA
AGTACGTGTTTCCAGCATAGTTTTTG 
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Cntf 
ciliary 
neurotrophic 
factor 
TRCN0000
065813 
NM_170786.1-
597s1c1 
CCGGCCTACCAGCTAGAGGAGTTAACTCGAGT
TAACTCCTCTAGCTGGTAGGTTTTTG 
Cntf 
ciliary 
neurotrophic 
factor 
TRCN0000
065814 
NM_170786.1-
335s1c1 
CCGGGCTCTTATGGAATCTTATGTACTCGAGTA
CATAAGATTCCATAAGAGCTTTTTG 
Csf1 
Macrophage 
colony-
stimulating 
factor, M-CSF 
TRCN0000
065908 
NM_007778.1-
1940s1c1 
CCGGGCCTACCAAGACTGGATGAAACTCGAGT
TTCATCCAGTCTTGGTAGGCTTTTTG 
Csf1 
Macrophage 
colony-
stimulating 
factor, M-CSF 
TRCN0000
065911 
NM_007778.1-
1692s1c1 
CCGGCCTCCTGTTCTACAAGTGGAACTCGAGTT
CCACTTGTAGAACAGGAGGTTTTTG 
Csf1 
Macrophage 
colony-
stimulating 
factor, M-CSF 
TRCN0000
065912 
NM_007778.1-
344s1c1 
CCGGCATGCCAGATTGCCTTTGAATCTCGAGAT
TCAAAGGCAATCTGGCATGTTTTTG 
Csf1 
Macrophage 
colony-
stimulating 
factor, M-CSF 
TRCN0000
065909 
NM_007778.1-
1411s1c1 
CCGGGCTCAGTTACTGCTTCCCAAACTCGAGTT
TGGGAAGCAGTAACTGAGCTTTTTG 
Csf1 
Macrophage 
colony-
stimulating 
factor, M-CSF 
TRCN0000
065910 
NM_007778.1-
942s1c1 
CCGGCGAGTCAACAGAGCAACCAAACTCGAGT
TTGGTTGCTCTGTTGACTCGTTTTTG 
Csf2 
Granulocyte-
macrophage 
colony-
stimulating 
factor, GM-CSF 
TRCN0000
054618 
NM_009969.2-
385s1c1 
CCGGCGGATTTCATAGACAGCCTTACTCGAGTA
AGGCTGTCTATGAAATCCGTTTTTG 
Csf2 
Granulocyte-
macrophage 
colony-
stimulating 
factor, GM-CSF 
TRCN0000
054619 
NM_009969.2-
200s1c1 
CCGGCGTCTCTAACGAGTTCTCCTTCTCGAGAA
GGAGAACTCGTTAGAGACGTTTTTG 
Csf2 
Granulocyte-
macrophage 
colony-
stimulating 
factor, GM-CSF 
TRCN0000
054620 
NM_009969.2-
314s1c1 
CCGGAGCCAGCTACTACCAGACATACTCGAGT
ATGTCTGGTAGTAGCTGGCTTTTTTG 
Csf2 
Granulocyte-
macrophage 
colony-
stimulating 
factor, GM-CSF 
TRCN0000
054621 
NM_009969.2-
170s1c1 
CCGGGCCTGTCACATTGAATGAAGACTCGAGT
CTTCATTCAATGTGACAGGCTTTTTG 
Csf2 
Granulocyte-
macrophage 
colony-
stimulating 
factor, GM-CSF 
TRCN0000
054622 
NM_009969.2-
122s1c1 
CCGGGAAGCATGTAGAGGCCATCAACTCGAGT
TGATGGCCTCTACATGCTTCTTTTTG 
Csf3 
Granulocyte 
colony-
stimulating 
factor, G-CSF 
TRCN0000
066008 
NM_009971.1-
441s1c1 
CCGGTGCAGGCTCTATCGGGTATTTCTCGAGA
AATACCCGATAGAGCCTGCATTTTTG 
Csf3 
Granulocyte 
colony-
stimulating 
factor, G-CSF 
TRCN0000
066009 
NM_009971.1-
494s1c1 
CCGGCAGCTGGATGTTGCCAACTTTCTCGAGA
AAGTTGGCAACATCCAGCTGTTTTTG 
Csf3 
Granulocyte 
colony-
stimulating 
factor, G-CSF 
TRCN0000
066010 
NM_009971.1-
225s1c1 
CCGGCCCTGGAGCAAGTGAGGAAGACTCGAGT
CTTCCTCACTTGCTCCAGGGTTTTTG 
 
 
 61 
Table II.1. (continued) 
 
Csf3 
Granulocyte 
colony-
stimulating 
factor, G-CSF 
TRCN0000
066011 
NM_009971.1-
628s1c1 
CCGGCCTGGCCATTTCGTACCTGCACTCGAGT
GCAGGTACGAAATGGCCAGGTTTTTG 
Csf3 
Granulocyte 
colony-
stimulating 
factor, G-CSF 
TRCN0000
066012 
NM_009971.1-
274s1c1 
CCGGGCAGTTGTGTGCCACCTACAACTCGAGT
TGTAGGTGGCACACAACTGCTTTTTG 
Ctf1 cardiotrophin 1, CT-1 
TRCN0000
066059 
NM_007795.1-
125s1c1 
CCGGCTCCTGACCAAATATGCAGAACTCGAGTT
CTGCATATTTGGTCAGGAGTTTTTG 
Ctf1 cardiotrophin 1, CT-1 
TRCN0000
066062 
NM_007795.1-
490s1c1 
CCGGCGCCACCCTCTTCACGGCCAACTCGAGT
TGGCCGTGAAGAGGGTGGCGTTTTTG 
Ctf1 cardiotrophin 1, CT-1 
TRCN0000
066058 
NM_007795.1-
140s1c1 
CCGGGCAGAACAACTTCTGGAGGAACTCGAGT
TCCTCCAGAAGTTGTTCTGCTTTTTG 
Ctf1 cardiotrophin 1, CT-1 
TRCN0000
066060 
NM_007795.1-
49s1c1 
CCGGCCACCAGACTGACTCCTCAATCTCGAGA
TTGAGGAGTCAGTCTGGTGGTTTTTG 
Ctf1 cardiotrophin 1, CT-1 
TRCN0000
066061 
NM_007795.1-
559s1c1 
CCGGCGGCCTCTATGGCGAGTGGGTCTCGAGA
CCCACTCGCCATAGAGGCCGTTTTTG 
Ctf2 cardiotrophin 2 TRCN0000190485 
NM_198858.1-
371s1c1 
CCGGGACGACCAGAGTTATCTGAATCTCGAGA
TTCAGATAACTCTGGTCGTCTTTTTTG 
Ctf2 cardiotrophin 2 TRCN0000190887 
NM_198858.1-
628s1c1 
CCGGCAAGGCTAAGTACTCAGCATACTCGAGT
ATGCTGAGTACTTAGCCTTGTTTTTTG 
Cx3cl1 
chemokine (C-
X3-C motif) 
ligand 1 
TRCN0000
065505 
NM_009142.2-
120s1c1 
CCGGCGGCATGACGAAATGCGAAATCTCGAGA
TTTCGCATTTCGTCATGCCGTTTTTG 
Cx3cl1 
chemokine (C-
X3-C motif) 
ligand 1 
TRCN0000
065506 
NM_009142.2-
579s1c1 
CCGGGCCTCAGAGCATTGGAAGTTTCTCGAGA
AACTTCCAATGCTCTGAGGCTTTTTG 
Cx3cl1 
chemokine (C-
X3-C motif) 
ligand 1 
TRCN0000
065507 
NM_009142.2-
827s1c1 
CCGGAGGAGATAAACCCAGTTCATACTCGAGT
ATGAACTGGGTTTATCTCCTTTTTTG 
Cxcl1 
chemokine (C-
X-C motif) 
ligand 1, KC 
TRCN0000
067209 
NM_008176.1-
130s1c1 
CCGGCCTCAAGAACATCCAGAGCTTCTCGAGA
AGCTCTGGATGTTCTTGAGGTTTTTG 
Cxcl1 
chemokine (C-
X-C motif) 
ligand 1, KC 
TRCN0000
067210 
NM_008176.1-
107s1c1 
CCGGCTGCAGACCATGGCTGGGATTCTCGAGA
ATCCCAGCCATGGTCTGCAGTTTTTG 
Cxcl1 
chemokine (C-
X-C motif) 
ligand 1, KC 
TRCN0000
067212 
NM_008176.1-
236s1c1 
CCGGGAAGCTCCCTTGGTTCAGAAACTCGAGT
TTCTGAACCAAGGGAGCTTCTTTTTG 
Cxcl1 
chemokine (C-
X-C motif) 
ligand 1, KC 
TRCN0000
067208 
NM_008176.1-
654s1c1 
CCGGGCTGTGTTTGTATGTCTTGAACTCGAGTT
CAAGACATACAAACACAGCTTTTTG 
Cxcl1 
chemokine (C-
X-C motif) 
ligand 1, KC 
TRCN0000
067211 
NM_008176.1-
124s1c1 
CCGGGATTCACCTCAAGAACATCCACTCGAGT
GGATGTTCTTGAGGTGAATCTTTTTG 
Cxcl10 
chemokine (C-
X-C motif) 
ligand 10 
TRCN0000
068208 
NM_021274.1-
895s1c1 
CCGGGCATTGTATATGGAAGAACTTCTCGAGAA
GTTCTTCCATATACAATGCTTTTTG 
Cxcl10 
chemokine (C-
X-C motif) 
ligand 10 
TRCN0000
068209 
NM_021274.1-
124s1c1 
CCGGCCGCTGCAACTGCATCCATATCTCGAGA
TATGGATGCAGTTGCAGCGGTTTTTG 
Cxcl10 
chemokine (C-
X-C motif) 
ligand 10 
TRCN0000
068212 
NM_021274.1-
268s1c1 
CCGGTCCGGAATCTAAGACCATCAACTCGAGTT
GATGGTCTTAGATTCCGGATTTTTG 
Cxcl11 
chemokine (C-
X-C motif) 
ligand 11 
TRCN0000
068243 
NM_019494.1-
310s1c1 
CCGGCGCCTCATAATGCAGGCAATACTCGAGT
ATTGCCTGCATTATGAGGCGTTTTTG 
Cxcl11 
chemokine (C-
X-C motif) 
ligand 11 
TRCN0000
068244 
NM_019494.1-
206s1c1 
CCGGCTTCTGTAATTTACCCGAGTACTCGAGTA
CTCGGGTAAATTACAGAAGTTTTTG 
Cxcl11 
chemokine (C-
X-C motif) 
ligand 11 
TRCN0000
068245 
NM_019494.1-
253s1c1 
CCGGGTTACTATGAAGGCTCATAAACTCGAGTT
TATGAGCCTTCATAGTAACTTTTTG 
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Cxcl12 
chemokine (C-
X-C motif) 
ligand 12 
TRCN0000
184347 
NM_013655.2-
315s1c1 
CCGGGATCCAAGAGTACCTGGAGAACTCGAGT
TCTCCAGGTACTCTTGGATCTTTTTTG 
Cxcl12 
chemokine (C-
X-C motif) 
ligand 12 
TRCN0000
196073 
NM_013655.2-
205s1c1 
CCGGGCCAACGTCAAGCATCTGAAACTCGAGT
TTCAGATGCTTGACGTTGGCTTTTTTG 
Cxcl12 
chemokine (C-
X-C motif) 
ligand 12 
TRCN0000
195944 
NM_013655.2-
132s1c1 
CCGGCATCAGTGACGGTAAACCAGTCTCGAGA
CTGGTTTACCGTCACTGATGTTTTTTG 
Cxcl12 
chemokine (C-
X-C motif) 
ligand 12 
TRCN0000
178772 
NM_013655.2-
268s1c1 
CCGGCTGAAGAACAACAACAGACAACTCGAGT
TGTCTGTTGTTGTTCTTCAGTTTTTTG 
Cxcl12 
chemokine (C-
X-C motif) 
ligand 12 
TRCN0000
183874 
NM_013655.2-
319s1c1 
CCGGCAAGAGTACCTGGAGAAAGCTCTCGAGA
GCTTTCTCCAGGTACTCTTGTTTTTTG 
Cxcl13 
chemokine (C-
X-C motif) 
ligand 13 
TRCN0000
068278 
NM_018866.1-
270s1c1 
CCGGGCCAAATGGTTACAAAGATTACTCGAGTA
ATCTTTGTAACCATTTGGCTTTTTG 
Cxcl13 
chemokine (C-
X-C motif) 
ligand 13 
TRCN0000
068279 
NM_018866.1-
162s1c1 
CCGGCTAAACATCATAGATCGGATTCTCGAGAA
TCCGATCTATGATGTTTAGTTTTTG 
Cxcl13 
chemokine (C-
X-C motif) 
ligand 13 
TRCN0000
068280 
NM_018866.1-
102s1c1 
CCGGGAAGCCCATTACACAAACTTACTCGAGTA
AGTTTGTGTAATGGGCTTCTTTTTG 
Cxcl14 
chemokine (C-
X-C motif) 
ligand 14 
TRCN0000
065368 
NM_019568.1-
628s1c1 
CCGGCAAGTGGTACAATGCCTGGAACTCGAGT
TCCAGGCATTGTACCACTTGTTTTTG 
Cxcl14 
chemokine (C-
X-C motif) 
ligand 14 
TRCN0000
065369 
NM_019568.1-
526s1c1 
CCGGCTGCGAGGAGAAGATGGTTATCTCGAGA
TAACCATCTTCTCCTCGCAGTTTTTG 
Cxcl14 
chemokine (C-
X-C motif) 
ligand 14 
TRCN0000
065370 
NM_019568.1-
610s1c1 
CCGGGAGCACCAAACGCTTCATCAACTCGAGT
TGATGAAGCGTTTGGTGCTCTTTTTG 
Cxcl15 
chemokine (C-
X-C motif) 
ligand 15 
TRCN0000
112211 
NM_011339.1-
259s1c1 
CCGGCCAATTACTAACAGGTTCCTACTCGAGTA
GGAACCTGTTAGTAATTGGTTTTTG 
Cxcl15 
chemokine (C-
X-C motif) 
ligand 15 
TRCN0000
112212 
NM_011339.1-
258s1c1 
CCGGCCCAATTACTAACAGGTTCCTCTCGAGA
GGAACCTGTTAGTAATTGGGTTTTTG 
Cxcl15 
chemokine (C-
X-C motif) 
ligand 15 
TRCN0000
112213 
NM_011339.1-
159s1c1 
CCGGGACCATTTACTGCAACAGAAACTCGAGTT
TCTGTTGCAGTAAATGGTCTTTTTG 
Cxcl16 
chemokine (C-
X-C motif) 
ligand 16 
TRCN0000
065695 
NM_023158.3-
180s1c1 
CCGGGCTGGAAGTTGTTCTTGTGATCTCGAGAT
CACAAGAACAACTTCCAGCTTTTTG 
Cxcl16 
chemokine (C-
X-C motif) 
ligand 16 
TRCN0000
065696 
NM_023158.3-
618s1c1 
CCGGGAGGCAAATGAGAAACAGCAACTCGAGT
TGCTGTTTCTCATTTGCCTCTTTTTG 
Cxcl2 
chemokine (C-
X-C motif) 
ligand 2 
TRCN0000
067258 
NM_009140.1-
172s1c1 
CCGGGCCAAGGGTTGACTTCAAGAACTCGAGT
TCTTGAAGTCAACCCTTGGCTTTTTG 
Cxcl2 
chemokine (C-
X-C motif) 
ligand 2 
TRCN0000
067259 
NM_009140.1-
252s1c1 
CCGGCCACTCTCAAGGGCGGTCAAACTCGAGT
TTGACCGCCCTTGAGAGTGGTTTTTG 
Cxcl2 
chemokine (C-
X-C motif) 
ligand 2 
TRCN0000
067260 
NM_009140.1-
325s1c1 
CCGGACTGAACAAAGGCAAGGCTAACTCGAGT
TAGCCTTGCCTTTGTTCAGTTTTTTG 
Cxcl5 
chemokine (C-
X-C motif) 
ligand 5 
TRCN0000
054598 
NM_009141.1-
254s1c1 
CCGGTCCCAAATTGATCGCTAATTTCTCGAGAA
ATTAGCGATCAATTTGGGATTTTTG 
Cxcl5 
chemokine (C-
X-C motif) 
ligand 5 
TRCN0000
054601 
NM_009141.1-
312s1c1 
CCGGGAAGTCATAGCTAAACTGAAACTCGAGTT
TCAGTTTAGCTATGACTTCTTTTTG 
Cxcl9 
chemokine (C-
X-C motif) 
ligand 9 
TRCN0000
067293 
NM_008599.1-
1075s1c1 
CCGGCCATCTTCAGAGCTTATTCTACTCGAGTA
GAATAAGCTCTGAAGATGGTTTTTG 
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Cxcl9 
chemokine (C-
X-C motif) 
ligand 9 
TRCN0000
067294 
NM_008599.1-
284s1c1 
CCGGGCTACACTGAAGAACGGAGATCTCGAGA
TCTCCGTTCTTCAGTGTAGCTTTTTG 
Cxcl9 
chemokine (C-
X-C motif) 
ligand 9 
TRCN0000
067295 
NM_008599.1-
450s1c1 
CCGGGTCGTCGTTCAAGGAAGACTACTCGAGT
AGTCTTCCTTGAACGACGACTTTTTG 
Ebi3 
Epstein-Barr 
virus induced 
gene 3 
TRCN0000
089278 
NM_015766.2-
1028s1c1 
CCGGGCTCCGAAGCACTGGATAATTCTCGAGA
ATTATCCAGTGCTTCGGAGCTTTTTG 
Ebi3 
Epstein-Barr 
virus induced 
gene 3 
TRCN0000
089279 
NM_015766.2-
846s1c1 
CCGGGCTCAGGACCTCACAGATTATCTCGAGA
TAATCTGTGAGGTCCTGAGCTTTTTG 
Ebi3 
Epstein-Barr 
virus induced 
gene 3 
TRCN0000
089280 
NM_015766.2-
413s1c1 
CCGGCACGTCCTTCATTGCCACTTACTCGAGTA
AGTGGCAATGAAGGACGTGTTTTTG 
Fasl 
Fas ligand 
(TNF 
superfamily, 
member 6) 
TRCN0000
066638 
NM_010177.2-
1604s1c1 
CCGGGCACAAATCATTCTCTACATACTCGAGTA
TGTAGAGAATGATTTGTGCTTTTTG 
Fasl 
Fas ligand 
(TNF 
superfamily, 
member 6) 
TRCN0000
066639 
NM_010177.2-
557s1c1 
CCGGCCAACCAAAGCCTTAAAGTATCTCGAGAT
ACTTTAAGGCTTTGGTTGGTTTTTG 
Fasl 
Fas ligand 
(TNF 
superfamily, 
member 6) 
TRCN0000
066640 
NM_010177.2-
771s1c1 
CCGGCTTCGTGTATTCCAAAGTATACTCGAGTA
TACTTTGGAATACACGAAGTTTTTG 
Flt3l 
FMS-like 
tyrosine kinase 
3 ligand 
TRCN0000
025060 
NM_013520.2-
411s1c1 
CCGGCCTGCTTAAAGATTACCCAGTCTCGAGA
CTGGGTAATCTTTAAGCAGGTTTTT 
Flt3l 
FMS-like 
tyrosine kinase 
3 ligand 
TRCN0000
025061 
NM_013520.2-
558s1c1 
CCGGCGTCAACACCGAGATACATTTCTCGAGA
AATGTATCTCGGTGTTGACGTTTTT 
Flt3l 
FMS-like 
tyrosine kinase 
3 ligand 
TRCN0000
025059 
NM_013520.2-
427s1c1 
CCGGCCAGTCACTGTGGCCGTCAATCTCGAGA
TTGACGGCCACAGTGACTGGTTTTT 
Gdf1 
growth 
differentiation 
factor 1 
TRCN0000
077058 
NM_008107.2-
823s1c1 
CCGGGTCGTCTTTGACCTGTCGAATCTCGAGAT
TCGACAGGTCAAAGACGACTTTTTG 
Gdf1 
growth 
differentiation 
factor 1 
TRCN0000
077059 
NM_008107.2-
1459s1c1 
CCGGTCCGTGCTCTTCTTCGACAATCTCGAGAT
TGTCGAAGAAGAGCACGGATTTTTG 
Gdf1 
growth 
differentiation 
factor 1 
TRCN0000
077060 
NM_008107.2-
1494s1c1 
CCGGCCTGCGACACTACGAAGACATCTCGAGA
TGTCTTCGTAGTGTCGCAGGTTTTTG 
Gdf10 
growth 
differentiation 
factor 10 
TRCN0000
067928 
NM_145741.2-
1636s1c1 
CCGGCCAGACAAGATGAACTCCCTTCTCGAGA
AGGGAGTTCATCTTGTCTGGTTTTTG 
Gdf10 
growth 
differentiation 
factor 10 
TRCN0000
067929 
NM_145741.2-
1083s1c1 
CCGGGCTACAGAGATACGACCCATTCTCGAGA
ATGGGTCGTATCTCTGTAGCTTTTTG 
Gdf10 
growth 
differentiation 
factor 10 
TRCN0000
067930 
NM_145741.2-
633s1c1 
CCGGGCCTGTGTATTTCTTCAACTTCTCGAGAA
GTTGAAGAAATACACAGGCTTTTTG 
Gdf11 
growth 
differentiation 
factor 11 
TRCN0000
067978 
XM_125935.4-
1439s1c1 
CCGGGCAAAGGAACAGAGAGGCAAACTCGAGT
TTGCCTCTCTGTTCCTTTGCTTTTTG 
Gdf11 
growth 
differentiation 
factor 11 
TRCN0000
067979 
XM_125935.4-
757s1c1 
CCGGCGAGTCCTAGAGAACACGAAACTCGAGT
TTCGTGTTCTCTAGGACTCGTTTTTG 
Gdf11 
growth 
differentiation 
factor 11 
TRCN0000
067980 
XM_125935.4-
477s1c1 
CCGGCCTGCAGATCTTACGACTGAACTCGAGT
TCAGTCGTAAGATCTGCAGGTTTTTG 
Gdf15 
growth 
differentiation 
factor 15 
TRCN0000
055183 
NM_011819.1-
1127s1c1 
CCGGGCAGGCAACTCTTGAAGACTTCTCGAGA
AGTCTTCAAGAGTTGCCTGCTTTTTG 
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Gdf15 
growth 
differentiation 
factor 15 
TRCN0000
055184 
NM_011819.1-
603s1c1 
CCGGGCCCTGGCAATGCCTGAACAACTCGAGT
TGTTCAGGCATTGCCAGGGCTTTTTG 
Gdf15 
growth 
differentiation 
factor 15 
TRCN0000
055185 
NM_011819.1-
536s1c1 
CCGGTCAACTGAGGTTCCTGCTGTTCTCGAGA
ACAGCAGGAACCTCAGTTGATTTTTG 
Gdf2 
growth 
differentiation 
factor 2 
TRCN0000
068023 
NM_019506.2-
1977s1c1 
CCGGCGTGTATTGATGGAGTCACTACTCGAGT
AGTGACTCCATCAATACACGTTTTTG 
Gdf2 
growth 
differentiation 
factor 2 
TRCN0000
068024 
NM_019506.2-
1151s1c1 
CCGGCCCAAGGAATATGACGCCTATCTCGAGA
TAGGCGTCATATTCCTTGGGTTTTTG 
Gdf2 
growth 
differentiation 
factor 2 
TRCN0000
068025 
NM_019506.2-
367s1c1 
CCGGCCAGTACATGATCGACTTGTACTCGAGTA
CAAGTCGATCATGTACTGGTTTTTG 
Gdf3 
growth 
differentiation 
factor 3 
TRCN0000
068073 
NM_008108.1-
1019s1c1 
CCGGCCCTTCTCAATGACCACGTATCTCGAGAT
ACGTGGTCATTGAGAAGGGTTTTTG 
Gdf3 
growth 
differentiation 
factor 3 
TRCN0000
068074 
NM_008108.1-
325s1c1 
CCGGGCAGGACTTATGCTACGTGAACTCGAGT
TCACGTAGCATAAGTCCTGCTTTTTG 
Gdf3 
growth 
differentiation 
factor 3 
TRCN0000
068075 
NM_008108.1-
703s1c1 
CCGGCCGACTGAAGAATTTGGACTTCTCGAGA
AGTCCAAATTCTTCAGTCGGTTTTTG 
Gdf5 
growth 
differentiation 
factor 5 
TRCN0000
068118 
NM_008109.1-
2028s1c1 
CCGGGCTCAGGAAAGGTGTTCTTAACTCGAGT
TAAGAACACCTTTCCTGAGCTTTTTG 
Gdf5 
growth 
differentiation 
factor 5 
TRCN0000
068119 
NM_008109.1-
1747s1c1 
CCGGGCCAACAACGTGGTGTATAAACTCGAGT
TTATACACCACGTTGTTGGCTTTTTG 
Gdf5 
growth 
differentiation 
factor 5 
TRCN0000
068120 
NM_008109.1-
969s1c1 
CCGGCGTGTTTGACATCAGTGCCTTCTCGAGA
AGGCACTGATGTCAAACACGTTTTTG 
Gdf6 
growth 
differentiation 
factor 6 
TRCN0000
088998 
NM_013526.1-
3103s1c1 
CCGGGCCAGGAGAAATAACTTAAATCTCGAGAT
TTAAGTTATTTCTCCTGGCTTTTTG 
Gdf6 
growth 
differentiation 
factor 6 
TRCN0000
088999 
NM_013526.1-
409s1c1 
CCGGGCTGTCAATCTACAAGACTTACTCGAGTA
AGTCTTGTAGATTGACAGCTTTTTG 
Gdf6 
growth 
differentiation 
factor 6 
TRCN0000
089000 
NM_013526.1-
545s1c1 
CCGGCGGAGACAGAAGTATTTGTTTCTCGAGA
AACAAATACTTCTGTCTCCGTTTTTG 
Gdf7 
growth 
differentiation 
factor 7 
TRCN0000
068153 
NM_013527.1-
1137s1c1 
CCGGGCCATTAGACTACGAGGCATACTCGAGT
ATGCCTCGTAGTCTAATGGCTTTTTG 
Gdf7 
growth 
differentiation 
factor 7 
TRCN0000
068154 
NM_013527.1-
276s1c1 
CCGGCCACTTCATGATGTCGCTTTACTCGAGTA
AAGCGACATCATGAAGTGGTTTTTG 
Gdf7 
growth 
differentiation 
factor 7 
TRCN0000
068155 
NM_013527.1-
806s1c1 
CCGGCGCAAAGGAAAGAGAGTCTGTCTCGAGA
CAGACTCTCTTTCCTTTGCGTTTTTG 
Gdf9 
growth 
differentiation 
factor 9 
TRCN0000
068223 
NM_008110.1-
1557s1c1 
CCGGCCAAGTGAAATGTAACTCATTCTCGAGAA
TGAGTTACATTTCACTTGGTTTTTG 
Gdf9 
growth 
differentiation 
factor 9 
TRCN0000
068224 
NM_008110.1-
473s1c1 
CCGGGCCATGGAACACTTGCTCAAACTCGAGT
TTGAGCAAGTGTTCCATGGCTTTTTG 
Gdf9 
growth 
differentiation 
factor 9 
TRCN0000
068225 
NM_008110.1-
979s1c1 
CCGGGCCACTTCTTACAGCATCCTTCTCGAGAA
GGATGCTGTAAGAAGTGGCTTTTTG 
Gpi1 
glucose 
phosphate 
isomerase 1 
TRCN0000
111855 
NM_008155.1-
1759s1c1 
CCGGCCGTGTCCCTTCTCACCATATCTCGAGAT
ATGGTGAGAAGGGACACGGTTTTTG 
Gpi1 
glucose 
phosphate 
isomerase 1 
TRCN0000
111856 
NM_008155.1-
653s1c1 
CCGGCCTGAGACTTCCCTCTTTATACTCGAGTA
TAAAGAGGGAAGTCTCAGGTTTTTG 
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Grem1 gremlin 1 TRCN0000098300 
NM_011824.3-
771s1c1 
CCGGCCCGATTCCTACTTGGCTTAACTCGAGTT
AAGCCAAGTAGGAATCGGGTTTTTG 
Grem1 gremlin 1 TRCN0000098301 
NM_011824.3-
413s1c1 
CCGGCGCAAGTATCTGAAGCGAGATCTCGAGA
TCTCGCTTCAGATACTTGCGTTTTTG 
Grem1 gremlin 1 TRCN0000098302 
NM_011824.3-
685s1c1 
CCGGCCGTTGCATATCCATCGACTTCTCGAGAA
GTCGATGGATATGCAACGGTTTTTG 
Grem2 
gremlin 2 
homolog, 
cysteine knot 
superfamily 
(Xenopus 
laevis) 
TRCN0000
248548 
NM_011825.1-
595s21c1 
CCGGCCTTCCAATCCTGCGCTTTCTCTCGAGA
GAAAGCGCAGGATTGGAAGGTTTTTG 
Grem2 
gremlin 2 
homolog, 
cysteine knot 
superfamily 
(Xenopus 
laevis) 
TRCN0000
248549 
NM_011825.1-
290s21c1 
CCGGGCTGGTAAAGGTAGCTGAAACCTCGAGG
TTTCAGCTACCTTTACCAGCTTTTTG 
Grem2 
gremlin 2 
homolog, 
cysteine knot 
superfamily 
(Xenopus 
laevis) 
TRCN0000
248550 
NM_011825.1-
2026s21c1 
CCGGGCCAATATAGAGGGTAGTAATCTCGAGA
TTACTACCCTCTATATTGGCTTTTTG 
Grn granulin TRCN0000089155 
NM_008175.2-
190s1c1 
CCGGCCTAGAATAACGAGCCATCATCTCGAGA
TGATGGCTCGTTATTCTAGGTTTTTG 
Grn granulin TRCN0000089153 
NM_008175.2-
1920s1c1 
CCGGACTCATCCTGAGTCACCCTATCTCGAGAT
AGGGTGACTCAGGATGAGTTTTTTG 
Il10 interleukin 10 TRCN0000066428 
NM_010548.1-
989s1c1 
CCGGCCCTTTGCTATGGTGTCCTTTCTCGAGAA
AGGACACCATAGCAAAGGGTTTTTG 
Il10 interleukin 10 TRCN0000066429 
NM_010548.1-
381s1c1 
CCGGCCCAGAAATCAAGGAGCATTTCTCGAGA
AATGCTCCTTGATTTCTGGGTTTTTG 
Il10 interleukin 10 TRCN0000066430 
NM_010548.1-
276s1c1 
CCGGCGACTCCTTAATGCAGGACTTCTCGAGA
AGTCCTGCATTAAGGAGTCGTTTTTG 
Il11 interleukin 11 TRCN0000066458 
NM_008350.1-
818s1c1 
CCGGCCTGTGGCTTATTTATACTTACTCGAGTA
AGTATAAATAAGCCACAGGTTTTTG 
Il11 interleukin 11 TRCN0000066459 
NM_008350.1-
217s1c1 
CCGGGCTGCACAGATGAGAGACAAACTCGAGT
TTGTCTCTCATCTGTGCAGCTTTTTG 
Il11 interleukin 11 TRCN0000066460 
NM_008350.1-
459s1c1 
CCGGCCGCCGTTTACAGCTCTTGATCTCGAGA
TCAAGAGCTGTAAACGGCGGTTTTTG 
Il12a interleukin 12a TRCN0000066513 
NM_008351.1-
702s1c1 
CCGGGCAGACCCTTACAGAGTGAAACTCGAGT
TTCACTCTGTAAGGGTCTGCTTTTTG 
Il12a interleukin 12a TRCN0000066514 
NM_008351.1-
200s1c1 
CCGGCCTCCTAAACCACCTCAGTTTCTCGAGAA
ACTGAGGTGGTTTAGGAGGTTTTTG 
Il12a interleukin 12a TRCN0000066515 
NM_008351.1-
576s1c1 
CCGGGCACTTCAGAATCACAACCATCTCGAGAT
GGTTGTGATTCTGAAGTGCTTTTTG 
Il12b interleukin 12b TRCN0000066568 
NM_008352.1-
1508s1c1 
CCGGCCAGGCCCTATTATGCAAATTCTCGAGAA
TTTGCATAATAGGGCCTGGTTTTTG 
Il12b interleukin 12b TRCN0000066569 
NM_008352.1-
948s1c1 
CCGGCCATTCCTACTTCTCCCTCAACTCGAGTT
GAGGGAGAAGTAGGAATGGTTTTTG 
Il12b interleukin 12b TRCN0000066570 
NM_008352.1-
796s1c1 
CCGGGCACGGCAGCAGAATAAATATCTCGAGA
TATTTATTCTGCTGCCGTGCTTTTTG 
Il13 interleukin 13 TRCN0000066623 
NM_008355.1-
284s1c1 
CCGGCCCTGACCAACATCTCCAATTCTCGAGAA
TTGGAGATGTTGGTCAGGGTTTTTG 
Il13 interleukin 13 TRCN0000066624 
NM_008355.1-
160s1c1 
CCGGCTGACCCTTAAGGAGCTTATTCTCGAGAA
TAAGCTCCTTAAGGGTCAGTTTTTG 
Il13 interleukin 13 TRCN0000066625 
NM_008355.1-
421s1c1 
CCGGCTGCTCAGCTACACAAAGCAACTCGAGT
TGCTTTGTGTAGCTGAGCAGTTTTTG 
Il15 interleukin 15 TRCN0000066668 
NM_008357.1-
1056s1c1 
CCGGGCTTCCTAACAAGGAGATAATCTCGAGAT
TATCTCCTTGTTAGGAAGCTTTTTG 
Il15 interleukin 15 TRCN0000066669 
NM_008357.1-
550s1c1 
CCGGGCTGGCATTCATGTCTTCATTCTCGAGAA
TGAAGACATGAATGCCAGCTTTTTG 
Il15 interleukin 15 TRCN0000066670 
NM_008357.1-
608s1c1 
CCGGCCAACTGGATAGATGTAAGATCTCGAGA
TCTTACATCTATCCAGTTGGTTTTTG 
Il16 interleukin 16 TRCN0000066498 
NM_010551.2-
4756s1c1 
CCGGGCCTTTGAAGACTCATAACATCTCGAGAT
GTTATGAGTCTTCAAAGGCTTTTTG 
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Il16 interleukin 16 TRCN0000066499 
NM_010551.2-
1430s1c1 
CCGGCCTGACTCTCAATGAAGTCTACTCGAGTA
GACTTCATTGAGAGTCAGGTTTTTG 
Il16 interleukin 16 TRCN0000066500 
NM_010551.2-
891s1c1 
CCGGGACAGCATTTACGGCCCTATTCTCGAGA
ATAGGGCCGTAAATGCTGTCTTTTTG 
Il17a interleukin 17A TRCN0000066719 
NM_010552.2-
187s1c1 
CCGGCCTCCAGAATGTGAAGGTCAACTCGAGT
TGACCTTCACATTCTGGAGGTTTTTG 
Il17a interleukin 17A TRCN0000066720 
NM_010552.2-
457s1c1 
CCGGCTTCACTTTCAGGGTCGAGAACTCGAGT
TCTCGACCCTGAAAGTGAAGTTTTTG 
Il17a interleukin 17A TRCN0000066721 
NM_010552.2-
297s1c1 
CCGGACCGCAATGAAGACCCTGATACTCGAGT
ATCAGGGTCTTCATTGCGGTTTTTTG 
Il17b interleukin 17B TRCN0000066758 
NM_019508.1-
284s1c1 
CCGGCCAGCCAAGAAGAAATGTGAACTCGAGT
TCACATTTCTTCTTGGCTGGTTTTTG 
Il17b interleukin 17B TRCN0000066760 
NM_019508.1-
227s1c1 
CCGGGAAGAGTATGAGCGGAACCTTCTCGAGA
AGGTTCCGCTCATACTCTTCTTTTTG 
Il17b interleukin 17B TRCN0000066761 
NM_019508.1-
214s1c1 
CCGGCTACGCTCGAATGGAAGAGTACTCGAGT
ACTCTTCCATTCGAGCGTAGTTTTTG 
Il17c interleukin 17C TRCN0000066808 
NM_145834.1-
95s1c1 
CCGGGCTACTCTGCTGAGGAATTATCTCGAGAT
AATTCCTCAGCAGAGTAGCTTTTTG 
Il17c interleukin 17C TRCN0000066809 
NM_145834.1-
321s1c1 
CCGGTCGCATCGACACAGATGAGAACTCGAGT
TCTCATCTGTGTCGATGCGATTTTTG 
Il17c interleukin 17C TRCN0000066810 
NM_145834.1-
28s1c1 
CCGGCCTACTGGGATGACCCACCAACTCGAGT
TGGTGGGTCATCCCAGTAGGTTTTTG 
Il17f interleukin 17F TRCN0000067414 
NM_145856.1-
142s1c1 
CCGGGACATTCGAATCTTCAACCAACTCGAGTT
GGTTGAAGATTCGAATGTCTTTTTG 
Il17f interleukin 17F TRCN0000067415 
NM_145856.1-
306s1c1 
CCGGTCAGGAAGACAGCACCATGAACTCGAGT
TCATGGTGCTGTCTTCCTGATTTTTG 
Il17f interleukin 17F TRCN0000067413 
NM_145856.1-
170s1c1 
CCGGGCATTTCTGTCCCACGTGAATCTCGAGAT
TCACGTGGGACAGAAATGCTTTTTG 
Il18 interleukin 18 TRCN0000054990 
NM_008360.1-
455s1c1 
CCGGCCTCTCTGTGAAGGATAGTAACTCGAGTT
ACTATCCTTCACAGAGAGGTTTTTG 
Il18 interleukin 18 TRCN0000054991 
NM_008360.1-
660s1c1 
CCGGGCTTTCAAACTCATTCTGAAACTCGAGTT
TCAGAATGAGTTTGAAAGCTTTTTG 
Il18 interleukin 18 TRCN0000054992 
NM_008360.1-
191s1c1 
CCGGCGTCAACTTCAAGGAAATGATCTCGAGAT
CATTTCCTTGAAGTTGACGTTTTTG 
Il19 interleukin 19 TRCN0000066953 
XM_283649.2-
962s1c1 
CCGGGCTGTGGTATTTATAGCAATACTCGAGTA
TTGCTATAAATACCACAGCTTTTTG 
Il19 interleukin 19 TRCN0000066954 
XM_283649.2-
616s1c1 
CCGGGCCTGGATTGACAGGAATCATCTCGAGA
TGATTCCTGTCAATCCAGGCTTTTTG 
Il19 interleukin 19 TRCN0000066955 
XM_283649.2-
270s1c1 
CCGGGCAAACTAAGGACACCTTTAACTCGAGTT
AAAGGTGTCCTTAGTTTGCTTTTTG 
Il1a interleukin 1 alpha 
TRCN0000
067048 
NM_010554.3-
1782s1c1 
CCGGCCAACCATCTAAAGATGGAAACTCGAGTT
TCCATCTTTAGATGGTTGGTTTTTG 
Il1a interleukin 1 alpha 
TRCN0000
067049 
NM_010554.3-
420s1c1 
CCGGCCAGAGTGATTTGAGATACAACTCGAGTT
GTATCTCAAATCACTCTGGTTTTTG 
Il1a interleukin 1 alpha 
TRCN0000
067050 
NM_010554.3-
778s1c1 
CCGGGCTGCTTATCCAGAGCTGTTTCTCGAGA
AACAGCTCTGGATAAGCAGCTTTTTG 
Il1b interleukin 1 beta 
TRCN0000
067103 
NM_008361.2-
1069s1c1 
CCGGGCAACCACTTACCTATTTATTCTCGAGAA
TAAATAGGTAAGTGGTTGCTTTTTG 
Il1b interleukin 1 beta 
TRCN0000
067104 
NM_008361.2-
602s1c1 
CCGGCCTCAAAGGAAAGAATCTATACTCGAGTA
TAGATTCTTTCCTTTGAGGTTTTTG 
Il1b interleukin 1 beta 
TRCN0000
067105 
NM_008361.2-
506s1c1 
CCGGCCACCTCAATGGACAGAATATCTCGAGA
TATTCTGTCCATTGAGGTGGTTTTTG 
Il1f10 
interleukin 1 
family, member 
10 
TRCN0000
067163 
NM_153077.1-
290s1c1 
CCGGGACCTATACAAGGGAGGTGAACTCGAGT
TCACCTCCCTTGTATAGGTCTTTTTG 
Il1f10 
interleukin 1 
family, member 
10 
TRCN0000
067164 
NM_153077.1-
117s1c1 
CCGGGAGACCCTGATTCAGACAATTCTCGAGA
ATTGTCTGAATCAGGGTCTCTTTTTG 
Il1f10 
interleukin 1 
family, member 
10 
TRCN0000
067165 
NM_153077.1-
143s1c1 
CCGGCCAGAGAAGGTCTGTATCCTTCTCGAGA
AGGATACAGACCTTCTCTGGTTTTTG 
Il1f5 
interleukin 1 
family, member 
5 (delta) 
TRCN0000
067213 
NM_019451.1-
205s1c1 
CCGGGCACGCAGAGAAGGTCATTAACTCGAGT
TAATGACCTTCTCTGCGTGCTTTTTG 
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Il1f5 
interleukin 1 
family, member 
5 (delta) 
TRCN0000
067214 
NM_019451.1-
545s1c1 
CCGGCCCATCACAGACTTCTACTTTCTCGAGAA
AGTAGAAGTCTGTGATGGGTTTTTG 
Il1f5 
interleukin 1 
family, member 
5 (delta) 
TRCN0000
067215 
NM_019451.1-
313s1c1 
CCGGCCTATCTTGTGGGACAGAGAACTCGAGT
TCTCTGTCCCACAAGATAGGTTTTTG 
Il1f6 
interleukin 1 
family, member 
6 
TRCN0000
067263 
NM_019450.2-
576s1c1 
CCGGCCACTCATTCTGACCCAAGAACTCGAGTT
CTTGGGTCAGAATGAGTGGTTTTTG 
Il1f6 
interleukin 1 
family, member 
6 
TRCN0000
067264 
NM_019450.2-
623s1c1 
CCGGCGAGATGATTGTGGTACATTACTCGAGTA
ATGTACCACAATCATCTCGTTTTTG 
Il1f6 
interleukin 1 
family, member 
6 
TRCN0000
067265 
NM_019450.2-
278s1c1 
CCGGGCAAACAGTTCCAGTCACTATCTCGAGAT
AGTGACTGGAACTGTTTGCTTTTTG 
Il1f8 
interleukin 1 
family, member 
8 
TRCN0000
067298 
XM_130058.1-
272s1c1 
CCGGCCTGTCATTCTTAGCTTGATACTCGAGTA
TCAAGCTAAGAATGACAGGTTTTTG 
Il1f8 
interleukin 1 
family, member 
8 
TRCN0000
067299 
XM_130058.1-
525s1c1 
CCGGGCTGGTTTATAGCCACCTCTTCTCGAGAA
GAGGTGGCTATAAACCAGCTTTTTG 
Il1f8 
interleukin 1 
family, member 
8 
TRCN0000
067300 
XM_130058.1-
343s1c1 
CCGGCCTGGGAATCAAGAACAGAAACTCGAGT
TTCTGTTCTTGATTCCCAGGTTTTTG 
Il1f9 
interleukin 1 
family, member 
9 
TRCN0000
067353 
NM_153511.1-
188s1c1 
CCGGGCAGGTGTGGATCTTTCGTAACTCGAGT
TACGAAAGATCCACACCTGCTTTTTG 
Il1f9 
interleukin 1 
family, member 
9 
TRCN0000
067354 
NM_153511.1-
475s1c1 
CCGGCCACCTTTGAATCAGTGGCTTCTCGAGA
AGCCACTGATTCAAAGGTGGTTTTTG 
Il1f9 
interleukin 1 
family, member 
9 
TRCN0000
067355 
NM_153511.1-
332s1c1 
CCGGGAATCCAGATAAATGCCTGTTCTCGAGAA
CAGGCATTTATCTGGATTCTTTTTG 
Il2 interleukin 2 TRCN0000067198 
NM_008366.2-
396s1c1 
CCGGGCTGAGAATTTCATCAGCAATCTCGAGAT
TGCTGATGAAATTCTCAGCTTTTTG 
Il2 interleukin 2 TRCN0000067199 
NM_008366.2-
536s1c1 
CCGGCATCTCAACAAGCCCTCAATACTCGAGTA
TTGAGGGCTTGTTGAGATGTTTTTG 
Il2 interleukin 2 TRCN0000067200 
NM_008366.2-
221s1c1 
CCGGCCTGAGCAGGATGGAGAATTACTCGAGT
AATTCTCCATCCTGCTCAGGTTTTTG 
Il20 interleukin 20 TRCN0000067338 
NM_021380.1-
623s1c1 
CCGGAGAACACTCCTGTCCAAGAATCTCGAGA
TTCTTGGACAGGAGTGTTCTTTTTTG 
Il20 interleukin 20 TRCN0000067339 
NM_021380.1-
320s1c1 
CCGGCGTCATCTAGTGAGATTCTATCTCGAGAT
AGAATCTCACTAGATGACGTTTTTG 
Il20 interleukin 20 TRCN0000067340 
NM_021380.1-
179s1c1 
CCGGGCAAACCTACAGGCAATACAACTCGAGT
TGTATTGCCTGTAGGTTTGCTTTTTG 
Il21 interleukin 21 TRCN0000067398 
NM_021782.1-
676s1c1 
CCGGCCCATTAACTAAGCAGACATTCTCGAGAA
TGTCTGCTTAGTTAATGGGTTTTTG 
Il21 interleukin 21 TRCN0000067399 
NM_021782.1-
296s1c1 
CCGGCCCTGGAAACAATAAGACATTCTCGAGA
ATGTCTTATTGTTTCCAGGGTTTTTG 
Il21 interleukin 21 TRCN0000067400 
NM_021782.1-
287s1c1 
CCGGGCCATCAAACCCTGGAAACAACTCGAGT
TGTTTCCAGGGTTTGATGGCTTTTTG 
Il22 interleukin 22 TRCN0000067013 
NM_016971.1-
525s1c1 
CCGGAGTGGAGAGATCAAGGCGATTCTCGAGA
ATCGCCTTGATCTCTCCACTTTTTTG 
Il22 interleukin 22 TRCN0000067014 
NM_016971.1-
560s1c1 
CCGGGCTGTTTATGTCTCTGAGAAACTCGAGTT
TCTCAGAGACATAAACAGCTTTTTG 
Il22 interleukin 22 TRCN0000067015 
NM_016971.1-
464s1c1 
CCGGCGACCAGAACATCCAGAAGAACTCGAGT
TCTTCTGGATGTTCTGGTCGTTTTTG 
Il23a 
interleukin 23, 
alpha subunit 
p19 
TRCN0000
067120 
NM_031252.1-
593s1c1 
CCGGCTTCTCCGTTCCAAGATCCTTCTCGAGAA
GGATCTTGGAACGGAGAAGTTTTTG 
Il23a 
interleukin 23, 
alpha subunit 
p19 
TRCN0000
067121 
NM_031252.1-
221s1c1 
CCGGTCTCGGAATCTCTGCATGCTACTCGAGTA
GCATGCAGAGATTCCGAGATTTTTG 
Il24 interleukin 24 TRCN0000065943 
NM_053095.1-
699s1c1 
CCGGCCGCAGAGCATTCAAACAGTTCTCGAGA
ACTGTTTGAATGCTCTGCGGTTTTTG 
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Il24 interleukin 24 TRCN0000065944 
NM_053095.1-
286s1c1 
CCGGCTGAGCCTAATCCTTCTTCTTCTCGAGAA
GAAGAAGGATTAGGCTCAGTTTTTG 
Il24 interleukin 24 TRCN0000065945 
NM_053095.1-
730s1c1 
CCGGGTCGCTTTGGTGAAAGCCTTTCTCGAGA
AAGGCTTTCACCAAAGCGACTTTTTG 
Il25 interleukin 25 TRCN0000066968 
NM_080729.1-
253s1c1 
CCGGGAGTTGGACAGGGACTTGAATCTCGAGA
TTCAAGTCCCTGTCCAACTCTTTTTG 
Il25 interleukin 25 TRCN0000066969 
NM_080729.1-
378s1c1 
CCGGCCACAACCAGACGGTCTTCTACTCGAGT
AGAAGACCGTCTGGTTGTGGTTTTTG 
Il25 interleukin 25 TRCN0000066970 
NM_080729.1-
366s1c1 
CCGGCGTCCCACTTTACCACAACCACTCGAGT
GGTTGTGGTAAAGTGGGACGTTTTTG 
Il27 interleukin 27 TRCN0000067088 
NM_145636.1-
239s1c1 
CCGGGATACCATCTTCCCAATGTTTCTCGAGAA
ACATTGGGAAGATGGTATCTTTTTG 
Il27 interleukin 27 TRCN0000067089 
NM_145636.1-
459s1c1 
CCGGTGCAGGATTCAAATGTTCAAACTCGAGTT
TGAACATTTGAATCCTGCATTTTTG 
Il27 interleukin 27 TRCN0000067090 
NM_145636.1-
56s1c1 
CCGGTGCTTCTGGTACAAGCTGGTTCTCGAGA
ACCAGCTTGTACCAGAAGCATTTTTG 
Il3 interleukin 3 TRCN0000077023 
NM_010556.2-
247s1c1 
CCGGCGGAGAGTAAACCTGTCCAAACTCGAGT
TTGGACAGGTTTACTCTCCGTTTTTG 
Il3 interleukin 3 TRCN0000077024 
NM_010556.2-
129s1c1 
CCGGCCACCGTTTAACCAGAACGTTCTCGAGA
ACGTTCTGGTTAAACGGTGGTTTTTG 
Il3 interleukin 3 TRCN0000077025 
NM_010556.2-
158s1c1 
CCGGGCTCTATTGTCAAGGAGATTACTCGAGTA
ATCTCCTTGACAATAGAGCTTTTTG 
Il34 interleukin 34 TRCN0000247082 
NM_029646.2-
708s21c1 
CCGGACCGGCTTCAGTACATGAAACCTCGAGG
TTTCATGTACTGAAGCCGGTTTTTTG 
Il34 interleukin 34 TRCN0000247083 
NM_029646.2-
1293s21c1 
CCGGATGCAATGTACAGCTACAAATCTCGAGAT
TTGTAGCTGTACATTGCATTTTTTG 
Il34 interleukin 34 TRCN0000247084 
NM_029646.2-
640s21c1 
CCGGATGGACTCTGACCCAAGATAACTCGAGT
TATCTTGGGTCAGAGTCCATTTTTTG 
Il5 interleukin 5 TRCN0000067503 
NM_010558.1-
679s1c1 
CCGGGCCAAGGATAACCTTGAATTTCTCGAGAA
ATTCAAGGTTATCCTTGGCTTTTTG 
Il5 interleukin 5 TRCN0000067504 
NM_010558.1-
324s1c1 
CCGGAGAAATACATTGACCGCCAAACTCGAGTT
TGGCGGTCAATGTATTTCTTTTTTG 
Il5 interleukin 5 TRCN0000067505 
NM_010558.1-
223s1c1 
CCGGGCTATGCATTGGAGAAATCTTCTCGAGAA
GATTTCTCCAATGCATAGCTTTTTG 
Il7 interleukin 7 TRCN0000067603 
NM_008371.2-
498s1c1 
CCGGGCTCGCAAGTTGAAGCAATTTCTCGAGA
AATTGCTTCAACTTGCGAGCTTTTTG 
Il7 interleukin 7 TRCN0000067604 
NM_008371.2-
642s1c1 
CCGGGCATGTTTCCTAAAGAGACTACTCGAGTA
GTCTCTTTAGGAAACATGCTTTTTG 
Il9 interleukin 9 TRCN0000067643 
NM_008373.1-
188s1c1 
CCGGCCGTCCCAACTGATGATTGTACTCGAGT
ACAATCATCAGTTGGGACGGTTTTTG 
Il9 interleukin 9 TRCN0000067644 
NM_008373.1-
367s1c1 
CCGGGCAGGCAACACACTGTCATTTCTCGAGA
AATGACAGTGTGTTGCCTGCTTTTTG 
Il9 interleukin 9 TRCN0000067645 
NM_008373.1-
100s1c1 
CCGGGACACCAATTACCTTATTGAACTCGAGTT
CAATAAGGTAATTGGTGTCTTTTTG 
Iltifb 
interleukin 10-
related T cell-
derived 
inducible factor 
beta 
TRCN0000
067058 
NM_054079.1-
488s1c1 
CCGGAGGCTGAAGGAGACAGTGAAACTCGAGT
TTCACTGTCTCCTTCAGCCTTTTTTG 
Iltifb 
interleukin 10-
related T cell-
derived 
inducible factor 
beta 
TRCN0000
067059 
NM_054079.1-
202s1c1 
CCGGCATCGTCAACCGCACCTTTATCTCGAGAT
AAAGGTGCGGTTGACGATGTTTTTG 
Iltifb 
interleukin 10-
related T cell-
derived 
inducible factor 
beta 
TRCN0000
067060 
NM_054079.1-
298s1c1 
CCGGCAGTGCTAAGGATCAGTGCTACTCGAGT
AGCACTGATCCTTAGCACTGTTTTTG 
Kitl kit ligand TRCN0000067871 
NM_013598.1-
405s1c1 
CCGGCTACGAGATATGGTAATACAACTCGAGTT
GTATTACCATATCTCGTAGTTTTTG 
Kitl kit ligand TRCN0000067872 
NM_013598.1-
897s1c1 
CCGGGCCTTATACTGGAAGAAGAAACTCGAGT
TTCTTCTTCCAGTATAAGGCTTTTTG 
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Lefty1 
left right 
determination 
factor 1 
TRCN0000
067908 
NM_010094.2-
238s1c1 
CCGGGCCCTGCTACAACACAGCCATCTCGAGA
TGGCTGTGTTGTAGCAGGGCTTTTTG 
Lefty1 
left right 
determination 
factor 1 
TRCN0000
067911 
NM_010094.2-
80s1c1 
CCGGTCTGGGCACTGTCGCTGGTTACTCGAGT
AACCAGCGACAGTGCCCAGATTTTTG 
Lefty1 
left right 
determination 
factor 1 
TRCN0000
067909 
NM_010094.2-
486s1c1 
CCGGCACCATTGAATGGCTGCGCTTCTCGAGA
AGCGCAGCCATTCAATGGTGTTTTTG 
Lefty2 
Left-right 
determination 
factor 2 
TRCN0000
066113 
NM_177099.3-
500s1c1 
CCGGCACCATTGAATGGCTGAGAGTCTCGAGA
CTCTCAGCCATTCAATGGTGTTTTTG 
Lefty2 
Left-right 
determination 
factor 2 
TRCN0000
066114 
NM_177099.3-
1043s1c1 
CCGGGCCCATGATTGTCAGTGTGAACTCGAGT
TCACACTGACAATCATGGGCTTTTTG 
Lefty2 
Left-right 
determination 
factor 2 
TRCN0000
066115 
NM_177099.3-
138s1c1 
CCGGGAACAGGTCCTGAGCAGTCTACTCGAGT
AGACTGCTCAGGACCTGTTCTTTTTG 
Lif leukemia inhibitory factor 
TRCN0000
067993 
NM_008501.1-
347s1c1 
CCGGGCGCCAATGCTCTCTTCATTTCTCGAGAA
ATGAAGAGAGCATTGGCGCTTTTTG 
Lif leukemia inhibitory factor 
TRCN0000
067996 
NM_008501.1-
429s1c1 
CCGGCATGACAGACTTCCCATCTTTCTCGAGAA
AGATGGGAAGTCTGTCATGTTTTTG 
Lta lymphotoxin A TRCN0000068038 
NM_010735.1-
423s1c1 
CCGGTGGCTTCTCTTTGAGCAACAACTCGAGTT
GTTGCTCAAAGAGAAGCCATTTTTG 
Lta lymphotoxin A TRCN0000068039 
NM_010735.1-
547s1c1 
CCGGGCACACGAGGTCCAGCTCTTTCTCGAGA
AAGAGCTGGACCTCGTGTGCTTTTTG 
Lta lymphotoxin A TRCN0000068040 
NM_010735.1-
613s1c1 
CCGGTCTGTGTATCCGGGACTTCAACTCGAGTT
GAAGTCCCGGATACACAGATTTTTG 
Ltb lymphotoxin B TRCN0000068090 
NM_008518.1-
834s1c1 
CCGGCGAGAGGGTCTACGTTAACATCTCGAGA
TGTTAACGTAGACCCTCTCGTTTTTG 
Ltb lymphotoxin B TRCN0000068091 
NM_008518.1-
518s1c1 
CCGGGCCAAGAAGAAGCGTTTCTGACTCGAGT
CAGAAACGCTTCTTCTTGGCTTTTTG 
Mif 
macrophage 
migration 
inhibitory factor 
TRCN0000
067343 
NM_010798.1-
449s1c1 
CCGGGCACCGCTGTTCTTTGAGCCTCTCGAGA
GGCTCAAAGAACAGCGGTGCTTTTTG 
Mif 
macrophage 
migration 
inhibitory factor 
TRCN0000
067344 
NM_010798.1-
360s1c1 
CCGGCCGGGTCTACATCAACTATTACTCGAGTA
ATAGTTGATGTAGACCCGGTTTTTG 
Mif 
macrophage 
migration 
inhibitory factor 
TRCN0000
067345 
NM_010798.1-
294s1c1 
CCGGCCAGAACCGCAACTACAGTAACTCGAGT
TACTGTAGTTGCGGTTCTGGTTTTTG 
Nodal nodal TRCN0000068168 
NM_013611.3-
823s1c1 
CCGGCCCAAGCAGTACAATGCCTATCTCGAGA
TAGGCATTGTACTGCTTGGGTTTTTG 
Nodal nodal TRCN0000068169 
NM_013611.3-
219s1c1 
CCGGCTGGACTTTCACGTTTGACTTCTCGAGAA
GTCAAACGTGAAAGTCCAGTTTTTG 
Nodal nodal TRCN0000068170 
NM_013611.3-
778s1c1 
CCGGCAGGTGGACTTCAACCTGATTCTCGAGA
ATCAGGTTGAAGTCCACCTGTTTTTG 
Osm oncostatin M TRCN0000065593 
XM_137493.3-
465s1c1 
CCGGCGGCACAATATCCTCGGCATACTCGAGT
ATGCCGAGGATATTGTGCCGTTTTTG 
Osm oncostatin M TRCN0000065594 
XM_137493.3-
580s1c1 
CCGGCAACACCAGATGTCTTTAATACTCGAGTA
TTAAAGACATCTGGTGTTGTTTTTG 
Osm oncostatin M TRCN0000065595 
XM_137493.3-
234s1c1 
CCGGGAATCACTCTTGGAGCCCTATCTCGAGA
TAGGGCTCCAAGAGTGATTCTTTTTG 
Pglyrp1 
peptidoglycan 
recognition 
protein 1 
TRCN0000
065598 
NM_009402.1-
435s1c1 
CCGGGCTGCCCTAAATCTTCTGGAACTCGAGTT
CCAGAAGATTTAGGGCAGCTTTTTG 
Pglyrp1 
peptidoglycan 
recognition 
protein 1 
TRCN0000
065599 
NM_009402.1-
355s1c1 
CCGGCCATCTGGAATCCCATGTCTACTCGAGTA
GACATGGGATTCCAGATGGTTTTTG 
Ppbp pro-platelet basic protein 
TRCN0000
301445 
NM_023785.2-
130s21c1 
CCGGCCCACTTCATAACCTCCAGATCTCGAGAT
CTGGAGGTTATGAAGTGGGTTTTTG 
Ppbp pro-platelet basic protein 
TRCN0000
301446 
NM_023785.2-
636s21c1 
CCGGCCTGCAATTTATGGTCTATTTCTCGAGAA
ATAGACCATAAATTGCAGGTTTTTG 
Ppbp pro-platelet basic protein 
TRCN0000
301448 
NM_023785.2-
388s21c1 
CCGGCGTCAAGAGAATCGTCATGAACTCGAGT
TCATGACGATTCTCTTGACGTTTTTG 
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Scg2 secretogranin II TRCN0000201714 
NM_009129.1-
328s1c1 
CCGGGACGAGTGGATGCGGATAATACTCGAGT
ATTATCCGCATCCACTCGTCTTTTTTG 
Scg2 secretogranin II TRCN0000217809 
NM_009129.2-
2244s1c1 
CCGGCTATGATAGTGTTGGCTAATGCTCGAGC
ATTAGCCAACACTATCATAGTTTTTTG 
Scg2 secretogranin II TRCN0000219456 
NM_009129.2-
1670s1c1 
CCGGCTTAGCCAGGATGCTAGTTAACTCGAGTT
AACTAGCATCCTGGCTAAGTTTTTG 
Scgb3a1 
secretoglobin, 
family 3A, 
member 1 
TRCN0000
190171 
NM_170727.1-
305s1c1 
CCGGCTAGCCTACCATTAAGCCACTCTCGAGA
GTGGCTTAATGGTAGGCTAGTTTTTTG 
Scgb3a1 
secretoglobin, 
family 3A, 
member 1 
TRCN0000
192491 
NM_054037.1-
102s1c1 
CCGGCTCTGGTGTTGCTTTCTTCATCTCGAGAT
GAAGAAAGCAACACCAGAGTTTTTTG 
Scgb3a1 
secretoglobin, 
family 3A, 
member 1 
TRCN0000
202129 
NM_170727.1-
364s1c1 
CCGGCCATTGGATCCTCTCATAGAGCTCGAGC
TCTATGAGAGGATCCAATGGTTTTTTG 
Slurp1 
secreted 
Ly6/Plaur 
domain 
containing 1 
TRCN0000
190210 
NM_020519.1-
174s1c1 
CCGGCCTGTAAGACTGTACTGGAGACTCGAGT
CTCCAGTACAGTCTTACAGGTTTTTTG 
Slurp1 
secreted 
Ly6/Plaur 
domain 
containing 1 
TRCN0000
190254 
NM_020519.1-
94s1c1 
CCGGCTTCCGATGCTATACCTGTGACTCGAGT
CACAGGTATAGCATCGGAAGTTTTTTG 
Slurp1 
secreted 
Ly6/Plaur 
domain 
containing 1 
TRCN0000
192879 
NM_020519.1-
125s1c1 
CCGGGCCATTAACTCATGCAAGAATCTCGAGAT
TCTTGCATGAGTTAATGGCTTTTTTG 
Spp1 
secreted 
phosphoprotein 
1 
TRCN0000
009602 
NM_009263.1-
678s1c1 
CCGGGAGGTCAAAGTCTAGGAGTTTCTCGAGA
AACTCCTAGACTTTGACCTCTTTTT 
Spp1 
secreted 
phosphoprotein 
1 
TRCN0000
054699 
NM_009263.1-
416s1c1 
CCGGAGGATGACTTTAAGCAAGAAACTCGAGTT
TCTTGCTTAAAGTCATCCTTTTTTG 
Spp1 
secreted 
phosphoprotein 
1 
TRCN0000
009601 
NM_009263.1-
1178s1c1 
CCGGGCAGGAATACTAACTGCTCATCTCGAGA
TGAGCAGTTAGTATTCCTGCTTTTT 
Spp1 
secreted 
phosphoprotein 
1 
TRCN0000
009603 
NM_009263.1-
1027s1c1 
CCGGCCTAAGAGTAAGGAAGATGATCTCGAGA
TCATCTTCCTTACTCTTAGGTTTTT 
Spp1 
secreted 
phosphoprotein 
1 
TRCN0000
009604 
NM_009263.1-
272s1c1 
CCGGTCCCGGTGAAAGTGACTGATTCTCGAGA
ATCAGTCACTTTCACCGGGATTTTT 
Thpo thrombopoietin TRCN0000066843 
NM_009379.2-
1112s1c1 
CCGGCCCAGTCCAAATCTCTGGATACTCGAGT
ATCCAGAGATTTGGACTGGGTTTTTG 
Thpo thrombopoietin TRCN0000066846 
NM_009379.2-
554s1c1 
CCGGCCCTTTGTCTATCCCTGTTCTCTCGAGAG
AACAGGGATAGACAAAGGGTTTTTG 
Tnf tumor necrosis factor 
TRCN0000
066183 
NM_013693.1-
640s1c1 
CCGGGCTATCTCATACCAGGAGAAACTCGAGT
TTCTCCTGGTATGAGATAGCTTTTTG 
Tnf tumor necrosis factor 
TRCN0000
066184 
NM_013693.1-
549s1c1 
CCGGCGATGGGTTGTACCTTGTCTACTCGAGT
AGACAAGGTACAACCCATCGTTTTTG 
Tnf tumor necrosis factor 
TRCN0000
066186 
NM_013693.1-
357s1c1 
CCGGCCTCCCTCTCATCAGTTCTATCTCGAGAT
AGAACTGATGAGAGGGAGGTTTTTG 
Tnfsf10 
tumor necrosis 
factor (ligand) 
superfamily, 
member 10 
TRCN0000
066234 
NM_009425.1-
449s1c1 
CCGGCGGAGAAGCAACTCAGCTTTACTCGAGT
AAAGCTGAGTTGCTTCTCCGTTTTTG 
Tnfsf10 
tumor necrosis 
factor (ligand) 
superfamily, 
member 10 
TRCN0000
066235 
NM_009425.1-
649s1c1 
CCGGCGCTTCCAAGATGGTCTCAAACTCGAGT
TTGAGACCATCTTGGAAGCGTTTTTG 
Tnfsf10 
tumor necrosis 
factor (ligand) 
superfamily, 
member 10 
TRCN0000
066236 
NM_009425.1-
316s1c1 
CCGGGCTCATTGAAGAGGTGACTTTCTCGAGA
AAGTCACCTCTTCAATGAGCTTTTTG 
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Tnfsf11 
tumor necrosis 
factor (ligand) 
superfamily, 
member 11, 
RANKL 
TRCN0000
066284 
NM_011613.2-
913s1c1 
CCGGCCCAAGTTCTCATAACCTGATCTCGAGAT
CAGGTTATGAGAACTTGGGTTTTTG 
Tnfsf11 
tumor necrosis 
factor (ligand) 
superfamily, 
member 11, 
RANKL 
TRCN0000
066285 
NM_011613.2-
387s1c1 
CCGGCGCAGATGGATCCTAACAGAACTCGAGT
TCTGTTAGGATCCATCTGCGTTTTTG 
Tnfsf11 
tumor necrosis 
factor (ligand) 
superfamily, 
member 11, 
RANKL 
TRCN0000
066286 
NM_011613.2-
760s1c1 
CCGGCATGACGTTAAGCAACGGAAACTCGAGT
TTCCGTTGCTTAACGTCATGTTTTTG 
Tnfsf11 
tumor necrosis 
factor (ligand) 
superfamily, 
member 11, 
RANKL 
TRCN0000
066283 
NM_011613.2-
1094s1c1 
CCGGGCTTTCAAAGTTCAGGACATACTCGAGTA
TGTCCTGAACTTTGAAAGCTTTTTG 
Tnfsf11 
tumor necrosis 
factor (ligand) 
superfamily, 
member 11, 
RANKL 
TRCN0000
066287 
NM_011613.2-
877s1c1 
CCGGGCTGATGGTGTATGTCGTTAACTCGAGTT
AACGACATACACCATCAGCTTTTTG 
Tnfsf12 
tumor necrosis 
factor (ligand) 
superfamily, 
member 12 
TRCN0000
066324 
NM_011614.1-
717s1c1 
CCGGCCTAACCTACTTTGGACTCTTCTCGAGAA
GAGTCCAAAGTAGGTTAGGTTTTTG 
Tnfsf12 
tumor necrosis 
factor (ligand) 
superfamily, 
member 12 
TRCN0000
066325 
NM_011614.1-
271s1c1 
CCGGCCTCGAAGAAGTGCTCCTAAACTCGAGT
TTAGGAGCACTTCTTCGAGGTTTTTG 
Tnfsf12 
tumor necrosis 
factor (ligand) 
superfamily, 
member 12 
TRCN0000
066326 
NM_011614.1-
244s1c1 
CCGGGTACCTTTCTTGGAACAACTACTCGAGTA
GTTGTTCCAAGAAAGGTACTTTTTG 
Tnfsf13 
tumor necrosis 
factor (ligand) 
superfamily, 
member 13 
TRCN0000
076983 
NM_023517.1-
1334s1c1 
CCGGTGGCTAGACAAAGGACAAGGACTCGAGT
CCTTGTCCTTTGTCTAGCCATTTTTG 
Tnfsf13 
tumor necrosis 
factor (ligand) 
superfamily, 
member 13 
TRCN0000
076984 
NM_023517.1-
628s1c1 
CCGGCGGTTGCTCTTTGGTTGAGTTCTCGAGA
ACTCAACCAAAGAGCAACCGTTTTTG 
Tnfsf13 
tumor necrosis 
factor (ligand) 
superfamily, 
member 13 
TRCN0000
076985 
NM_023517.1-
1182s1c1 
CCGGGCAGGTGTCTTTCATTTACATCTCGAGAT
GTAAATGAAAGACACCTGCTTTTTG 
Tnfsf13b 
tumor necrosis 
factor (ligand) 
superfamily, 
member 13b 
TRCN0000
066368 
NM_033622.1-
671s1c1 
CCGGGCCATTCTCAACATGATGATACTCGAGTA
TCATCATGTTGAGAATGGCTTTTTG 
Tnfsf13b 
tumor necrosis 
factor (ligand) 
superfamily, 
member 13b 
TRCN0000
066369 
NM_033622.1-
263s1c1 
CCGGGCTCCGAGAAAGGAGAAGATACTCGAGT
ATCTTCTCCTTTCTCGGAGCTTTTTG 
Tnfsf13b 
tumor necrosis 
factor (ligand) 
superfamily, 
member 13b 
TRCN0000
066370 
NM_033622.1-
1079s1c1 
CCGGCTCGGGAGAATGCACAGATTTCTCGAGA
AATCTGTGCATTCTCCCGAGTTTTTG 
Tnfsf14 
tumor necrosis 
factor (ligand) 
superfamily, 
member 14 
TRCN0000
066398 
NM_019418.1-
528s1c1 
CCGGGCCCGGTTACTACTATGTGTACTCGAGT
ACACATAGTAGTAACCGGGCTTTTTG 
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Tnfsf14 
tumor necrosis 
factor (ligand) 
superfamily, 
member 14 
TRCN0000
066400 
NM_019418.1-
358s1c1 
CCGGGAGAAGCTGATACAAGATCAACTCGAGT
TGATCTTGTATCAGCTTCTCTTTTTG 
Tnfsf14 
tumor necrosis 
factor (ligand) 
superfamily, 
member 14 
TRCN0000
066399 
NM_019418.1-
813s1c1 
CCGGCAGGTCCTATTTCGGAGCTTTCTCGAGA
AAGCTCCGAAATAGGACCTGTTTTTG 
Tnfsf15 
tumor necrosis 
factor (ligand) 
superfamily, 
member 15 
TRCN0000
066434 
NM_177371.1-
287s1c1 
CCGGCGAGAGCACACCTGACAATTACTCGAGT
AATTGTCAGGTGTGCTCTCGTTTTTG 
Tnfsf15 
tumor necrosis 
factor (ligand) 
superfamily, 
member 15 
TRCN0000
066435 
NM_177371.1-
426s1c1 
CCGGCCCAGAGTCAGGAGACTATTTCTCGAGA
AATAGTCTCCTGACTCTGGGTTTTTG 
Tnfsf15 
tumor necrosis 
factor (ligand) 
superfamily, 
member 15 
TRCN0000
066436 
NM_177371.1-
579s1c1 
CCGGCCGCCTACTAACAGGGTCCAACTCGAGT
TGGACCCTGTTAGTAGGCGGTTTTTG 
Tnfsf4 
tumor necrosis 
factor (ligand) 
superfamily, 
member 4 
TRCN0000
066529 
NM_009452.1-
414s1c1 
CCGGGCAGAACAATTCGGTTGTCATCTCGAGA
TGACAACCGAATTGTTCTGCTTTTTG 
Tnfsf4 
tumor necrosis 
factor (ligand) 
superfamily, 
member 4 
TRCN0000
066531 
NM_009452.1-
546s1c1 
CCGGCGATGGTCGAAGGATTGTCTTCTCGAGA
AGACAATCCTTCGACCATCGTTTTTG 
Tnfsf8 
tumor necrosis 
factor (ligand) 
superfamily, 
member 8 
TRCN0000
066728 
NM_009403.2-
823s1c1 
CCGGGCTGCATTACTTACAGGTCAACTCGAGTT
GACCTGTAAGTAATGCAGCTTTTTG 
Tnfsf8 
tumor necrosis 
factor (ligand) 
superfamily, 
member 8 
TRCN0000
066729 
NM_009403.2-
404s1c1 
CCGGGCGATCATTCTGGTACTGGTACTCGAGT
ACCAGTACCAGAATGATCGCTTTTTG 
Tnfsf8 
tumor necrosis 
factor (ligand) 
superfamily, 
member 8 
TRCN0000
066730 
NM_009403.2-
647s1c1 
CCGGCCTGGCTTGTACTTCATCGTTCTCGAGAA
CGATGAAGTACAAGCCAGGTTTTTG 
Tnfsf9 
tumor necrosis 
factor (ligand) 
superfamily, 
member 9 
TRCN0000
077039 
NM_009404.1-
175s1c1 
CCGGCCTGCGGTTAATGTTCGGGATCTCGAGA
TCCCGAACATTAACCGCAGGTTTTTG 
Tnfsf9 
tumor necrosis 
factor (ligand) 
superfamily, 
member 9 
TRCN0000
077040 
NM_009404.1-
746s1c1 
CCGGAGAACAAGTTAGTGGACCGTTCTCGAGA
ACGGTCCACTAACTTGTTCTTTTTTG 
Tnfsf9 
tumor necrosis 
factor (ligand) 
superfamily, 
member 9 
TRCN0000
077041 
NM_009404.1-
473s1c1 
CCGGCGTTGTGCAATACAACTCTGACTCGAGT
CAGAGTTGTATTGCACAACGTTTTTG 
Tslp thymic stromal lymphopoietin 
TRCN0000
076993 
NM_021367.1-
521s1c1 
CCGGCCACTGGTGTTTATTCTTTAACTCGAGTT
AAAGAATAAACACCAGTGGTTTTTG 
Tslp thymic stromal lymphopoietin 
TRCN0000
076994 
NM_021367.1-
418s1c1 
CCGGCCTTCATGCAATCTCCAGAATCTCGAGAT
TCTGGAGATTGCATGAAGGTTTTTG 
Tslp thymic stromal lymphopoietin 
TRCN0000
076995 
NM_021367.1-
316s1c1 
CCGGGCTACCCTGAAACTGAGAGAACTCGAGT
TCTCTCAGTTTCAGGGTAGCTTTTTG 
Xcl1 chemokine (C motif) ligand 1 
TRCN0000
065448 
NM_008510.1-
226s1c1 
CCGGGTGCTGATCCAGAAGCCAAATCTCGAGA
TTTGGCTTCTGGATCAGCACTTTTTG 
Xcl1 chemokine (C motif) ligand 1 
TRCN0000
065450 
NM_008510.1-
255s1c1 
CCGGGCAGCGATCAAGACTGTGGATCTCGAGA
TCCACAGTCTTGATCGCTGCTTTTTG 
Xcl1 chemokine (C motif) ligand 1 
TRCN0000
065449 
NM_008510.1-
101s1c1 
CCGGAGAAGAGAGTAGCTGTGTGAACTCGAGT
TCACACAGCTACTCTCTTCTTTTTTG 
Control  non-targeting hairpin   
CCGGCCTAAGGTTAAGTCGCCCTCGCTCGAGC
GAGGGCGACTTAACCTTAGGTTTTTG 
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Table II.2. Gene-specific primers for RT-PCR 
 
Gene Forward primer sequence Reverse primer sequence 
Ccl9 tgcctgtcctataactcacg tctctgaactctccgatcac 
Ccl17 gagtgctgcctggattactt ggtctgcacagatgagcttg 
Cmtm5 gacaagaccttcctgtcttc gtgtgatgaggaactctagc 
Cxcl9 atcatcttcctggagcagtg tctccgttcttcagtgtagc 
Cxcl10 ctgcaactgcatccatatcg ggattcagacatctctgctc 
Cxcl12 agccaacgtcaagcatctg caggtactcttggatccac 
Cxcl14 ggtccaagtgtaagtgttcc cctggacatgctcttggtg 
Gdf3 cgagtttcaagactctgacc gctccttcacgtagcataag 
Gdf15 agaggactcgaactcagaac tcagcaggagcagcgctc 
IL1f9 ttgtgacagttccacgaagc ggtgtccattaacttccttac 
IL18 cctgtgttcgaggatatgac ggagagggtagacattttac 
Tnfa gagcacagaaagcatgatcc tcagtagacagaagagcgtg 
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Table II.3. RNAi screening identifies potential regulators of myoblast 
differentiation 
 
RNAi-based functional screening of 134 mouse cytokine genes revealed 29 
candidate regulators of myoblast differentiation, of which 6 are potentially positive 
regulators, and 23 negative regulators. They are further divided into 4 classes based on 
knockdown phenotypes. Class I: decrease in all myotube parameters. Class II: decrease 
in fusion index and average myonuclei number, with unchanged differentiation index. 
Class III: increase in all myotube parameters. Class IV: increase in differentiation and 
fusion indexes, with unchanged average myonuclei number. Those highlighted (bold, 
italic) are examples with data shown in Figs. II.2-6. Data for all the genes listed here are 
shown in Table II.4. 
  
Positive Negative 
I II III IV 
Ccl8 Gdf15 Ccl1 Gdf3 Ccl9 IL18 
Cxcl9 Scgb3a1 Cmtm5 IL5 Ccl17 IL21 
Flt3L  Cmtm6 IL17b Cmtm2a IL1f9 
Tnfsf14  Ctf2 IL17c Ebi3 ILtifb 
  Cxcl2 Scg2   
  Cxcl10 Tnfα    
  Cxcl14 Tnfsf10   
  FasL    
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Table II.4.  Quantification of myotube formation for 29 candidate genes 
Differentiation (“Diff.”) index, fusion index and myotube size (average nuclei 
number per myotube) were calculated for the knockdown of the genes listed in Table 1. 
The data shown are mean ± standard deviation (n=3-6). The experiments were 
performed in 12-well plates in several groups, with the non-targeting control shRNA 
included in each group for viral packaging, infection and differentiation for side-by-side 
comparison. Variation in control values between groups was primarily the result of 
varying cell densities at the induction of differentiation. Statistical analyses were 
performed by t tests to compare each data to the matching control. *P<0.05, **P<0.01.  
 
Gene/shRNA Diff. index Fusion index Myotube size 
Ccl8 
Control 0.24±0.07 0.20±0.07 11.0±5.4 
shRNA #1 0.13±0.05** 0.04±0.01** 2.5±0.2** 
shRNA #2 0.09±0.02** 0.04±0.01** 2.6±0.2** 
Cxcl9 
Control 0.36±0.01 0.34±0.01 8.6±1.3 
shRNA #1 0.25±0.03* 0.22±0.03** 4.9±0.6* 
shRNA #2 0.22±0.02** 0.21±0.04* 4.4±2.1* 
Flt3L 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.15±0.02** 0.12±0.02** 3.8±1.2* 
shRNA #2 0.09±0.02** 0.07±0.02** 2.5±0.5** 
Tnfsf14 
Control 0.27±0.04 0.24±0.04 13.9±1.9 
shRNA #1 0.25±0.04* 0.19±0.04* 5.0±1.5** 
shRNA #2 0.22±0.03* 0.12±0.03* 2.5±0.1** 
Gdf15 
Control 0.29±0.03 0.28±0.04 6.0±1.4 
shRNA #1 0.29±0.02 0.17±0.05* 3.0±0.3* 
shRNA #2 0.26±0.05 0.19±0.01* 2.6±0.5* 
Scgb3a1 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.24±0.03 0.15±0.03* 3.8±0.4** 
shRNA #2 0.24±0.03 0.13±0.06* 4.3±1.3* 
Ccl1 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.34±0.02* 0.33±0.03* 9.2±2.8* 
shRNA #2 0.31±0.01* 0.29±0.03* 10.6±4.0* 
Cmtm5 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.28±0.08* 0.25±0.07* 8.2±1.5* 
shRNA #2 0.27±0.03* 0.24±0.04* 7.1±1.8* 
Cmtm6 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.30±0.09* 0.28±0.10* 12.5±1.2** 
shRNA #2 0.26±0.01* 0.24±0.01* 8.1±2.1* 
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Ctf2 
Control 0.24±0.03 0.22±0.03 6.4±0.6 
shRNA #1 0.32±0.08* 0.30±0.08* 23.2±11.9** 
shRNA #2 0.40±0.08** 0.37±0.10** 16.2±7.4** 
Cxcl2 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.43±0.05** 0.41±0.05** 8.3±0.2* 
shRNA #2 0.40±0.05** 0.39±0.05** 21.6±10.6* 
shRNA #3 0.33±0.06* 0.32±0.06** 15.6±8.1* 
Cxcl10 
Control 0.28±0.03 0.27±0.04 5.7±1.1 
shRNA #1 0.38±0.02* 0.36±0.02* 7.7±1.2* 
shRNA #2 0.35±0.03* 0.34±0.03* 7.2±0.6* 
Cxcl14 
Control 0.27±0.04 0.24±0.04 13.9±1.9 
shRNA #1 0.64±0.01** 0.62±0.01** 49.7±12.1** 
shRNA #2 0.69±0.05** 0.66±0.06** 45.6±18.5** 
FasL 
Control 0.34±0.06 0.31±0.06 8.6±1.0 
shRNA #1 0.43±0.05** 0.43±0.04** 18.0±3.3** 
shRNA #2 0.37±0.03* 0.36±0.02* 13.7±5.8** 
Gdf3 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.33±0.01* 0.32±0.01* 10.2±1.2* 
shRNA #2 0.30±0.02* 0.29±0.02* 9.3±2.5* 
shRNA #3 0.29±0.04* 0.28±0.04* 9.8±2.6* 
Il5 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.35±0.09* 0.31±0.08* 12.4±7.2* 
shRNA #2 0.27±0.08* 0.23±0.09* 8.0 ±0.1* 
Il17b 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.34±0.06* 0.31±0.09* 28.2±6.7** 
shRNA #2 0.32±0.10* 0.31±0.10* 9.3±1.8* 
Il17c 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.37±0.05** 0.36±0.05** 34.4±16.2** 
shRNA #2 0.29±0.01* 0.28±0.02* 11.0±1.7** 
Scg2 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.37±0.12** 0.36±0.11** 22.1±8.1** 
shRNA #2 0.32±0.06* 0.28±0.04* 11.3±4.5* 
Tnfa 
Control 0.30±0.04 0.26±0.03 6.4±1.0 
shRNA #1 0.36±0.03* 0.31±0.02* 8.7±1.8* 
shRNA #2 0.39±0.02* 0.32±0.02* 7.9±1.3* 
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Table II.4.  (continued) 
 
Tnfsf10 
Control 0.27±0.04 0.24±0.04 13.9±1.9 
shRNA #1 0.43±0.05** 0.40±0.06** 19.0±5.1* 
shRNA #2 0.45±0.07** 0.43±0.08** 40.5±13.5** 
shRNA #3 0.51±0.06** 0.50±0.06** 27.2±4.0** 
Ccl9 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.29±0.04* 0.26±0.04* 6.3±1.1 
shRNA #2 0.38±0.06** 0.34±0.06** 6.8±0.9 
Ccl17 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.29±0.12* 0.27±0.13* 7.1±4.0 
shRNA #2 0.34±0.06** 0.32±0.05* 7.6±1.9 
Cmtm2a 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.29±0.08* 0.28±0.07* 7.7±2.2 
shRNA #2 0.30±0.07* 0.29±0.08* 7.8±5.4 
shRNA #3 0.32±0.03* 0.31±0.02* 8.4±2.7 
Ebi3 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.28±0.09* 0.24±0.09* 4.8±1.0 
shRNA #2 0.27±0.06* 0.26±0.07* 7.6±1.9 
Il18 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.35±0.06** 0.33±0.06** 6.2±3.3 
shRNA #2 0.31±0.08* 0.30±0.08* 9.5±4.4 
Il21 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.30±0.11* 0.29±0.11* 7.9±2.9 
shRNA #2 0.31±0.04* 0.26±0.01* 4.3±2.0 
Il1f9 
Control 0.35±0.03 0.33±0.03 7.8±1.4 
shRNA #1 0.47±0.05* 0.45±0.06* 7.7±2.1 
shRNA #2 0.44±0.05* 0.39±0.02* 7.1±2.6 
Iltifb 
Control 0.25±0.04 0.22±0.03 6.2±0.7 
shRNA #1 0.47±0.06** 0.45±0.06** 7.9±2.5 
shRNA #2 0.35±0.05** 0.32±0.06** 5.4±2.1 
shRNA #3 0.35±0.07** 0.33±0.06** 8.6±5.7 
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CHAPTER III: MYOCYTE-DERIVED TNFSF14 IS A SURVIVAL FACTOR 
NECESSARY FOR MYOBLAST DIFFERENTIATION AND SKELETAL MUSCLE 
REGENERATION2 
 
III.1. Introduction 
 Tumor Necrosis Factor Superfamily Member 14 (Tnfsf14), also known as 
LIGHT (homologous to lymphotoxins, shows inducible expression, and competes with 
herpes simplex virus glycoprotein D for herpesvirus entry mediator (HVEM), a receptor 
expressed by T lymphocytes), exists in two main forms: a type II transmembrane 
glycoprotein that projects extracellularly, and a soluble cytokine formed by cleavage 
of the extracellular portion of the protein off of the cell membrane.[1] Through its 
receptors in the Tumor Necrosis Factor Receptor (TNFR) superfamily, HVEM (also 
known as TNFRSF14) and Lymphotoxin-β Receptor (LTβR), Tnfsf14 signaling is 
involved in lymphoid organ development and organization, as well as innate and 
adaptive immune responses.[2-4] In recent years Tnfsf14 has also emerged as a 
promising candidate for cancer immunotherapy. [5] 
Tnfsf14 regulates cell survival and apoptosis in lymphocytes and tumor cells, 
and the cellular context determines whether Tnfsf14 is pro-survival or pro-
apoptosis.[5-7] Neither the expression nor the function of Tnfsf14 or its receptors has 
been reported in skeletal muscles. Our current study uncovers Tnfsf14 as a critical 
regulator of myoblast differentiation and muscle regeneration by governing myoblast 
survival, and implicates Tnfsf14 in potential therapeutic development for 
maintenance of muscle health.  																																																								2	This work was published as: Waldemer-Streyer, Rachel J. and Jie Chen. Myocyte-
derived Tnfsf14 is a survival factor necessary for myoblast differentiation and skeletal 
muscle regeneration. Cell Death and Disease, 2015: e2026. 	
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III.2. Materials and Methods 
III.2.1. Antibodies and other reagents  
Anti-MHC (MF20) and Ad5-luciferase adenovirus were obtained from the 
Developmental Studies Hybridoma Bank developed under the auspices of the NICHD, 
National Institutes of Health and maintained by The University of Iowa, Department of 
Biological Sciences. Anti-Tnfsf14 (C-20 or FL-240 [used in IHC for co-labeling with 
myoD]) and anti-HVEM (D-5) for Western and immunohistochemistry were from Santa 
Cruz Biotechnology (Dallas, TX). Anti-tubulin was from Abcam (Cambridge, MA). Anti-
LTβR was from Sigma-Aldrich (St. Louis, MO). Anti-myoD was from Novus Biologicals 
(Littleton, CO). All other primary antibodies were from Cell Signaling Technology 
(Danvers, MA). All secondary antibodies were from Jackson ImmunoResearch 
Laboratories, Inc. (West Grove, PA). Gelatin and BrdU were from Sigma-Aldrich (St. 
Louis, MO). Rat-tail collagen I was from Gibco, Life Technologies. Recombinant 
sTnfsf14 was from PeproTech (Rocky Hill, NJ). Triciribine was from EMD Millipore. 
ELISA kit for detection of mouse sTnfsf14 was from Cloud Clone Corp. (Houston, TX). 
The pCMV6-myristoylated-HA-Akt (c.a.-Akt) plasmid was previously reported.[8] 
III.2.2. Cell culture  
C2C12 myoblasts were maintained in DMEM (4.5 g/L glucose) supplemented 
with 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C with 7.5% CO2. To 
induce differentiation, cells were plated on tissue culture plates coated with 0.2% gelatin 
and grown to 100% confluence before switching to differentiation medium (DMEM 
containing 2% horse serum). The cells were replenished with fresh differentiation 
medium daily for 3 days. 
III.2.3. Mouse primary myoblast isolation and differentiation  
Primary myoblasts were isolated from 2- to 5-day-old FVB neonates as described 
previously,[9] and maintained at low density on 50 ug/ml collagen-coated tissue culture 
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plates. Differentiation was induced at 70-80% cell density in differentiation medium for 2 
days. 
III.2.4. Immunofluorescence microscopy and quantitative analysis of 
myocytes  
C2C12 cells and primary myoblasts differentiated in 12-well plates were fixed 
and stained for MHC and with DAPI as previously described.[9] When probing for 
mTnfsf14, the permeabilization step was omitted. Cells were examined with a Leica DMI 
4000B fluorescence microscope. The fluorescent images were captured using a 
RETIGA EXi camera, and analyzed with Image Pro Express software (Media 
Cybernetics). The fusion index was calculated as the percentage of nuclei in myotubes 
with ≥2 nuclei. Each data point was generated from quantifying all cells in 5 randomly 
chosen microscopic fields, totaling 2000–3500 nuclei for C2C12 cells and 300-900 nuclei 
for primary myoblasts.  
III.2.5. Lentivirus-mediated RNAi  
shRNAs in the pLKO.1-puro vector were purchased from Sigma-Aldrich 
(MISSION® TRC). Clone IDs are: shTnfsf14 #1, TRCN0000066398; shTnfsf14 #2, 
TRCN0000066400; shHVEM #1, TRCN0000065856; shHVEM #2, TRCN0000065857; 
shLTβR #1,	TRCN0000065456; shLTβR #2: TRCN0000065457. A hairpin of scrambled 
sequence (shScramble) as a negative control and lentivirus packaging were previously 
described.[10] Virally transduced C2C12 cells were selected in 3 µg/ml puromycin for 2 
days, followed by differentiation in media containing puromycin for 3 days. Virally 
transduced primary myoblasts were induced to differentiate without puromycin selection. 
III.2.6. Adenovirus-mediated Tnfsf14 overexpression  
Adenovirus expressing Tnfsf14 (Ad-mTnfsf14; a kind gift from Dr. Yang-Xin Fu of 
the University of Chicago) [11] and a control Ad5 adenovirus expressing luciferase (Ad-
luc) were amplified in HEK AD293 cells. Briefly, a small amount of virus was used to 
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infect AD293 cells. Two to three days post-transfection, the cells were detached from the 
plate via pipetting and centrifuged at 400x g for 5 minutes.  Cells were then resuspended 
in PBS and subjected to four rounds of freeze/thaw cycles. The samples were 
centrifuged again at 10,000x g for 10 minutes, after which the supernatant was collected 
and used directly to infect C2C12 cells or primary myoblasts. 
III.2.7. Quantitative RT-PCR  
C2C12 cells or regenerating muscles were lysed in Trizol (Invitrogen), and RNA 
was isolated following the manufacturer's protocol. cDNA was synthesized from 1 µg 
RNA using the RealMasterScript SuperMix cDNA synthesis kit (5Prime) following the 
manufacturer's protocol, followed by quantitative PCR on a StepOne Plus (Applied 
Biosystems) using gene specific primers. β-actin was used as a reference to obtain the 
relative fold change for target samples using the comparative CT method.  Mouse β-actin 
primers: forward 5′-ttgctgacaggatgcagaag-3′; reverse 5′-atccacatctgctggaaggt-3′. Pre-
validated mouse Tnfsf14 primers were purchased from Qiagen (QuantiTect Primer 
Assays). Mouse HVEM and LTβR primers were previously published.[12, 13] 
III.2.8. Western blotting  
Cells were lysed in SDS sample buffer with 10% β-mercaptoethanol. Proteins 
were resolved by SDS-PAGE and transferred onto polyvinylidene fluoride (PVDF) 
membrane (Millipore) and incubated with various antibodies following the manufacturers’ 
recommendations. Detection of horseradish peroxidase-conjugated secondary 
antibodies was performed with chemiluminescence solution (100 mM Tris-HCl, 0.009% 
H2O2, 225 µM coumaric acid, 1.25 mM luminol) and developed on x-ray films. 
Quantification of western blot band intensities was performed by densitometry of x-ray 
images using the ImageJ software. 
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III.2.9. Cell proliferation and apoptosis assays  
To measure proliferation of C2C12 cells, BrdU labeling was performed as 
previously described.[10] To assess apoptosis, TUNEL assays were performed following 
manufacturer’s manual (Promega).  
III.2.10. Injury-induced muscle regeneration and manipulation of Tnfsf14 
expression in mice  
Male FVB mice aged 8-10 weeks were used in all the regeneration experiments. 
Muscle injury was induced by injection of BaCl2 (50 µl of 1.2% w/v in saline) into TA 
muscles as previously described.[14] On various days after injury, the mice were 
euthanized, and the TA muscles were collected, followed by RNA extraction, or 
cryosection and staining. To knock down Tnfsf14, shTnfsf14 viruses (and shScramble as 
control) as described above but concentrated to 100x via ultracentifugation were co-
injected with BaCl2 into mouse hind limb TA muscles. To overexpress Tnfsf14, Ad-
mTnfsf14 (Ad-luc as control) described above was co-injected with BaCl2 into TA 
muscles. The injected muscles were collected 5, 7, or 14 days after injury and subjected 
to RNA isolation or cryosection. 
III.2.11. Muscle tissue cryosection, hematoxylin and eosin staining, and 
immunohistochemistry  
TA muscles were isolated, frozen in liquid-nitrogen-cooled 2-methylbutane, and 
embedded in TBS tissue freezing medium (Thermo Fisher Scientific). Sections of 10-µm 
thickness were obtained with a cryostat (Microm HM550; Thermo Fisher Scientific) at 
−20°C, placed on uncoated slides, and stained with hematoxylin and eosin (H&E). 
Separately, the sections were fixed by 1.5% paraformaldehyde, incubated with anti-
Tnfsf14, HVEM, LTβR, or cleaved PARP antibody, followed by incubation with Alexa-
conjugated secondary antibodies and DAPI. Imaging was performed with a fluorescence 
microscope (DMI 4000B; Leica) with a 20× dry objective (Fluotar, numerical aperture 
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0.4; Leica). The bright field and fluorescence images were captured at 24 bit and 8 bit, 
respectively, at room temperature using a camera (RETIGA EXi; Q-Imaging) equipped 
with Image Pro Express software (Media Cybernetics). The images were then processed 
in Photoshop CS5 (Adobe), where brightness and contrast were adjusted. Fluorescence 
images were pseudo-colored and adjusted, when necessary, by identical parameters for 
all samples in the same experiment. A total area of 464,000 µm2 from the degenerated 
regions of each TA muscle was scored for centrally nucleated regenerating myofiber 
numbers and their cross-sectional area (CSA).  The CSA of a minimum of 100 myofibers 
was measured to generate each data point. 
III.2.12. Statistics  
All data shown are representative results of at least 3 independent experiments, 
or n ≥ 5 for animal experiments. All quantitative data are presented as mean ± standard 
deviation (SD).  Whenever necessary, statistical significance of the data comparison was 
analyzed by performing one-sample or paired two-tailed t-tests. * P<0.05; ** P<0.01. 
III.2.13. Study Approval  
All animal experiments in this study followed protocols approved by the Animal 
Care and Use Committee at the University of Illinois at Urbana-Champaign.  
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III.3. Results 
III.3.1. Tnfsf14 is required for myoblast differentiation 
 The mouse myoblast cell line C2C12 offers a convenient in vitro system to study 
myoblast differentiation as well as the effects of gene knockdown by lentivirus-delivered 
shRNA. We found that knockdown of Tnfsf14 (Fig. 1A) significantly impaired C2C12 
myotube formation, as indicated by myosin heavy chain (MHC) staining of the myocytes 
and quantification of the fusion index (Fig. 1B).  Two independent shRNAs yielded 
similar results, confirming the specificity of RNAi targeting. Moreover, Tnfsf14 depletion 
in C2C12 cells reduced the expression of muscle differentiation-specific proteins (Fig. 
1C), including the early myogenic markers MEF2A, p21, and myogenin. This result 
suggests that Tnfsf14 functions during the early stages of differentiation.  
We set out to examine the expression and function of Tnfsf14 in myoblasts. As 
shown in Fig. 1D, we found that Tnfsf14 expression increased over the course of 
differentiation at the mRNA level. The amount of the soluble cytokine (sTnfsf14) 
detected in the media by ELISA also increased during differentiation significantly (Fig. 
1E), although the concentrations were only at the lowest detection threshold of the 
assay. To probe the membrane-bound form (mTnfsf14), we immunofluorescently labeled 
differentiating myoblasts that had been washed to remove sTnfsf14, but that were not 
permeabilized, thus ensuring that all signal came from the external side of the cells. We 
observed that mTnfsf14 is lowly expressed in proliferating cells, but appeared suddenly 
at 24 hours of differentiation and persisted in fusing cells as differentiation progressed 
(Fig. 1F). The specificity of antibody labeling was confirmed by Tnfsf14 knockdown (Fig. 
1G). It is possible that mTnfsf14 is the predominant form of this cytokine in muscle cells. 
Nevertheless, the addition of recombinant sTnfsf14 to the differentiation media rescued 
myotube formation in cells depleted of Tnfsf14 (Fig. 1H). A constitutively membrane-
bound form of recombinant Tnfsf14 delivered by adenovirus [11] also fully reversed 
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Tnfsf14 knockdown phenotype (Fig. 1I). Hence, the two forms of Tnfsf14 appeared to 
function similarly in myocytes. These results further validated the on-target effect of 
RNAi. Tnfsf14 knockdown in mouse primary myoblasts also led to impaired myotube 
formation, which was rescued by adding recombinant sTnfsf14 protein to the media (Fig. 
2). Taken together, these observations strongly suggest that Tnfsf14 plays a positive 
cell-autonomous role in skeletal muscle differentiation.  
III.3.2. Tnfsf14 is necessary for maintaining sufficient cell numbers for 
differentiation 
In addition to inhibiting myotube formation, knockdown of Tnfsf14 also reduced 
the number of cells present in culture over the course of differentiation (Fig. 3A). 
Importantly, this decrease in cell number was corrected by adding recombinant sTnfsf14 
to differentiating cells (Fig. 3A). We wondered whether the lower number of cells upon 
Tnfsf14 knockdown was a result of reduced survival in this cell population. Indeed, 
Tnfsf14 depletion increased apoptosis in differentiating myoblasts, as indicated by a 
markedly increased incidence of TUNEL labeling (Fig. 3B) as well as elevated caspase-
3 activation and PARP cleavage (Fig. 3C).  Addition of recombinant sTnfsf14 in Tnfsf14-
depleted cells reversed the cell death rate to normal levels (Fig. 3B). Interestingly, we 
found that Tnfsf14 could also function as a survival factor in proliferating myoblasts 
exposed to etoposide, which is known to induce apoptosis in C2C12 cells.[15] As shown 
in Fig. 4A, recombinant sTnfsf14 drastically reduced the apoptosis rate in etoposide-
treated cells. Hence, the function of Tnfsf14 in supporting myoblast survival is not limited 
to the differentiation process. Of note, cell proliferation as measured by 
bromodeoxyuridine (BrdU) labeling was also diminished by Tnfsf14 knockdown 24 hours 
after the onset of differentiation; BrdU labeling could be restored to normal levels by 
recombinant sTnfsf14 (Fig. 4B). However, since by 24 hours of differentiation myoblasts 
have largely withdrawn from the cell cycle, the further reduction of proliferation is unlikely 
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to contribute significantly to the reduced cell number in Tnfsf14-depleted cells. Instead, 
loss of cell survival is likely responsible.  
In light of the results above, we next asked whether the impaired differentiation 
phenotype upon Tnfsf14 knockdown was a direct consequence of reduced cell number. 
To probe this question, we plated C2C12 cells depleted of Tnfsf14 at increasing 
densities, thus normalizing cell numbers to those of the control by the end of 
differentiation. Remarkably, we found that Tnfsf14-knockdown cells differentiated 
normally when the cell numbers were brought up to control levels (Fig. 3D). This 
observation suggests that Tnfsf14 promotes myogenesis by maintaining a sufficient 
number of myoblasts in the differentiating population. 
III.3.3. HVEM and LTβR, receptors for Tnfsf14, are required for myoblast 
differentiation and survival 
 HVEM and LTβR are established receptors for Tnfsf14 in various types of cells 
[3]. To assess whether Tnfsf14 would also signal through one or both of these receptors 
in skeletal muscle, we first examined the expression of these two receptors in muscle 
cells.  Indeed, we found both receptors to be expressed in C2C12 cells. HVEM 
expression was drastically upregulated over the course of differentiation at both the 
mRNA and protein levels (Fig. 5A, B), whereas LTβR levels were not significantly 
changed (Fig. 5A, B).  Importantly, knockdown of either HVEM or LTβR by lentivirus-
delivered shRNA led to a similar phenotype to that of Tnfsf14 knockdown: impaired 
myotube formation and a lower cell number (Fig. 5C, D, E). The effects were observed 
with two independent shRNAs (Fig. 5F). We did not observe an additive effect on 
myogenesis or cell number when both receptors were depleted simultaneously, although 
knockdown efficiency for each gene was typically inferior when the cells were co-
infected by two shRNA viruses targeting two separate genes (data not shown). 
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Collectively, these data suggest that both HVEM and LTβR may function as the 
myogenic receptors of Tnfsf14 in a non-redundant fashion.  
To further validate the roles of HVEM and LTβR in mediating the action of 
Tnfsf14, we examined the effect of depleting the receptors on cell survival. We observed 
increased TUNEL signal in C2C12 cells depleted of either receptor (Fig. 5G). Notably, 
this increased cell death was not reversed by the addition of recombinant sTnfsf14. This 
is in contrast to the impaired survival phenotype seen in cells depleted of Tnfsf14, which 
could be rescued by the recombinant protein, and is consistent with Tnfsf14 acting 
through these receptors. These observations suggest that both HVEM and LTβR may 
mediate Tnfsf14 function in cell survival. We also measured BrdU labeling in C2C12 
cells with HVEM or LTβR knockdown. A lower fraction of BrdU-positive cells was 
observed upon the depletion of LTβR, but not of HVEM (Fig. 6), reminiscent of Tnfsf14 
knockdown (Fig. 4B). Hence, both LTβR and HVEM are involved in cell survival, 
whereas only LTβR plays a role in cell proliferation. 
III.3.4. Akt mediates Tnfsf14 signaling 
We next considered the molecular pathway that mediates Tnfsf14’s myogenic 
function. One of the most attractive candidates was Akt, which is a known mediator of 
cell survival and proliferation.[16, 17] Akt is also a key regulator of myogenic 
differentiation [18] and muscle mass,[19] and its role in myoblast survival has been 
reported.[20, 21] Additionally, HVEM signaling has been previously linked to Akt 
activation in T cells [22]. Indeed, we observed decreased levels of phosphorylated Akt in 
both primary myoblasts and C2C12 cells depleted of Tnfsf14 (Fig. 7A). Knockdown of 
HVEM also impaired Akt phosphorylation during the early stages of differentiation, 
whereas LTβR depletion had a similar effect at a later time of differentiation (Fig. 7B). 
Therefore, HVEM and LTβR may both signal through Akt, but in a temporally-regulated 
manner. To assess the functional releva
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expressed a constitutively active (c.a.) Akt [23] in C2C12 cells. As shown in Fig. 7C, the 
impaired differentiation observed after Tnfsf14 knockdown was fully rescued by the 
expression of c.a.-Akt. Notably, c.a.-Akt also rescued differentiation in myoblasts 
depleted of HVEM or LTβR, providing further evidence that both receptors signal 
independently through Akt (Fig. 7D). Taken together, our observations strongly suggest 
that Tnfsf14 regulates myoblast differentiation via Akt. 
III.3.5. Tnfsf14 is necessary for robust skeletal muscle regeneration 
 In order to probe the physiological relevance of Tnfsf14’s myogenic function, we 
utilized a well-established murine model of post-injury skeletal muscle regeneration.[14, 
24] Barium chloride (BaCl2) was injected into the tibialis anterior (TA) muscle of the 
hindlimb to induce localized necrosis. As shown in Figure 8A, Tnfsf14 mRNA levels 
measured by qRT-PCR rose on day 3 after injury (AI) and returned to basal levels by 
day 5 AI.  Because multiple cell types present in regenerating muscle could contribute to 
this Tnfsf14 mRNA expression, we performed immunohistochemistry on sections of 
regenerating TA muscles. As shown in Fig. 9A, no Tnfsf14 expression was detected in 
undamaged muscle, but Tnfsf14 staining was noted in mononucleated cells on day 3 AI. 
To determine whether these Tnfsf14-positive cells were myogenic, we co-labeled injured 
muscles for both Tnfsf14 and MyoD, a marker of activated and proliferating satellite 
cells. As shown in Fig. 8B, we observed cells that were positive for both markers at day 
3 AI, demonstrating that myogenic progenitors express Tnfsf14 during early 
regeneration. We also observed Tnfsf14+/MyoD- cells, which could represent either 
infiltrating immune cells or myogenic progenitors not yet expressing MyoD. Strikingly, 
strong Tnfsf14 staining was also clearly observed in the newly formed myofibers visible 
on day 5 AI (Fig. 9A), unequivocally revealing the expression of Tnfsf14 by regenerating 
muscle cells.   
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We also performed immunohistochemistry to examine the two Tnfsf14 receptors 
in muscle as shown in Fig. 9A. Unlike Tnfsf14, HVEM and LTβR were both found at the 
periphery of myofibers in uninjured muscles. Interestingly, most mononucleated cells in 
the early stages of regeneration exhibited a strong HVEM signal, while LTβR signal was 
only weakly present in a small number of mononucleated cells. Newly regenerated 
myofibers on day 5 AI stained strongly for LTβR and were also positive for HVEM, 
although the latter continued to be predominantly expressed in mononucleated cells. By 
day 7 AI, both receptors were found at the periphery of the new myofibers. Hence, both 
Tnfsf14 and its receptors are expressed in regenerating myofibers during early stages of 
regeneration.  
To probe the physiological function of Tnfsf14, we introduced Tnfsf14 shRNA at 
the time of muscle injury by co-injecting lentivirus expressing the shRNA with BaCl2 into 
TA muscles. Efficient knockdown of Tnfsf14 was confirmed by immunostaining (Fig. 9B). 
Strikingly, muscle regeneration was markedly impaired by the knockdown, as evidenced 
by significantly fewer regenerating myofibers in the shTnfsf14-injected muscles 
compared to control shRNA-injected muscles during early regeneration (Fig. 9B,C). 
While some regenerating myofibers were present in the Tnfsf14-knockdown muscles, 
they were of a significantly reduced size as measured by cross-sectional area (Fig. 
9B,D). Interestingly, muscles with reduced Tnfsf14 expression also exhibited increased 
cleaved PARP labeling during early regeneration, indicating higher levels of cell death 
(Fig. 8C). These results are in line with our in vitro data demonstrating that Tnfsf14 
functions as pro-survival factor in myogenic cells (Fig. 3A-C; Fig. 4A). Taken together, 
our observations provide strong evidence that Tnfsf14 is necessary for muscle 
regeneration post-injury. 
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III.3.6. Tnfsf14 overexpression enhances skeletal muscle regeneration via 
activation of Akt 
 Next, we examined the effect of Tnfsf14 overexpression on muscle regeneration. 
Adenovirus expressing mTnfsf14 was co-injected with BaCl2 into TA muscles. 
Remarkably, significantly larger regenerating myofibers were observed on day 7 and day 
14 AI in mTnfsf14 adenovirus-injected muscles compared to muscles injected with a 
control adenovirus (Fig. 10A).  To test whether this regeneration-promoting effect of 
Tnfsf14 was through activation of Akt, we repeated this experiment in the presence of 
the Akt inhibitor triciribine. As shown in Fig. 10B, daily injections of triciribine abrogated 
the effect of mTnfsf14 and the regenerating myofibers returned to a normal size. 
Therefore, overexpression of Tnfsf14 can enhance normal muscle regeneration post-
injury in an Akt-dependent manner. 
 
III.4. Discussion 
We have identified Tnfsf14 as a novel and essential regulator of skeletal 
myogenesis. Our findings reveal that Tnfsf14 functions as a pro-survival factor during 
myogenic differentiation, an effect mediated by its receptors HVEM and LTβR in an 
Akt-dependent manner. Furthermore, we show that Tnfsf14 is both essential for 
robust skeletal muscle regeneration, and capable of enhancing normal regeneration 
when administered exogenously. To date, only a handful of skeletal myocyte-secreted 
factors have been demonstrated to regulate myogenesis in a cell-autonomous manner, 
despite evidence that muscle cells are prolific cytokine secretors.[25-27] We expect that 
future studies will reveal a large network of such cytokines involved in skeletal muscle 
cell differentiation and muscle tissue regeneration. 
Our findings indicate that by promoting myoblast survival Tnfsf14 plays a key 
role in ensuring a sufficient number of cells available for fusion during differentiation. 
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Interestingly, the reported effects of Tnfsf14 on cell division, survival, and death 
appear to be pleiotropic. Tnfsf14 has been described as pro-proliferation, anti-
proliferation, pro-apoptosis, and anti-apoptosis depending on the cellular contexts.[5-7] 
A recent study suggests that the relative ratio of LTβR to HVEM levels in the cell may 
determine the biological effects of Tnfsf14: in cells with higher levels of LTβR than 
HVEM, Tnfsf14 induced apoptosis, whereas cells expressing the two receptors 
equally favored survival upon Tnfsf14 stimulation.[28] Consistent with this model, the 
LTβR:HVEM ratio may be relatively high in undifferentiated myoblasts. Subsequently, 
upon entering differentiation, the LTβR:HVEM ratio may drop as HVEM levels rise 
while LTβR levels remain steady (Fig. 5A), potentially resulting in cell survival. 
However, our observation that depletion of either receptor promotes apoptosis 
suggests that it is not simply a balancing act between the two receptors. Rather, both 
LTβR and HVEM are necessary for the pro-survival function of Tnfsf14 during 
myogenesis. 
This level of complexity may be characteristic of cytokine action in regulating cell 
fate. For instance, the founding member of the tumor necrosis factor superfamily, TNFα, 
is infamously capable of inducing either survival or apoptosis through variable activation 
of downstream pathways.[29] TNFα has also been long suspected of involvement in 
cachexia progression.[30] Interestingly, Tnfsf14 has been demonstrated to specifically 
block TNFα-mediated apoptosis in primary hepatocytes, but not liver cancer cell 
lines.[31] While the exact mechanism and physiological source of TNFα in cachexic 
skeletal muscle atrophy is still unclear, Tnfsf14 may be an intriguing therapeutic target 
for further development. 
We have found Akt to be a key mediator of Tnfsf14 action. Akt can prevent cell 
death by phosphorylation-mediated inactivation of a variety of important players in 
apoptosis, including the Bcl2-related protein BAD, caspase-9, and the Forkhead 
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transcription factor FKHRL1,[32-34] as well as via activation of the major survival 
signaling molecule NF-κB.[35] Although HVEM has been previously linked to Akt 
activation,[22] the mechanism for this phenomenon is not fully understood. HVEM and 
LTβR are both TNFR superfamily members that lack the canonical TNFR death domain. 
Such TNFRs typically transduce signals by binding directly to TNF Receptor Associated 
Factors (TRAFs),[36] and several TRAFs are believed to be involved in the activation of 
Akt via distinct mechanisms.[37] HVEM and LTβR have been reported to bind TRAF1, 
2, 3, 5, and TRAF2, 3, 5, respectively.[38-41] The exact mechanism(s) by which these 
two receptors activate Akt is certainly an area of potentially fruitful investigations in 
the future. 
Of the reported muscle-secreted factors, insulin-like growth factor 1 and 2 
(IGF1 and IGF2), both signaling through IGF1 receptor, have been well established 
to support myoblast survival.[42] Differentiation of myoblasts in culture requires the 
autocrine action of IGF2, and is stimulated by both exogenous IGF1 and IGF2.[43] In 
vivo, localized IGF1 overexpression promotes myofiber hypertrophy [44] and 
accelerates muscle regeneration post-injury.[45, 46] Our discovery of Tnfsf14’s role 
expands the muscle cell’s repertoire of secreted factors that regulate myoblast 
survival and muscle regeneration in vivo. It should be noted that many facets of IGF 
regulation in myoblasts, including survival, proliferation, and myogenic gene 
expression, likely contribute to myogenic differentiation.[43] In contrast, Tnfsf14 
regulation of differentiation appears to be primarily through its survival function, as 
simply increasing cell number fully rescued fusion from Tnfsf14 deficiency (Fig. 3D). 
It should also be noted that some degree of apoptosis during differentiation is 
believed to be necessary for myoblast fusion.[47] It is conceivable that a network of 
cytokines governs the balance between apoptosis and survival during myoblast 
differentiation. Indeed, our functional screen of cytokines has revealed several known 
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apoptosis-inducing factors as potential regulators.[48] Future characterization of 
those candidates may be rewarding. 
Throughout the process of skeletal muscle regeneration in vivo, there is a 
complex interplay between infiltrating immune cells, dying myofibers, activated muscle 
progenitor cells, and regenerating fibers.[49] It is important to note that the lentiviruses 
and adenoviruses that we used to manipulate Tnfsf14 levels in vivo were not muscle 
cell-specific. Thus, although muscle cells should be the prevailing cell type present 
around the time of intramuscular injection, it is conceivable that other cell types (for 
example, infiltrating macrophages) could also have been subjected to Tnfsf14 
knockdown or overexpression during muscle injury. Tnfsf14 ablation specifically in 
muscle cells, such as in a muscle-specific knockout mouse, would allow more 
definitive studies probing the contribution of muscle-derived Tnfsf14 in adult muscle 
regeneration. Nevertheless, our study is the first to reveal Tnfsf14 expression in 
regenerating myofibers and the critical role of Tnfsf14 in myogenesis.  
We observed that introduction of exogenous mTnfsf14 during muscle injury 
led to more robust muscle regeneration. Interestingly, this phenomenon does not 
translate to cultured cells in vitro. For example, sTnfsf14 can rescue—but not 
enhance—the fusion index, total nuclei number, and changes to cell survival and 
proliferation seen with Tnfsf14 knockdown in C2C12 cells (Fig. 1H; Fig. 3A, B; Fig. 
4B). This discrepancy with our in vivo results likely stems from the very different 
environments that surround cells in culture versus those in an animal.  The injury 
caused by BaCl2 and subsequent inflammation in vivo surely introduces stronger pro-
death signals than those found in differentiating C2C12 cells. It is possible that 
Tnfsf14 expression has a more potent effect in tissues facing a greater challenge to 
survival. Our observation that sTnfsf14 does protect control C2C12 cells from death 
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when treated with etoposide, a strong exogenous pro-death signal (Fig. 4A), may be 
further evidence for this hypothesis. 
Our observation that exogenously administered Tnfsf14 enhanced muscle 
regeneration may have important implications in future development of therapeutics. 
Despite its myogenic potential, IGF1 is a growth factor that can promote cancer 
progression, and is thus a poor therapeutic tool in the context of cancer-associated 
cachexia.[30] This is in stark contrast to Tnfsf14, which is a promising candidate for anti-
tumor immunotherapy due to its ability both to recruit and activate T-lymphocytes and 
dendritic cells to the tumor microenvironment, as well as to directly induce apoptosis of 
cancer cells.[5] Indeed, mesenchymal stem cells overexpressing Tnfsf14 are capable of 
targeting tumors and inhibiting their growth in mice.[50] Development of a cancer 
therapy that treats both the tumor and cancer “side-effects” such as cachexia could 
simultaneously improve patient survival rates and quality of life. Tnfsf14 may be a 
promising candidate to pursue in the search for such a multitasking treatment.  
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III.5. Figures 
 
 
Fig. III.1. Tnfsf14 is a positive regulator of myoblast differentiation 
(A) C2C12 cells were infected with lentiviruses expressing shTnfsf14 or shScramble 
(negative control), selected for 2 days, followed by cell lysis and western analysis (n=4).  
(B) Cells treated as in (A) were differentiated for 72 hrs, followed by staining for MHC 
(green) and DAPI (pseudocolored magenta), and quantification of fusion index (n=5).  
(C) Cells treated as in (A) were differentiated, and at indicated time points (“Hrs diff”) 
were lysed and subjected to western analysis (n=4).  
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Fig. III.1. (continued) 
 
(D) RNA was isolated from differentiating C2C12 cells at indicated time points and 
subjected to qRT-PCR analysis for Tnfsf14 mRNA levels (n=6).  
(E) Cell media over the course of differentiation were subjected to ELISA assay to 
determine sTnfsf14 levels (n=8). 
(F) C2C12 cells were differentiated until the indicated time points (“Hrs diff”), then 
stained without permeabilization for Tnfsf14 (red) and DAPI (blue) (n=4). 
(G) Cells treated as in (A) were differentiated for 24 hrs, followed by staining for Tnfsf14 
(red) and DAPI (blue) (n=3). 
(H) C2C12 cells were treated as in (A), and then differentiated in the presence or 
absence of 25 ng/mL recombinant sTnfsf14 for 3 days, followed by staining for MHC and 
DAPI, and quantification of fusion index (n=3).  
(I) C2C12 cells were treated as in (A), and then infected with adenoviruses expressing 
mTnfsf14 or luciferease (luc; negative control), followed by differentiation for 3 days and 
then staining for MHC and DAPI. The fusion index was quantified (n=3). 
One-sample 2-tailed t test was performed for data in (D), and paired 2-tailed t tests for all 
other data. *P<0.05; **P<0.01. All error bars represent SD of independent replicates. 
Scale bars: 50 µm. 
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Fig. III.2. Tnfsf14 is necessary for primary myoblast differentiation 
Mouse primary myoblasts were infected with shRNA lentiviruses and differentiated for 48 
hrs with or without 50 ng/mL sTnfsf14, followed by staining for MHC (green) and with 
DAPI (red). The fusion index was quantified (n=3). 
Scale bar: 50 µm. All error bars represent SD of independent replicates.  
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Fig. III.3. Tnfsf14 maintains sufficient cell numbers for differentiation 
(A) C2C12 cells were infected with lentiviruses expressing shTnfsf14 or shScramble, 
selected for 2 days, followed by differentiation for 72 hrs in the presence or absence of 
25 ng/mL recombinant sTnfsf14 and subsequent staining with DAPI. Stained nuclei were 
counted (n=3). 
(B) Cells were treated as in (A) but differentiated for 24 hrs, followed by TUNEL assay to 
detect apoptotic cells (n=4). 
(C) Primary myoblasts were infected with shRNA lentiviruses and differentiated for 24 
hrs, followed by cell lysis and western analysis (n=3). 
(D) C2C12 cells were infected with shRNA lentiviruses and then plated at different 
densities in order to compensate for the lower cell number seen in Tnfsf14-knockdown 
cells.  Cells were differentiated for 72 hrs and subsequently stained for MHC. Nuclei 
number and fusion index were quantified (n=4). Scale bar: 50 µm. 
One-sample 2-tailed t test was performed for data in (A), and paired 2-tailed t tests for all 
other data. **P<0.01. All error bars represent SD of independent replicates. 
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Fig. III.4. Tnfsf14 suppresses apoptosis and promotes proliferation of C2C12 cells 
(A) Proliferating C2C12 cells were exposed to 10 µM etoposide for 24 hours in the 
presence or absence of 25 ng/mL recombinant sTnfsf14. TUNEL assays were 
performed to assess the percentage of apoptotic cells (n=5). 
(B) C2C12 cells were treated as in (A) and subjected to BrdU labeling to assess cell 
proliferation (n=4). 
All error bars represent SD of independent replicates. 
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Fig. III.5. Both HVEM and LTβR are required for myoblast differentiation and 
survival 
(A) HVEM or LTβR mRNA transcripts were measured over the course of C2C12 
differentiation by qRT-PCR (n=4 for HVEM and n=3 for LTβR).  
(B) HVEM and LTβR protein levels during C2C12 cell differentiation were analyzed by 
western blotting (n=4). 
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Fig. III.5 (continued) 
 
(C) C2C12 cells were infected with shRNA lentiviruses as indicated, selected for 2 days, 
followed by differentiation for 72 hrs and subsequent staining for MHC and with DAPI. 
Scale bar: 50 µm. 
(D-E) Fusion index and total nuclei number were quantified for experiments in (C) (n=5).  
(F) Lentivirus-mediated knockdown of HVEM and LTβR in C2C12 cells were confirmed 
by western analysis (n=3 for HVEM and n=4 for LTβR).  
(G) C2C12 cells treated as in (C) but differentiated for 24 hrs were subjected to TUNEL 
assays, and the percentage of apoptotic cells was measured (n=4).  
One-sample 2-tailed t test was performed for data in (A) and relative nuclei number in 
(D-E), paired 2-tailed t tests for all other data. *P<0.05; **P<0.01. All error bars represent 
SD of independent replicates. 
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Fig. III.6. Tnfsf14 receptors in cell proliferation 
C2C12 cells were infected with shRNA lentiviruses as indicated and differentiated for 24 
hrs in the presence or absence of 25 ng/mL recombinant sTnfsf14, followed by BrdU 
labeling to assess cell proliferation (n=4). All error bars represent SD of independent 
replicates. 
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Fig. III.7. Tnfsf14 regulates myoblast differentiation through Akt 
(A) Primary mouse myoblasts (n=4) and C2C12 cells (n=5) were infected with shRNA 
lentiviruses and differentiated for 24 hrs, followed by cell lysis and western analysis. 
(B) C2C12 cells were infected with shRNA lentiviruses as indicated and differentiated for 
24 or 72 hrs, followed by cell lysis and western analysis (n=5). 
(C-D) C2C12 cells were infected with shRNA lentiviruses as indicated, and then 
transfected with a constitutively-active Akt (c.a.-Akt) or a control (pcDNA) construct, 
followed by differentiation for 72 hrs and subsequent staining for MHC and with DAPI. 
Fusion index and total nuclei number were quantified (n=4). 
One-sample 2-tailed t test was performed for data in (B) and paired 2-tailed t tests for 
data in (C-D). *P<0.05; **P<0.01. All error bars represent SD of independent replicates. 
  
	 108 
 
Fig. III.8. Tnfsf14 expression during muscle regeneration 
(A) TA muscles were injured by BaCl2 injection, and isolated on days 3, 5, 7, and 14 
after injury (AI). RNA was isolated and subjected to qRT-PCR assays to measure 
relative levels of Tnfsf14 mRNA (n=3). All error bars represent SD of independent 
replicates. 
(B) TA muscles were injured by BaCl2 injection, and isolated on day 3 after injury (AI). 
Upon cryosection, immunofluorescence staining for Tnfsf14 (green), MyoD (red), and 
DAPI (blue) was performed (n=3). Scale bar: 25 µm. 
(C) TA muscles were co-injected with BaCl2 and shRNA viruses, and isolated on day 3 
AI. Upon cryosection, immunofluorescence staining for cleaved PARP (green) and DAPI 
(blue) was performed (n=3). Scale bar: 50 µm. 
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Fig. III.9. Tnfsf14 is required for robust muscle regeneration in vivo 
(A) TA muscles were injured by BaCl2 injection, and isolated on days 3, 5, 7, and 14 
after injury (AI). Upon cryosection, H&E staining or immunofluorescence staining for 
Tnfsf14, HVEM and LTβR (green) together with DAPI (blue) were performed (n=3). 
(B) TA muscles were co-injected with BaCl2 and shRNA viruses, and then processed as 
described in (A). 
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Fig. III.9. (continued) 
 
(C) Quantification of the number of regenerating myofibers on muscle sections from (B). 
(D) Quantification of the regenerating myofiber cross-sectional area (CSA) on muscle 
sections from (B). For each time point in (B-D) 5 or 6 mice were analyzed. 
Paired 2-tailed t test was performed to compare shScramble and shTnfsf14 at each time 
point. **P<0.01. All error bars represent SD of independent replicates.  Scale bars: 50 
µm.  
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Fig. III.10. Local overexpression of Tnfsf14 enhances skeletal muscle regeneration 
in an Akt-dependent manner 
(A) TA muscles were co-injected with BaCl2 and adenoviruses expressing mTnfsf14 (Ad-
mTnfsf14) or luciferase (Ad-luc), and isolated on days 5, 7, and 14 AI. Upon cryosection, 
H&E staining was performed, and regenerating myofiber CSA was quantified. For each 
time point 5 to 7 mice were analyzed. 
(B) The procedure described in (A) was repeated, and the animals received daily 
intraperitoneal injection of 100 µL triciribine (0.26 µg/µl) or 20% DMSO as a control, 
starting on the day of BaCl2 injection. For each condition 6 mice were analyzed.  
All error bars represent SD of independent replicates. Scale bars: 50 µm. 
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CHAPTER IV: CXCL14 INHIBITION ACCELERATES SKELETAL MYOGENESIS BY 
PROMOTING CELL CYCLE WITHDRAWAL  
 
IV.1. Introduction 
The physiological function of chemokine (C-X-C motif) ligand 14 (Cxcl14) is 
poorly understood. Also known as BRAK (breast and kidney-expressed chemokine), 
Cxcl14 expression is relatively high in many normal tissues but lost in various types 
of malignancies [1-6]. Interestingly, there are also a number of reports demonstrating 
Cxcl14 overexpression in various tumor microenvironments [7-10] and implicating 
Cxcl14 in invasion and metastasis [11, 12], indicating that its role in cancer may be cell-
type specific. Cxcl14 has also been linked to obesity and insulin resistance [13-15], and 
may be involved in the immune response, as it has antimicrobial activity against 
respiratory tract bacteria and opportunistic skin pathogens [16, 17]. Cxcl14 displays 
chemotactic ability in vitro for some immune cells, such as immature dendritic cells and 
natural killer cells [5, 6, 18-20]. However, a Cxcl14 -/- mouse line displayed no 
deficiencies in activation, migration, or peripheral tissue recruitment of monocytes, 
macrophages, dendritic cells, Langerhans cells, or lymphocytes [21]. Expression of 
Cxcl14 in muscle lysates has been previously reported [1], though no myogenic function 
for the cytokine was known. Our current study reveals Cxcl14 as a negative regulator 
of skeletal muscle regeneration through its role in cell cycle progression. To the best 
of our knowledge, this is the first report of Cxcl14 function in muscle development, or 
in regeneration of any tissue type. 
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IV.2. Materials and Methods 
IV.2.1. Antibodies and other reagents 
Anti-MHC (MF20) and anti-myogenin (F5D) were obtained from the 
Developmental Studies Hybridoma Bank developed under the auspices of the NICHD, 
National Institutes of Health, and maintained by The University of Iowa, Department of 
Biological Sciences. Anti-Cxcl14 and anti-MyoD were from Novus Biologicals (Littleton, 
CO). Anti-tubulin was from Abcam (Cambridge, MA). All other primary antibodies were 
from Cell Signaling Technology (Danvers, MA). Alexa Fluor fluorescent secondary 
antibodies were from Thermo Fisher Scientific (Waltham, MA). All other secondary 
antibodies were from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA). 
Gelatin, BrdU, and AraC were from Sigma-Aldrich (St. Louis, MO). Recombinant Cxcl14 
protein was from Novus Biologicals (Littleton, CO). U0126 and ELISA kit for detection of 
mouse Cxcl14 was from Thermo Fisher Scientific (Waltham, MA). 
IV.2.2. Cell culture 
See III.2.2. 
IV.2.3. Immunofluorescence microscopy and quantitative analysis of 
myocytes 
See III.2.4. 
IV.2.4. Lentivirus-mediated RNAi 
See II.2.3. shRNAs in the pLKO.1-puro vector were purchased from Sigma-
Aldrich (MISSION® TRC). Clone IDs are: shCxcl14 #1, TRCN0000065369; shCxcl14 #2, 
TRCN0000065370.  
IV.2.5. Quantitative RT-PCR 
See III.2.7. Mouse β-actin primers: forward 5′-ttgctgacaggatgcagaag-3′; reverse 
5′-atccacatctgctggaaggt-3′. Mouse Cxcl14 primers: forward 5′-ggtccaagtgtaagtgttcc-3′; 
reverse 5′-cctggacatgctcttggtg-3′. 
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IV.2.6. Western blotting 
See III.2.8. 
IV.2.7. Cell proliferation and apoptosis assays 
 See III.2.9. 
IV.2.8. Injury-induced muscle regeneration and manipulation of Cxcl14 
expression in mice 
See III.2.10. Male FVB mice aged 8-10 weeks were used in all the regeneration 
experiments, unless otherwise indicated. Male and female FVB mice mice of various 
ages (4, 6, 8, 12, or 18 months old) were used in the aging muscle experiments.  
IV.2.9. Muscle tissue cryosection, hematoxylin and eosin staining, and 
immunohistochemistry 
See III.2.11. 
IV.2.10. Statistics 
See III.2.12. ANOVA was also performed as indicated. 
IV.2.11. Study Approval 
All animal experiments in this study followed protocols approved by the Animal 
Care and Use Committee at the University of Illinois at Urbana-Champaign. 
 
IV.3. Results 
 
IV.3.1. Cxcl14 is expressed in muscle cells in vitro and in vivo 
Cxcl14 previously emerged from our RNAi screen as a potential negative 
regulator of myogenesis [22], though no function for the cytokine had previously been 
speculated in muscle development or maintenance. Thus, we sought to better 
characterize the expression of Cxcl14 in myogenic cells. We first examined whether 
Cxcl14 expression changes over the course of in vitro differentiation using the C2C12 
murine myoblast cell line. As shown in Figs. IV.1A and B, Cxcl14 expression was 
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observed at both the mRNA and protein levels in C2C12 cells. Interestingly, the mRNA 
expression profile did not match the pattern of secreted Cxcl14 protein. Cxcl14 
transcripts were highest in myoblasts before induction of differentiation, and 
progressively declined throughout the myogenic time course (Fig. IV.1A). In contrast, the 
soluble Cxcl14 protein increased in conditioned media after the onset of differentiation, 
and peaked during the early stages differentiation before falling back down (Fig. IV.1B).  
 We next evaluated the expression profile of Cxcl14 in vivo using a well-
established model of muscle regeneration [23, 24]. Localized necrosis of the tibialis 
anterior (TA) muscle of the hindlimb was induced via intramuscular injection of barium 
chloride (BaCl2). Saline injection into the TA muscle of the contralateral hindlimb served 
as a non-injury control. We did not observe Cxcl14 signal in undamaged myofibers, 
though its expression was rapidly induced during early regeneration (Fig. IV.1C). Three 
days after injury, Cxcl14 was observed in both damaged myofibers and mononucleated 
cells within the injured area, which progressively decreased over the course of 
regeneration. This pattern of expression was similar to that of secreted Cxcl14 protein in 
C2C12 cells. To determine whether the Cxcl14-postive mononucleated cells were of 
myogenic origin, we co-labeled injured muscles for Cxcl14 and MyoD, a marker of 
activated and proliferating satellite cells and myoblasts. As shown in Fig. IV.1D, we 
observed a striking pattern of cellular co-localization, strongly suggesting that the 
Cxcl14-positive cells seen during regeneration are myogenic progenitors. 
IV.3.2. Cxcl14 is a negative regulator of myoblast differentiation 
We used the mouse myoblast cell line C2C12 in order to dissect the effect of 
Cxcl14 gene knockdown by lentivirus-delivered shRNA. We found that depletion of 
Cxcl14 expression by two independent shRNA drastically increased C2C12 
differentiation and fusion, leading to the formation of large, hypertrophied myotubes (Fig. 
IV.2A). This increase in cell fusion was accompanied by earlier expression of muscle 
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differentiation-specific proteins such as MEF2A, myogenin, and myosin heavy chain 
(MHC) compared to control cells (Fig. IV.2B). Early expression of the cell cycle inhibitor 
p21 was also observed in Cxcl14 knockdown cells, indicating more rapid withdrawal 
from the cell cycle and induction of differentiation (Fig. IV.2B). The enhanced fusion 
index and hypertrophy phenotype upon Cxcl14 knockdown were reversed by adding 
recombinant Cxcl14 protein (rCxcl14) to the cell growth media, confirming the specificity 
of RNAi targeting (Fig. IV.2C). Notably, supplementing control cells with rCxcl14 further 
decreased the fusion index below normal levels (Fig. IV.2C). Taken together, these 
results strongly suggest that Cxcl14 functions as an inhibitor of myogenesis at an early 
stage of the process. 
IV.3.3. Cxcl14 suppresses myogenesis by promoting cell cycle 
progression 
In addition to enhancing expression of myogenic markers, knockdown of Cxcl14 
also reduced the total number of cells present in culture (Fig. IV.3A). Importantly, this 
decrease in cell number was corrected by adding rCxcl14 to the media (Fig. IV.3A). We 
reasoned that the lower number of cells upon Cxcl14 knockdown could be either a result 
of reduced proliferation or increased cell death. Given our observation that Cxcl14 
knockdown increased p21 expression—an effect that was reversed by supplementation 
with rCxcl14 (Fig. IV.3B)—we thought cell cycle regulation may be the more likely 
mechanism. Indeed, Cxcl14 knockdown significantly decreased proliferation in 
myoblasts, as indicated by a markedly lower incidence of BrdU incorporation (Fig. 
IV.3C). Addition of rCxcl14 reversed the proliferation rate to normal levels in Cxcl14-
depleted cells and further increased it in control cells (Fig. IV.3C). In contrast, 
knockdown of Cxcl14 had no significant effect on the rate of myoblast apoptosis as 
measured by TUNEL labeling (Fig. IV.3D). 
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We wondered whether the strikingly enhanced myogenesis phenotype upon 
Cxcl14 knockdown was caused simply by more rapid cell cycle withdrawal and 
consequently induction of differentiation. To test this hypothesis, we repeated our cell 
fusion rescue experiment by knocking down Cxcl14, adding rCxcl14 to proliferating 
myoblasts, and then differentiating the cells. However, to some cells we also added the 
cell cycle inhibitor cytosine β-D-arabinofuranoside (Ara-C) with rCxcl14. As shown in Fig. 
IV.3D, the introduction of Ara-C ablated the normalizing effect of rCxcl14 on cell fusion. 
These data indicate that Cxcl14 promotes myoblast cell cycle progression, and that this 
function is responsible for its anti-myogenic effect. 
IV.3.4. ERK mediates Cxcl14’s anti-myogenic effect 
 We next sought to better characterize the signaling mechanism underlying the 
anti-myogenic function of Cxcl14. The MAP kinase ERK1/2 has an established role in 
G1- to S-phase cell cycle transition, thereby promoting cell proliferation (reviewed in 
[25]), and has been reported to inhibit the initiation of myogenesis [26-28]. Cxcl14 
has also been linked to ERK1/2 activation in fibroblasts [10]. Given these facts, we 
wondered whether Cxcl14’s pro-proliferative function was mediated through ERK1/2 
signaling. Indeed, we observed reduced ERK1/2 phosphorylation in cells depleted of 
Cxcl14 (Fig. IV.4A). Conversely, myoblasts exposed to rCxcl14 rapidly activated 
ERK1/2 (Fig. IV.4B).  
To assess the functional relevance of ERK1/2 in Cxcl14’s anti-myogenic 
effects, we used the pharmacological inhibitor U0126 to inhibit MEK1/2, the upstream 
activator of ERK1/2. As shown in Fig. IV.4C, treatment with U0126 prior to rCxcl14 
exposure prevented the normalizing effect of rCxcl14 on myoblast fusion in both 
control and Cxcl14 knockdown cells. Taken together, these data strongly suggest 
that Cxcl14’s anti-myogenic function is dependent on the MEK/ERK signaling axis.  
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IV.3.5. Cxcl14 does not inhibit myogenesis via Cxcl12 antagonism 
Currently, there is no established receptor for Cxcl14. One study proposed 
that Cxcl14 is a ligand for chemokine (C-X-C motif) receptor 4 (CXCR4), and 
functions as an antagonist for the cognate ligand of CXCR4, chemokine (C-X-C 
motif) ligand 12 (Cxcl12) [29, 30]. This report is controversial, as another study 
demonstrated that Cxcl14 does not directly modulate CXCR4 in other cell types [31]. 
However, Cxcl12 is a known pro-myogenic cytokine [32], so Cxcl14 working as an 
antagonist to Cxcl12 activity seemed plausible in our model system. To test this 
relationship, we introduced recombinant Cxcl12 (rCxcl12) to proliferating cells either 
alone or with rCxcl14 and then induced differentiation. We observed no evidence of 
antagonism between the two cytokines, in either their effects on proliferation or 
myoblast fusion (Fig. IV.5). BrdU incorporation was weakly but significantly enhanced 
with rCxcl12 exposure, which is not surprising as this cytokine is known to activate 
ERK1/2 in other cell types [33, 34]. Our observation that rCxcl12 had no significant 
effect on cell fusion when introduced exclusively to proliferating cells is also not 
entirely unexpected, since Cxcl12’s established function as a regulator of second-
stage fusion necessitates a later window of expression and activity [32]. Thus, our 
data indicate that the anti-myogenic function of Cxcl14 is not through antagonism of 
Cxcl12. The identity of the Cxcl14 receptor remains elusive and warrants future 
research efforts. 
IV.3.6. Cxcl14 knockdown accelerates muscle regeneration in vivo 
 Given the striking enhancement of differentiation seen with Cxcl14 knockdown 
in vitro (Fig. IV.2A-C), we wondered if manipulating the levels of Cxcl14 would have a 
similarly significant effect on myogenesis in vivo. We utilized the same method of TA 
muscle injury described earlier, but now introduced Cxcl14 shRNA via co-injection 
with BaCl2.  As shown in Fig. IV.6A, Cxcl14 shRNA effectively reduced Cxcl14 
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protein expression in mononucleated cells at day 3 after injury (AI). At days 5 and 7 
AI, we observed a striking enhancement in the size of regenerating myofibers upon 
Cxcl14 knockdown (Fig. IV.6A, B). Interestingly, there was no significant difference 
between Cxcl14-depleted muscles and control muscles a week later at day 14 AI. 
These results indicate that loss of Cxcl14 during muscle injury speeds up the 
regenerative process without enhancing net myofiber size. This interpretation is in 
line with our in vitro data, which suggests that Cxcl14 inhibition simply leads to more 
rapid cell cycle exit, allowing for a speedier differentiation process. To confirm this 
hypothesis in vivo, we evaluated the relative levels of dividing cells in early 
regeneration by probing day 3 AI muscle sections for the proliferative marker Ki-67. 
As expected, Cxcl14 knockdown muscles did indeed show strikingly lower labeling 
for Ki-67, and thus lower levels of proliferation (Fig. IV.6C). 
IV.3.7. Reduction of Cxcl14 expression enhances regeneration in aging 
muscle 
Aging is accompanied by dysregulation of cytokines and increased incidence 
of inflammation, both at the overall organismal level and in the musculoskeletal 
system in particular (reviewed in [35]). Similarly, it is a well-established phenomenon 
that muscle regenerative capacity declines with age, likely through changes in 
satellite cell quantity, quality, and extrinsic changes to their niche (reviewed in [36, 
37]). We wondered whether muscular Cxcl14 levels changed throughout the lifespan, 
and also whether this correlated to any functional defects in myogenesis. Rodent 
studies of aging muscle tend to focus on molecular changes and regenerative decline 
in very old animals (i.e. ≥2 years old). However, we were interested in understanding 
when exactly muscle regenerative ability begins to decline in our mouse model.  
To answer this question, we performed TA muscle injury and regeneration 
experiments in progressively aged mice. As shown in Fig. IV.7A, the average size of 
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regenerated myofibers in mice injected with BaCl2 began to decline at 6 months old, and 
was significantly smaller by one year of age. We also performed qPCR to evaluate the 
relative mRNA levels of Cxcl14 over the aging time course. However, we did not observe 
a significant change to Cxcl14 expression (Fig. IV.7B), indicating that normal 
regenerative decline in older mice is not linked to increased inhibitory signals from this 
particular cytokine. Despite this finding, we wondered whether knockdown of Cxcl14 in 
aging muscle could still recapitulate the rapid regeneration phenotype seen in young 
animals, or even prove therapeutic. Indeed, we observed that Cxcl14 depletion not only 
significantly enhanced regeneration 7 days AI in aged muscle, but actually enhanced it 
to the same degree as in young mice (Fig. IV.7C). Taken together, these results suggest 
that Cxcl14 is not responsible for aging-induced regenerative decline, but that limiting its 
expression may be able to therapeutically restore regeneration in aged animals.   
 
IV.4. Discussion 
We have identified Cxcl14 as a novel negative regulator of skeletal myogenesis. 
Our data show that Cxcl14 functions by inhibiting cell cycle exit, thereby preventing 
myoblast differentiation and fusion into mature myotubes. Cxcl14 has been previously 
implicated in promoting proliferation, particularly in cancer cells [7, 9, 10, 38], though this 
is the first report of a role for Cxcl14 in muscle development. Interestingly, Cxcl14’s 
mechanism of action appears to directly counter the myogenic role of FMS-like tyrosine 
kinase 3 ligand (Flt3L), another cytokine that emerged from our functional RNAi screen 
[39]. Further studies from our lab revealed that Flt3L promotes myogenesis by 
enhancing myoblast cell cycle withdrawal via suppression of ERK1/2 [40]. Considering 
the prolific ability of muscle cells to secrete cytokines [41-43], it is possible that other 
antagonistic pairs of cytokines exist to allow fine-tuning flexibility during muscle 
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development. Further exploration of the network of cytokines secreted by and regulating 
muscle cells will likely prove very interesting for the future. 
We demonstrated that inhibiting endogenous Cxcl14 has a physiologically 
significant effect in promoting earlier muscle regeneration. The role of Cxcl14 in tissue 
regeneration in general has not been well studied. Cxcl14 expression was noted in a 
recent study of regenerating dental pulp [38], and Li and colleagues demonstrated that 
antibody-mediated neutralization of Cxcl14 protects the liver from CCl4-induced acute 
liver injury [44]. However, they also note that Cxcl14 has an inhibitory effect on 
proliferation, in contrast to our results. Their findings also indicate that the main effect of 
Cxcl14 neutralization in the liver is prevention of necrosis and steatosis following injury, 
which is not the case in our skeletal myogenesis model. Thus Cxcl14’s mechanism of 
action in muscle regeneration appears distinct from its role in protection from liver injury. 
It is important to note that our regeneration studies evaluated the effect of Cxcl14 
knockdown, rather than complete knockout of Cxcl14 gene expression. This may be an 
important consideration; it stands to reason that while limiting myoblast proliferation after 
injury can speed up myogenesis, a severe proliferation defect in muscle progenitors may 
instead blunt effective muscle regeneration. It is perhaps unlikely that knockout of a 
single cytokine could produce such a severe proliferation defect; however, Cxcl14 
knockout mice do exist, and testing their muscle regenerative abilities may prove fruitful. 
Interestingly, CXCL14-/- mice develop normally and display no obvious phenotype, with 
the exception of decreased weight and feeding behavior, though a disturbed Mendelian 
breeding pattern and occasional postnatal death of newborns at day 2 to 3 was noted 
[13, 21].  
It is possible that the enhanced cell cycle withdrawal observed with Cxcl14 
inhibition could prove therapeutic for muscle diseases. For example, recent studies of 
Duchenne muscular dystrophy have revealed that activated dystrophin-deficient satellite 
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cells undergo defective asymmetrical division, leading to abnormally high numbers of 
quiescent satellite cells and lower numbers of myoblasts capable of differentiation [45, 
46]. Intriguingly, one microarray study noted higher levels of Cxcl14 mRNA in the 
muscles of DMD model mdx mice compared to control mice [47]. While the 
pathogenesis of muscular dystrophy is multifaceted, it would be interesting in future 
studies to re-evaluate the functional significance of Cxcl14 depletion in the context of this 
disease. 
Our current understanding of sarcopenia places chronic inflammation as a key 
player in the progression of this disease [35, 48]. And yet, still very little is known about 
the effects of cytokines on skeletal muscle tissue under normal physiological conditions 
or pathological states. We demonstrated that Cxcl14 inhibition continues to enhance the 
pace of regeneration in aging mice. Though Cxcl14 expression did not significantly 
change during aging in our study, it is possible that other muscle-derived cytokines do 
become dysregulated over time. A deeper understanding of the network of cytokines 
involved in the maintenance of muscle mass—as well as how those cytokines are 
regulated—could shed some light on why muscle catabolism increases with age and 
how to prevent it. 	  
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IV.5. Figures  
 
 
 
 
Fig. IV.1. Cxcl14 expression in muscle cells 
(A) C2C12 cells were lysed at indicated time points (“Hrs diff”) during differentiation. 
RNA was isolated from lysates and the resulting cDNA was probed for Cxcl14 mRNA 
levels using qRT-PCR. 
(B) C2C12 cell media over the course of differentiation were subjected to ELISA assay 
to determine secreted Cxcl14 levels. 
(C) TA muscles were injured by BaCl2 injection, and isolated on days 3, 5, 7, and 14 
after injury (AI). Upon cryosection, H&E staining or immunofluorescence staining for 
Cxcl14 (green) together with DAPI (blue) was performed. Scale bars: 50 µm. 
(D) The procedure described in (B) was repeated. Muscle sections isolated on day 3 AI 
were immunofluorescently probed for MyoD (red), Cxcl14 (green), and DAPI (blue). 
Scale bar: 25 µm. 
Paired 2-tailed t test was performed for data in (A) and (B). *P<0.05; **P<0.01. All error 
bars represent SD of independent replicates. 
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Fig. IV.2. Cxcl14 knockdown enhances C2C12 differentiation 
(A) C2C12 cells were infected with lentiviruses expressing shCxcl14 or shScramble 
(negative control), selected for 2 days then differentiated for 72 hrs, followed by staining 
for MHC (green) and DAPI (pseudocolored red). Scale bar: 50 µm. 
(B) Cells treated as in (A) were differentiated, and at indicated time points (“Hrs diff”) 
were lysed and subjected to western analysis. 
(C) C2C12 cells were treated as in (A), then grown in the presence or absence of 25 
ng/mL recombinant Cxcl14 (rCxcl14) for 24 hrs after selection. Cells were then 
differentiated for 3 days, followed by staining for MHC and DAPI and quantification of 
fusion index. Scale bar: 50 µm. 
Paired 2-tailed t test was performed for data in (C). *P<0.05; **P<0.01. All error bars 
represent SD of independent replicates. 
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Fig. IV.3. Cxcl14 promotes cell cycle progression  
(A) C2C12 cells were infected with lentiviruses expressing shCxcl14 or shScramble, 
selected for 2 days, grown in the presence or absence of 25 ng/mL rCxcl14 for 24 hrs, 
followed by differentiation for 72 hrs and subsequent staining with DAPI. Stained nuclei 
were counted. 
(B) Cells were treated as in (A) but only stimulated with 10 ng/mL rCxcl14 for the 
indicated amount of time. Cells were then lysed and subjected to western analysis. 
(C) Cells were treated as in (A) but differentiated for 24 hrs, followed by BrdU 
incorporation for 2 hrs. Cells were immunofluorescently stained for BrdU and DAPI, then 
counted. 
(D) Cells were treated as in (A) but differentiated for 24 hrs, followed by TUNEL assay to 
detect apoptotic cells. 
(E) Cells were treated as in (A) but grown in the presence or absence of Ara-C for 24 
hrs, then differentiated and immunofluorescently stained for MHC (green) or DAPI 
(psuedocolored red). The fusion index was calculated. Scale bar: 50 µm. 
Paired 2-tailed t test was performed for data in (E), and one-sample 2-tailed t tests for all 
other data. **P<0.01. All error bars represent SD of independent replicates. 
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Fig. IV.4. ERK1/2 mediates Cxcl14’s anti-myogenic effect  
(A) C2C12 cells were infected with shRNA lentiviruses and selected, followed by cell 
lysis and western analysis. 
(B) Cells were treated as in (A), then stimulated with 10 ng/mL rCxcl14 for the indicated 
amount of time, followed by cell lysis and western analysis. 
(C) C2C12 cells were infected with shRNA lentiviruses as indicated, then grown in the 
presence or absence of 25 ng/mL rCxcl14 and U0126 for 24 hrs. Cells were then 
differentiatiated for 72 hrs and subsequently stained for MHC and with DAPI, followed by 
quantification of the fusion index. Scale bar: 50 µm. 
Paired 2-tailed t test was performed for data in (C). *P<0.05; **P<0.01. All error bars 
represent SD of independent replicates. 
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Fig. IV.5. Cxcl14 does not antagonize Cxcl12 in the early stage of myogenesis 
C2C12 cells were grown in the presence or absence of rCxcl12 and rCxcl14 for 24 hrs, 
then differentiated 24 hrs followed by BrdU incorporation or differentiated for 72 hrs and 
subsequently stained for MHC and with DAPI. The number of BrdU+ cells and the fusion 
index were quantified.  
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Fig. IV.6. Cxcl14 knockdown speeds up muscle regeneration post-injury 
(A) TA muscles were co-injected with BaCl2 and shRNA viruses, and isolated on days 3, 
5, 7, and 14 after injury (AI). Upon cryosection, H&E staining or immunofluorescence 
staining for Cxcl14 (green) along with DAPI (blue) were performed. Scale bars: 50 µm. 
(B) Quantification of the regenerating myofiber cross-sectional area (CSA) on muscle 
sections from (A). 
(C) TA muscles were treated as in (A) and isolated on day 3 AI, then 
immunofluorescently stained for Ki-67 (red) and with DAPI (blue). Scale bar: 50 µm. 
Paired 2-tailed t test was performed to compare shScramble and shCxcl14 at each time 
point. **P<0.01. All error bars represent SD of independent replicates.   
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Fig. IV.7. Cxcl14 enhances regeneration in aging mice 
(A) TA muscles were injured with BaCl2, and isolated on day 7 AI. Upon cryosection, 
H&E staining was performed and regenerating myofiber cross-sectional area (CSA) was 
quantified. 
(B) TA muscles sections treated as in (A) were isolated on day 7 AI and the RNA was 
isolated. Horizontal bars represent the mean of individually plotted data points. 
(C) TA muscles from 2-month-old and 12-month-old mice were co-injected with the 
indicated shRNA viruses and BaCl2, then processed and analyzed as in (A). 
One-way ANOVA was used to analyze data in (B), and paired 2-tailed t test was 
performed in (C). * P<0.05 **P<0.01. 
All error bars represent SD of independent replicates.  Scale bar: 50 µm. 
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CHAPTER V: CCL8 IS REQUIRED FOR SKELETAL MYOGENESIS AND MAY BE 
TRANSCRIPTIONALLY REGULATED BY MTOR  
 
V.1. Introduction 
Chemokine (C-C motif) ligand 8 (Ccl8) is a potent pro-inflammatory cytokine. 
Also known as monocyte chemoattractant protein 2 (MCP-2), Ccl8 has long been 
recognized as a chemoattractant for a variety of immune cells in vitro, including 
monocytes, natural killer cells, lymphocytes, basophils, and eosinophils [1]. Through its 
inflammatory effects, Ccl8 is involved in the innate immune response [2, 3], but also 
promotes atopic dermatitis [4] and has been proposed as a biomarker to evaluate the 
severity of graft versus host disease [5]. Perhaps not surprisingly, induction of Ccl8 
expression has been linked to bacterial infection [6] and can be modulated by other 
cytokines [7, 8]. 
Ccl8 signaling is likely complex, primarily due to the promiscuity of chemokine 
ligand-receptor pairs. In humans, Ccl8 is an agonist for several CC-chemokine type 
receptors (CCRs), including CCR1, CCR2, CCR3 and CCR5 [9-11]. In mice, Ccl8 also 
functions through CCR8, but may not be an agonist for CCR2, 3, or 5 [4]. Interestingly, 
though Ccl8 is canonically known as a pro-inflammatory cytokine, there are reports of 
anti-inflammatory activity after proteolytic processing and/or post-translational 
modification, likely through competitive binding to the CCRs but failure to activate them 
[12, 13]. To add another layer of complexity, Ccl8 can form either a canonical 
homotrimer to bind the CCRs, but is also capable of heterotrimerization with other CC-
motif cytokines [14].  
Little is known about the role of Ccl8 in skeletal muscle. Ccl8 expression in 
mouse primary myoblasts and C2C12 cells has been previously reported [15, 16], 
though an in-depth characterization of Ccl8 function during myogenesis is still lacking 
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from the literature. One study in human skeletal muscle cells reported that Ccl8 
expression was induced by peroxisome proliferator-activated receptor-gamma 
coactivator 1 alpha (PGC-1α) [17], a transcriptional co-activator linked to mitochondrial 
biogenesis and cellular metabolism. Intriguingly, both Ccl8 and its receptors (CCR1, 2 
and 5) are also upregulated in the muscles of mdx mice [18], a model of Duchenne 
muscular dystrophy. 
 
V.2. Materials and Methods 
V.2.1. Antibodies and other reagents. 
Anti-MHC (MF20) was obtained from the Developmental Studies Hybridoma 
Bank developed under the auspices of the NICHD, National Institutes of Health, and 
maintained by The University of Iowa, Department of Biological Sciences. Anti-Ccl8 was 
from R&D Systems (Minneapolis, MN). Anti-tubulin was from Abcam (Cambridge, MA). 
All other primary antibodies were from Cell Signaling Technology (Danvers, MA). Alexa 
Fluor fluorescent secondary antibodies were from Thermo Fisher Scientific (Waltham, 
MA). All other secondary antibodies were from Jackson ImmunoResearch Laboratories, 
Inc. (West Grove, PA). Recombinant Ccl8 protein was from PeproTech (Rocky Hill, NJ). 
Gelatin, collagen I, BrdU, and Actinomycin D were from Sigma-Aldrich (St. Louis, MO).  
V.2.2. Cell culture. 
See III.2.2 
V.2.3. Mouse primary myoblast isolation and differentiation.  
See III.2.3. 
V.2.4. Immunofluorescence microscopy and quantitative analysis of 
myocytes. 
See III.2.4. 
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V.2.5. Lentivirus-mediated RNAi. 
See II.2.3. shRNAs in the pLKO.1-puro vector were purchased from Sigma-
Aldrich (MISSION® TRC). Clone IDs are: shCcl8 #1, TRCN0000068176; shCcl8 #2, 
TRCN0000068174.  
V.2.6. Quantitative RT-PCR. 
See III.2.7. Mouse β-actin primers: forward 5′-ttgctgacaggatgcagaag-3′; reverse 
5′-atccacatctgctggaaggt-3′. Mouse Ccl8 primers: forward 5′-cacctgctgctttcatgtac-3′; 
reverse 5′-ttggtctggaaaaccacagc-3′. 
V.2.7. Western blotting. 
See III.2.8. 
V.2.8. Cell proliferation and apoptosis assays. 
 See III.2.9.  
V.2.9. Injury-induced muscle regeneration and manipulation of Ccl8 
expression in mice. 
See III.2.10.  
V.2.10. Muscle tissue cryosection, hematoxylin and eosin staining, and 
immunohistochemistry. 
See III.2.11. 
V.2.11. Statistics. 
See III.2.12. 
V.2.12. Study Approval. 
All animal experiments in this study followed protocols approved by the Animal 
Care and Use Committee at the University of Illinois at Urbana-Champaign. 
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V.3. Results 
 
V.3.1. Ccl8 is expressed in skeletal muscle cells 
Since Ccl8 previously emerged from our RNAi screen as a potential positive 
regulator of myogenesis [19], we examined whether Ccl8 expression is regulated during 
in vitro differentiation using the C2C12 murine myoblast cell line. As shown in Fig. V.1A, 
Ccl8 mRNA levels progressively increased over the course of differentiation. We 
observed a similar trend in Ccl8 expression at the protein level in cell lysates (Fig. V.1B). 
A lentivirally-delivered shRNA against Ccl8 was used to confirm specificity of the 
antibody. This expression pattern is slightly different from a previous report of Ccl8 
expression in C2C12 cells, which found Ccl8 levels to rise after two days, but then fall by 
five days of differentiation [15]. This discrepancy may be explained by the slightly 
different time points examined, or may simply be due to clonal variation between cell 
lines. 
 We next evaluated the expression profile of Ccl8 in vivo using a well-established 
model of muscle regeneration [20, 21], described previously in chapters III and IV of this 
dissertation. As shown in Fig. V.1C, we observed Ccl8 signal around the periphery of 
undamaged myofibers, indicating a basal level of Ccl8 expression in muscle tissue. 
Three days after injury, Ccl8 was also observed in both damaged myofibers and 
mononucleated cells within the injured area (Fig. V.1C). Ccl8 signal in mononucleated 
cells persisted over the course of regeneration (Fig. V.1C). In order to determine 
whether these mononucleated cells are of myogenic or immune origin, co-labeling with 
cell-specific markers will be necessary. Examples include MyoD, which specifically 
labels activated satellite cells and their daughter myoblasts, and macrophage-specific 
F4/80. 
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V.3.2. Ccl8 expression is required for myogenic differentiation in vitro 
The mouse myoblast cell line C2C12 was used to evaluate the functional 
effect of Ccl8 gene knockdown by lentivirus-delivered shRNA. We found that depletion 
of Ccl8 expression by two independent shRNA strikingly inhibited C2C12 differentiation 
(Fig. V.2A). Fewer multinucleated myotubes were present after Ccl8 knockdown, and 
those that did form were small (Fig. V.2A). qRT-PCR confirmed the reduction of Ccl8 
expression for both shRNA (Fig. V.2B). This decrease in cell fusion upon Ccl8 depletion 
was accompanied by delayed or reduced expression of muscle differentiation-specific 
proteins such as MEF2A, MEF2C, and myosin heavy chain (MHC) (Fig. V.2C). 
Moreover, we observed the same phenotype in mouse primary myoblast cells (Fig. 
V.2D). Taken together, these results strongly suggest that Ccl8 functions as a positive 
regulator of myogenesis. 
V.3.3. Ccl8 depletion inhibits skeletal muscle regeneration in vivo 
Given the importance of Ccl8 expression in myogenesis in vitro, we wondered 
if manipulating the levels of Ccl8 would have a physiologically relevant effect on 
skeletal muscle regeneration in vivo. We utilized the same method of TA muscle 
injury described previously in chapters III and IV, but now introduced Ccl8 shRNA via 
co-injection with BaCl2.  As shown in Fig. V.3, we observed a marked reduction in the 
size of regenerating myofibers upon Cxcl14 knockdown at days 5, 7, and 14 after 
injury (AI) (Fig. V.3A, B). This inhibitory effect was most significant at day 5 AI, 
possibly indicating an early role for Ccl8 (Fig. V.3B). These results strongly suggest 
that Ccl8 is required for robust skeletal muscle regeneration after injury, and provide 
further evidence that Ccl8 positively regulates myogenesis. 
V.3.4. Ccl8 may regulate myogenesis through two distinct mechanisms 
We next sought to characterize the cellular mechanisms that Ccl8 regulates to 
affect myogenesis. In addition to decreasing cell fusion and expression of myogenic 
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markers, knockdown of Ccl8 also reduced the total number of C2C12 cells present in 
culture (Fig. V.4A). We examined both cell proliferation and apoptosis to find potential 
causes for this reduced cell number. Interestingly, Ccl8 knockdown both significantly 
decreased proliferation and increased cell death in myoblasts, as indicated by a 
markedly lower incidence of BrdU incorporation (Fig. V.4B) and increased TUNEL 
labeling (Fig. V.4C).  
We wondered whether the impaired differentiation phenotype we observed upon 
Ccl8 knockdown was simply caused by too few cells available to fuse, as was the case 
with Tnfsf14 (Chapter III, [22]). To test this hypothesis, we plated Ccl8-depleted C2C12 
cells at higher densities to compensate for the cell number reduction, so that the final 
cell number was not significantly different from control cells after differentiation. As 
shown in Fig. V.4D, when Ccl8-knockdown cells were plated at higher densities, they 
differentiated normally and did not exhibit a fusion defect. At first glance, these data 
seem to suggest that Ccl8 promotes myogenesis solely through maintenance of a 
sufficient pool of myoblasts to fuse, via either increased proliferation or enhanced 
survival. However, it is possible that Ccl8 also regulates early steps in myogenesis—
such as myoblast migration or cell-cell adhesion—and that plating the cells at higher 
densities can overcome the negative effect of Ccl8 knockdown on these processes. 
Indeed, when differentiating Ccl8-depleted cells were exposed to recombinant Ccl8 
(rCcl8), the fusion index was significantly increased despite no change to the overall 
cell number (Fig. V.4E). It should be noted that while cell fusion improved upon rCcl8 
treatment, it was not restored to control levels (Fig. V.4E). Thus, it is possible that 
Ccl8 has two distinct and important roles in myogenesis: (1) regulation of cell number 
via proliferation and survival in proliferating myoblasts, and (2) a pro-myogenic role 
independent of cell number in differentiating myoblasts. Further experiments should 
be performed to confirm this hypothesis. 
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V.3.5. Ccl8 depletion disrupts numerous cell signaling pathways 
We next wondered which cell signaling pathway mediates Ccl8’s effect in 
myogenesis. To probe this question, we evaluated changes to the activation of 
various signaling molecules with a known role in myogenic differentiation in C2C12 
cells after Ccl8 knockdown. As shown in Fig. V.5, Ccl8-depletion inhibits the 
phosphorylation of p38, AKT, and ERK1/2. All three of these protein kinases are 
members of signaling pathways that have been linked to regulation of proliferation, 
survival, and various stages of myogenesis [23-33]. As such, it is likely that 
involvement of one of more of these molecules could mediate the diverse effects of 
Ccl8 in muscle cells. Thus far, only one study has reported the ability of recombinant 
Ccl8 to stimulate ERK1/2 activation in C2C12 cells [15]. Further experiments will be 
necessary to pinpoint the relative contribution and timing of each pathway in Ccl8 
signaling. 
V.3.6. Ccl8 expression may be regulated by mTOR 
 Given the striking myogenic inhibition observed upon Ccl8 knockdown, we 
hypothesized that muscle cells must have a robust mechanism for regulating the 
expression of Ccl8. The mammalian target of rapamycin (mTOR) is a master 
regulator of diverse cellular processes and a key player in the coordination of 
myogenesis [21, 34-38]. Indeed, in vitro exposure of differentiating myoblasts to the 
mTOR inhibitor rapamycin is sufficient to inhibit myogenic differentiation and fusion, 
and secretion of myogenic factors may be regulated by mTOR [36]. Intriguingly, we 
observed that rapamycin treatment also prevented the rise of Ccl8 mRNA transcripts 
in differentiating C2C12 cells (Fig. V.6A). This same inhibition was also noted at the 
protein level (Fig. V.6B). These data suggest that mTOR may positively regulate 
expression of Ccl8. We also investigated rapamycin-sensitive expression changes of 
other cytokines from our screen during C2C12 differentiation. Expression of some 
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cytokines, like Flt3L, was only affected by mTOR inhibition at certain time points (Fig. 
V.7A). Others, such as Cxcl14, showed rapamycin-sensitivity throughout 
differentiation at the mRNA level (Fig. V.7B), but this trend was not observed at the 
protein level (unpublished observations). However, the vast majority of cytokines 
were not affected by rapamycin treatment (Fig. V.7C-F), indicating that mTOR 
regulation of Ccl8 transcripts may be cytokine-specific rather than a general 
phenomenon. 
We wondered whether the increased expression of Ccl8 normally seen during 
differentiation was due to increased gene transcription or merely enhanced stability 
of Ccl8 mRNA, leading to an accumulation of Ccl8 transcripts. To answer this 
question, we exposed differentiating myoblasts to the global transcription inhibitor 
actinomycin D (ActD). As shown in Fig. V.6C, ActD prevented the rise of Ccl8 mRNA 
transcripts during early differentiation, indicating that increased Ccl8 gene 
transcription is responsible for the rise in Ccl8 expression during myogenesis. Taken 
together, these results suggest that Ccl8 expression is regulated by mTOR at the 
transcriptional level; however, more experiments will be required to confirm this 
hypothesis. 
 
V.4. Discussion 
We have identified Ccl8 as a novel positive regulator of skeletal muscle 
differentiation and regeneration. Our results indicate that Ccl8 may have multiple 
functions in myoblasts. For example, it appears that Ccl8 promotes cell proliferation and 
cell survival (Fig. V.4A-C), but adding rCcl8 to differentiating cells does not affect the cell 
number (Fig. V.4E), despite clear enhancement of cell fusion. It is possible that Ccl8 
functions to maintain adequate cell numbers in proliferating myoblasts, and then 
switches to a distinct pro-differentiation function in differentiating myoblasts. To dissect 
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the exact time frame and cellular mechanism of Ccl8 function, it will be necessary to 
introduce rCcl8 at different stages of myoblast proliferation or differentiation and then 
evaluate changes to cell fusion, proliferation, and death. 
A switch in Ccl8 function during the different phases of myoblast differentiation 
may be possible through variable regulation of one or more of its receptors. However, 
the functional receptors of Ccl8 remain a contentious issue across species. One study 
by Islam and colleagues found that—in contrast to human Ccl8—many immune cells do 
not migrate to mouse Ccl8, including those that express CCR2, 3, and 5 [4]. They 
concluded that mouse Ccl8 is not an agonist for the aforementioned CCRs, but instead 
is a ligand for CCR8 [4]. In light of these results, CCR1 and CCR8 may be the best 
candidates to pursue for a functional Ccl8 receptor in muscle cells. However, due to the 
inactivating effect of proteolytic processing and post-translational modifications on Ccl8 
[12, 13], it cannot yet be ruled out that the other CCRs play a role in Ccl8 signaling in 
myogenesis. 
Another question that remains in the story of Ccl8 is how the cell regulates Ccl8 
expression. Our data suggest that mTOR may positively regulate Ccl8 levels during 
differentiation, though a link between mTOR and Ccl8 has never been reported. To test 
this hypothesis, it will be interesting to utilize our lab’s transgenic mice expressing 
mutant mTOR proteins. The first mouse line expresses a rapamycin-resistant (RR) 
mTOR, while the second expresses an mTOR protein that is both rapamycin-resistant 
and kinase-inactive (RRKI) [21, 35, 36]. Experiments performed in these mice—as well 
as primary myoblasts isolated from them—will be useful for determining if mTOR 
signaling is indeed necessary for Ccl8 expression, and whether this phenomenon is 
dependent on the catalytic function of mTOR. 
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V.5. Figures  
 
 
 
 
Fig. V.1. Ccl8 is expressed in skeletal muscle cells 
(A) C2C12 cells were lysed at indicated time points (“Hrs diff”) during differentiation. 
RNA was isolated from lysates and the resulting cDNA was probed for Ccl8 mRNA 
levels using qRT-PCR. 
(B) C2C12 cells were differentiated and at indicated time points (“Hrs diff”) were lysed 
and subjected to western analysis. 
(C) TA muscles were injured by BaCl2 injection, and isolated on days 3, 5, 7, and 14 
after injury (AI). Saline was performed on opposite limb as a control. Upon cryosection, 
H&E staining or immunofluorescence staining for Ccl8 (green) together with DAPI (blue) 
was performed. Scale bars: 50 µm. 
One-sample 2-tailed t test was performed for data in (A).  **P<0.01. All error bars 
represent SD of independent replicates. 
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Fig. V.2. Ccl8 knockdown inhibits myogenesis in vitro 
(A) C2C12 cells were infected with lentiviruses expressing shCcl8 or shScramble 
(negative control), selected for 2 days then differentiated for 72 hrs, followed by staining 
for MHC (green) and DAPI (pseudocolored red). The fusion index was then quantified 
from the resulting images. Scale bar: 50 µm. 
(B) Cells treated as in (A) were differentiated and lysed for RNA isolation. qRT-PCR was 
performed on the resulting cDNA to confirm knockdown of Ccl8 gene expression. 
(C) Cells treated as in (A) were differentiated, and at indicated time points (“Hrs diff”) 
were lysed and subjected to western analysis. 
(D) Mouse primary myoblasts were infected with lentiviruses expressing shCcl8 or 
shScramble, differentiated for 48 hrs then stained for MHC and DAPI, followed by 
quantification of the fusion index. Scale bar: 50 µm. 
Paired 2-tailed t test was performed for data in (A) and (D). One-sample 2-tailed t test 
was performed for data in (B). *P<0.05; **P<0.01. All error bars represent SD of 
independent replicates. 
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Fig. V.3. Ccl8 is required for robust muscle regeneration in vivo  
(A) TA muscles were co-injected with BaCl2 and shRNA viruses, and isolated on days 5, 
7, and 14 after injury (AI). Upon cryosection, H&E staining was performed. Scale bar: 50 
µm. 
(B) Quantification of the regenerating myofiber cross-sectional area (CSA) on muscle 
sections from (A). 
Paired 2-tailed t test was performed to compare shScramble and shCcl8 at each time 
point. *P<0.05; **P<0.01. All error bars represent SD of independent replicates.   
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Fig. V.4. Cxcl14 promotes cell proliferation 
(A) C2C12 cells were infected with lentiviruses expressing shCcl8 or shScramble and 
selected for 2 days, followed by differentiation for 72 hrs and subsequent staining with 
DAPI. Stained nuclei were counted. 
(B) Cells were treated as in (A) but differentiated for 24 hrs, followed by BrdU 
incorporation for 2 hrs. Cells were immunofluorescently stained for BrdU and DAPI, then 
counted. 
(C) Cells were treated as in (A) but differentiated for 24 hrs, followed by TUNEL assay to 
detect apoptotic cells. 
(D) Cells were treated as in (A) but Ccl8-depleted cells were initially plated at a higher 
density than control cells to make up for the difference in cell number that forms during 
differentiation. Differentiated cells were immunofluorescently stained for MHC and DAPI, 
followed by quantification of the fusion index.  
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Fig. V.4. (continued) 
 
(E) Cells were treated as in (A) but differentiated in the presence or absence of 
recombinant Ccl8 (rCcl8), then immunofluorescently stained for MHC or DAPI. The 
fusion index was calculated. 
One-sample 2-tailed t test was performed for data in (A), and paired 2-tailed t tests for all 
other data. *P<0.05; **P<0.01. All error bars represent SD of independent replicates. 
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Fig. V.5. Ccl8 knockdown inhibits multiple signaling molecules 
C2C12 cells were infected with lentiviruses expressing shCcl8 or shScramble and 
selected for 2 days, followed by differentiation for 72 hrs. At the indicated time points 
(“Hrs diff”), cells were lysed and subjected to western analysis.  
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Fig. V.6. Ccl8 expression may be regulated by mTOR 
(A) C2C12 cells were differentiated in the presence or absence of 50 nM rapamycin (R) 
for 72 hrs. At the indicated time points (“Hrs diff”), cells were lysed and RNA was 
isolated. The resulting cDNA was probed for Ccl8 mRNA levels using qRT-PCR. 
(B) Cells treated as in (A) were lysed at the indicated time points and subjected to 
western analysis. 
(C) Cells treated as in (A) were differentiated in the presence or absence of 5 ug/ml 
ActD. At the indicated time points, cells were lysed and RNA was isolated. The resulting 
cDNA was probed for Ccl8 mRNA levels using qRT-PCR. 
One-sample 2-tailed t test was performed for all data. * P<0.05;**P<0.01. All error bars 
represent SD of independent replicates.   
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Fig. V.7. mTOR has variable effects on expression of cytokines during C2C12 
differentiation 
(A) C2C12 cells were differentiated in the presence or absence of 50 nM rapamycin (R) 
for 72 hrs. At the indicated time points (“Hrs diff”), cells were lysed and RNA was 
isolated. The resulting cDNA was probed for Flt3L mRNA levels using qRT-PCR. 
(B) Cells treated as in (A) were probed for Cxcl14 transcripts. 
(C) Cells treated as in (A) were probed for IL-18 transcripts. 
(D) Cells treated as in (A) were probed for Cxcl5 transcripts. 
(E) Cells treated as in (A) were probed for Ccl17 transcripts. 
(F) Cells treated as in (A) were probed for Tnfsf14 transcripts. 
One-sample 2-tailed t test was performed for all data. * P<0.05. All error bars represent 
SD of independent replicates.   
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CHAPTER VI: CONCLUSIONS AND PERSPECTIVES 
 
 For a long while, the story went that skeletal muscle cells were passive reactors 
to most of the cytokines and other soluble factors secreted during muscle regeneration. 
These cytokines were presumably produced exclusively by the immune cells that 
infiltrate the muscle tissue in response to the cellular injury inherent in strenuous 
exercise, disease, and trauma. The past decade has brought about a shift in 
perspective, however, with new reports of skeletal muscle cells playing a more active 
role in this myogenic process. We now know that myocytes express and secrete a wide 
variety of cytokines at different points during proliferation and the stages of differentiation 
and fusion, which have the capacity to work in an autocrine or paracrine manner. Still, 
the functions and underlying molecular mechanisms of these muscle-derived cytokines 
remain largely unexplored.  
 We performed the RNAi screen in order to better understand the roles of these 
muscle-derived cytokines in myogenesis. After screening 134 cytokine genes, we were 
able to categorize the resulting 29 positive hits into four functional groups (Table II.3). 
Class I and II cytokines represent potential positive regulators of myogenesis, while 
Class III and IV cytokines are potential myogenic inhibitors. We were interested in 
characterizing in detail the molecular mechanisms used by these candidate cytokines to 
affect myoblast differentiation and fusion. Through the studies described in this thesis, I 
found that Tnfsf14 (Class I) promotes myogenesis through cell survival, by maintaining a 
sufficient number of myoblasts available to fuse into myotubes.  Cxcl14 (Class III) is a 
negative regulator of myogenesis, and works by preventing myoblast cell cycle 
withdrawal and thus subsequent differentiation. Lastly, Ccl8 (Class I) may be 
multifunctional: it promotes sufficient myoblast number by enhancing proliferation and 
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survival in proliferating cells, and possibly functions in differentiating cells through a 
distinct pro-myogenic mechanism that has not been fully elucidated. 
As we began to characterize the regulation and function of our candidate 
cytokines, some patterns started to emerge. For example, some cytokines, such as Flt3L 
(Class I) and Cxcl14 (Class III), appear to directly antagonize one another in their overall 
effect on myogenesis, timing, and signaling pathways used. We were also surprised to 
see significantly higher numbers of negative regulators (Classes III and IV) compared to 
positive regulators (Classes I and II), though it is possible that the design of our RNAi 
screen biased our results toward uncovering myogenic inhibitors. Additionally, all of the 
Class III cytokines our lab has studied thus far—including Cxcl14 (Chapter IV), and 
Tnfsf10 and FasL (Singh and Chen, unpublished observations)—seem to function 
primarily through control of myoblast proliferation. These observations opened the door 
to further questions: Is it possible that cell cycle withdrawal represents a critical 
regulatory checkpoint for myoblasts? Why would myoblasts need so many negative 
regulators of myogenesis in their toolkit? Are there cytokines that work together as a 
network, antagonizing or amplifying the effects of other cytokines during myogenesis?  
To gain insight into some of these questions, I used Integrative Multi-species 
Prediction (IMP) 2.0, an online tool developed by the Troyanskaya lab at Princeton 
University [1], to create network maps of known and predicted gene interactions of the 
myogenic cytokines identified in our RNAi screen (Fig. VI.1-4). I was intrigued to find a 
Class III cytokine candidate—Tnfα—on our Class I candidate network map (Fig. VI.1), 
potentially indicating antagonistic regulation between the two classes. Also of note are 
some of the predicted interaction partners. For example, Oxt—the gene encoding the 
hormone oxytocin—was a major node in the Class III cytokine interaction network, and 
linked to three of our RNAi candidates: IL-5, Ccl1, and Gdf3 (Fig. VI.3). Interestingly, 
plasma oxytocin levels decrease with age, and supplementation with the hormone during 
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muscle injury can ameliorate the impaired skeletal muscle regeneration observed in 
sarcopenic mice [2]. Oxt also appeared as a predicted interaction partner in the Class II 
cytokine network (Fig. VI.2.). Thus, it is possible that oxytocin functions as an 
underappreciated regulator of cytokine signaling during myogenesis. 
 Ultimately, it seems clear that the cytokine signaling network in skeletal muscle is 
complex, and there are still many questions that remain to be answered. Most of the 
candidates we identified in our RNAi screen have no reported function in muscle. 
Similarly unknown are the mechanisms regulating the expression of these cytokines 
during myogenesis. More complete characterization of these secreted factors and the 
signaling pathways they fit into can help us to better understand how skeletal muscle is 
developed, maintained, and regenerated. Indeed, these cytokines may represent 
untapped therapeutic targets for muscular diseases and for maintaining healthier 
muscles over the course of a lifetime. 
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VI.1. Figures  
 
 
 
 
 
 
 
Fig. VI.1. Class I cytokines  
Functional gene network predicted for the Class I cytokines (highlighted here in green) 
identified in our RNAi screen (see Chapter II) using IMP 2.0 (http://imp.princeton.edu). 
Minimum relationship confidence set to 0.35. 	
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Fig. VI.2. Class II cytokines 
Functional gene network predicted for the Class II cytokines (highlighted here in orange) 
identified in our RNAi screen (see Chapter II) using IMP 2.0 (http://imp.princeton.edu). 
Minimum relationship confidence set to 0.35. 
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Fig. VI.3. Class III cytokines 
Functional gene network predicted for the Class III cytokines (highlighted here in red) 
identified in our RNAi screen (see Chapter II) using IMP 2.0 (http://imp.princeton.edu). 
Minimum relationship confidence set to 0.35. 
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Fig. VI.4. Class IV cytokines 
Functional gene network predicted for the Class IV cytokines (highlighted here in blue) 
identified in our RNAi screen (see Chapter II) using IMP 2.0 (http://imp.princeton.edu). 
Minimum relationship confidence set to 0.35. 
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